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Neuropsychiatrische symptomen, ook wel probleemgedrag 
genoemd, komen veel voor bij mensen met dementie. Het 
omgaan met dit apathisch, angstig, achterdochtig, agressief 
of dwaalgedrag maakt het zorgen thuis voor de naaste van 
de persoon met dementie extra zwaar. Vaak is dit gedrag 
een reden voor opname in verpleeg- en verzorgingshuizen. 
Verzorgend en verplegend personeel van deze instellingen 
hebben ook dagelijks te maken met probleemgedrag bij 
bewoners met dementie. 
In dit proefschrift beschrijft Sytse Zuidema de resultaten van 
een grootschalig Nederlands onderzoek (WAALBED studie) 
in verpleeghuizen naar de aanwezigheid en oorzaken van 
probleemgedrag. Ook gaat hij in op de medicamenteuze 
behandelmogelijkheden en psychosociale interventies, om 
deze symptomen en de belasting die dit voor verzorgenden 
en verpleegkundigen met zich meebrengt te verminderen.
Dit proefschrift is een aanrader voor verpleeghuisartsen, 
sociaal geriaters, psychologen, psychiaters, klinisch geriaters 
en zorgmanagers, die regelmatig te maken hebben met 
mensen met dementie.
Sytse Zuidema (1967) is als verpleeghuisarts-onderzoeker 
werkzaam op de afdeling Verpleeghuisgeneeskunde van het 
UMC St Radboud te Nijmegen en bij Stichting Kalorama 
te Beek-Ubbergen.
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Introduction
In our ageing society, dementia can cause considerable morbidity and mortality. Over 
the last decades this progressive disease shows ever increasing prevalence and incidence 
rates. The estimated worldwide prevalence is 27.7 million demented persons.1 Of 
the 16 million inhabitants in the Netherlands, dementia is prevalent among 175,000 
people. As the Dutch population itself is ageing, the prevalence will rise to 355,000 
in the year 2030.2 The effect of the disease on cognition, activities of daily living and 
behaviour causes considerable loss of quality of life in both patient and caregivers. 
Particularly the behavioural problems, such as agitation/ aggression are a burden for 
the caregiver 3-5 and are often the main reason for institutionalization.6-8 
Consequently, neuropsychiatric symptoms are highly prevalent in nursing home 
patients, are diffi cult to deal with and can be a serious burden to the staff.9, 10 
Psychotropic medications 11-17 and physical restraints 18, 19 are often used to manage 
behavioral changes in nursing home patients. 
Neuropsychiatric symptoms, defi nition and 
taxonomy
Defi nitions of what constitutes behavioural changes and ‘problem behaviours’ in 
particular, vary widely. To some extent this variation in defi nitions refl ects the 
emerging new area of research and the accompanying ideological differences in 
point of view of those defi ning symptoms in dementia. In 1996, the International 
Psychogeriatric Association launched the concept of Behavioural and Psychological 
Symptoms in Dementia (BPSD), which are ‘signs and symptoms of disturbed 
perception, thought content, mood, or behaviour that frequently occur in patients 
with dementia’.20 This umbrella term not only covered behavioural problems, such 
as agitation or aggression, but also includes psychological symptoms as delusions, 
hallucinations, misidentifi cations, anxiety, depressed mood, or apathy. The concept of 
BPSD was meant to focus attention on the non-cognitive symptoms in dementia, 
and initiated a lot of scientifi c research on this subject. However, it is disputable 
whether this umbrella term is useful for both research and clinical practice,21 because 
neuropsychiatric symptoms are heterogeneous and may not refl ect one single unifying 
concept. 22
The Dutch association of nursing home physicians (NVVA) advocates using the term 
‘problem behaviour’. It is defi ned as ‘any type of patient behaviour that is diffi cult 
to be dealt with by patients themselves and/or their carers’.23 However, the NVVA 
guideline is not specifi cally developed for dementia patients only and covers a wide 
range of symptoms in different patient populations including such as dementia 
and stroke. Problem behaviour in this guideline focuses on overt behaviour such 
as agitated and aggressive behaviour and apathy. Psychosis and depression are not 
considered as behaviour, but as mental disorders underlying problem behaviour. 
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We feel that the term neuropsychiatric symptoms – most widely used in the U.S.A. 
and recently re-adopted by the International Psychogeriatric Association 24 – is a more 
neutral term better suited for the broad range of behaviours and mood-disturbances 
common in dementia. Neuropsychiatric symptoms can be clustered into aggression, 
(psychomotor) agitation, psychosis, depression / affective behaviour, and apathy. 22, 25 
This terminology is clinically meaningful and can be used for practical purposes such 
as in clinical trials.
Throughout this thesis, the term neuropsychiatric symptoms will be used, unless it is 
meant to focus on specifi c symptoms such as agitation. 
Dutch nursing home care
In the Netherlands, 30,000 of the institutionalized patients with dementia are residing 
in nursing homes and another 30,000 in residential homes.2
Nursing homes in the Netherlands differ from their counterparts in other countries 
in that the staff includes specially trained nursing home physicians (one full-time 
doctor per 100 patients), physical therapists, occupational therapists, speech therapists, 
pastoral workers, dietarians, psychologists, social workers and, occasionally, music 
therapists and psychomotor therapists, all of whom are employed by the nursing 
home.26-28 Multidisciplinary care for people with dementia is provided in special care 
units (SCUs). SCUs are designed to provide care for 6–40 people with dementia (per 
unit). The SCU’s environment is usually adapted to meet the needs of the patient 
with dementia, by the presence of camoufl aged closed-door systems, (therapeutic) 
gardens and patios, presence of an walking circuit, tape lines on the fl oor or devices to 
improve orientation. 
Due to capacity problems in the institutional health care sector and the expected 
increase of the number of (demented) patients making an appeal to nursing home 
care, nursing homes try to adapt to these developments by delivering nursing home 
care in the community and in residential homes (so-called ‘outreaching nursing home 
care’). The aim of providing outreaching nursing home care is enabling people with 
dementia to stay in their (residential) homes as long as possible and thereby postpone 
or prevent nursing home admission.29 
In recently built nursing homes, the ward-unit size tends to be smaller, in order to 
mimic the home situation. Currently the usefulness and effi cacy of this ‘small scale 
housing units’ is a matter of debate. Clinicians and workers in the fi eld who support 
this concept claim that the quality of care in these particular units is higher with 
more person-centered care, which increases quality of life, preserves ADL functioning, 
and reduces the amount of neuropsychiatric symptoms with less prescription of 
psychotropic medication as a consequence.30 Yet, there is no evidence in favour of 
small scale housing or other interventions that may improve the quality of the physical 
environment of nursing homes in the Netherlands. 
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Aim of this thesis 
Determinants of psychopathology are probably multifactorial in nature and include 
biological, psychological, social factors. The biopsychosocial model proved to be useful 
in explaining behavioral changes in community-dwelling dementia patients in the 
Maastricht Study of Behaviour in Dementia (MAASBED) study.31, 32 It is against this 
background that hypotheses on the biopsychosocial correlates of neuropsychiatric 
symptoms in nursing home patients with dementia were generated. 
To examine the magnitude of the neuropsychiatric symptoms in patients with 
dementia and the usefulness of the biopsychosocial model in Dutch nursing homes, 
we conducted a large cross-sectional study, the WAAL Behaviour in Dementia 
(WAALBED) study – a name obviously derived from the MAASBED study. 
Insight in prevalence and predictors of neuropsychiatric symptoms has consequences 
for effi cient use of staff, and could provide valuable information for psychosocial and 
pharmacological interventions to improve quality of life. Insight in the relation of 
neuropsychiatric symptoms and the physical environment could have consequences 
for development of appropriate services for nursing home residents.
The aim of the thesis is to gain further insight in (1) the prevalence of 
neuropsychiatric symptoms in dementia patients residing in Dutch nursing homes 
and in residential homes (receiving outreaching nursing home care) and (2) the 
patient- and environmental correlates of neuropsychiatric symptoms.
Research questions and general outline
The following research questions are addressed:
1.  What is the prevalence of neuropsychiatric symptoms in dementia patients receiving 
 nursing home care?
Chapter 2 gives an overview of the literature on the prevalence and predictors of 
neuropsychiatric symptoms in cognitively impaired nursing home patients. Few 
nursing home based studies evaluated neuropsychiatric symptoms in dementia 
patients using specifi c diagnostic criteria. Therefore, also studies on the prevalence 
of neuropsychiatric symptoms in ´cognitively impaired´ patients are reviewed. Only 
a limited number of studies showed some evidence that specifi c environmental 
characteristics of the dementia special care units are associated with neuropsychiatric 
symptoms, a fi nding that – among other factors related to dementia severity – 
distinguishes these SCU patients from those residing in the community.
Chapter 4 describes the actual prevalence rates of neuropsychiatric symptoms 
in the WAALBED study in patients with dementia in Dutch nursing homes 
and patients receiving outreaching nursing home care in residential homes. 
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Neuropsychiatric symptoms in general and agitation in particular were assessed with 
the Neuropsychiatric Inventory – Nursing Home version (NPI-NH) and the Cohen-
Mansfi eld Agitation Inventory (CMAI), specifi cally. These assessment instruments are 
very often used in both prevalence studies and in intervention studies. 
2.  What is the effi cacy and adverse events of antipsychotic medication for neuropsychiatric  
 symptoms in patients with dementia?
Chapter 3 gives a systematic overview of the current evidence of the effi cacy and 
adverse events of antipsychotic drugs as the main pharmacological therapy for 
neuropsychiatric symptoms. These drugs are frequently prescribed to patients with 
dementia, who are prone to develop adverse events, due to the age, co-morbidity and 
frailty.
3.  What is the factor structure of the NPI-NH and CMAI in Dutch nursing home 
 patients with dementia?
Chapters 5 and 6 are methodological chapters concerning the NPI-NH and CMAI. 
The chapters describe the factor structure of the NPI-NH (chapter 5) and CMAI 
(chapter 6) of the WAALBED study. Factor analysis is a statistical technique used to 
examine validity of a rating scale, to gain a better understanding of the behavioural 
dimensions that underlie many different neuropsychiatric symptoms in general (NPI-
NH) or -in this case- agitation/aggression (CMAI) in particular. Factor structure 
invariance was examined in different stages of dementia to investigate whether 
fi ndings were robust across different patient samples (chapter 5). Factor analysis of 
the CMAI was used to investigate whether specifi c symptom clusters can be used as 
subscales, for both research or practical purposes (chapter 6).
4.  What is the infl uence of patient-related factors on the prevalence of  neuropsychiatric   
 symptoms in nursing home patients with dementia?
Chapter 2 gives an overview of the literature of factors associated with patient 
demographics (gender, age, race, marital status) and factors associated with the type 
and severity of the disease on neuropsychiatric symptoms.
Chapter 7 describes the patient related factors of neuropsychiatric symptoms in the 
Dutch nursing home population with dementia (WAALBED study), in specifi c the 
infl uence of dementia severity and gender. These factors were considered as important 
predictors in community-dwelling patients, but there is only limited evidence of the 
contribution of this factors on neuropsychiatric symptoms in nursing homes.   
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5.  What is the infl uence of factors associated with the physical and psychosocial environment  
 of the special care units on the prevalence of neuropsychiatric symptoms in Dutch nursing  
 home patients with dementia?
Chapter 2 gives an overview of the current literature of the environmental factors on 
neuropsychiatric symptoms, such as the use of physical restraints and factors associated 
with the physical and social environment.
Chapter 8 describes the infl uence of environmental characteristics related to the 
special care unit on the prevalence of the neuropsychiatric symptoms in the nursing 
home population of the WAALBED study. In this chapter the differences of SCU 
symptom prevalences are described and related to the environmental characteristics 
of the SCU, such as the number of patients, the number of staff, presence of an 
walking circuit in order to gain further insight in the infl uence of the physical and 
psychosocial environment on neuropsychiatric symptoms. 
Finally, in chapter 9 the main fi ndings of this thesis were summarized by addressing 
the research questions. We discussed the strengths and limitations of the study  
followed by the clinical implications for researchers, physicians and psychologists, 
carers, architects, nursing home management and policy makers. This chapter ends 
with suggestions for future research and a general conclusion.
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Abstract
The prevalence of neuropsychiatric symptoms and the infl uence of predictive factors 
in cognitively impaired nursing home patients were reviewed. Articles were identifi ed 
by means of a MEDLINE and PsycInfo literature search. Neuropsychiatric symptoms 
were present in more than 80% of the cognitively impaired patients. Prevalences 
ranged considerably, from 3 to 54% for delusions, 1 to 39% for hallucinations, 8 to 
74% for depressed mood, 7 to 69% for anxiety, 17 to 84% for apathy, 48 to 82% for 
aggression or agitation, and 11 to 44% for physical aggression. Neuropsychiatric 
symptoms seemed to be predicted not only by dementia type or stage but also by the 
psychosocial environment and the amount of psychoactive medication and physical 
restraints used. Neuropsychiatric symptoms are common and infl uenced by both the 
disease itself and the psychosocial environment of the institutional setting. The latter 
may have important consequences for staff planning and education and the future 
design of care facilities.
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Introduction
Patients presenting with neuropsychiatric symptoms cause considerable suffering to 
themselves as well as to family members and other caregivers.1-3 The behaviour itself 
4-6 or accompanying caregiver distress7 may result in the patient being institutionalized 
in a nursing home or another type of care facility. This institutional setting provides 
the ideal framework for reviewing this particular aspect of dementia, because the 
already high prevalence rates of these symptoms can be expected to be enhanced 
further by the social environment, in which patients with severe dementia are usually 
spending a considerable portion of their daytime hours with other patients. Patients 
with neuropsychiatric symptoms can be a serious burden to the staff of nursing homes 
and other long-term care facilities, possibly leading to an increase in staff distress,8, 9 
and the patients themselves are often subjected to high levels of psychotropic 
medication10, 11 and physical restraints.12 Moreover, the care for patients with 
neuropsychiatric symptoms results in high economic costs.13
Many studies have estimated the prevalence of neuropsychiatric symptoms in 
demented or cognitively impaired patients. The majority of these studies has 
included community-dwelling patients or patients temporarily admitted to hospitals 
or research clinics. However, a considerably large group of demented patients are 
admitted to institutions; for example, in the Netherlands, 35% of dementia patients 
reside in nursing homes or other long-term care facilities, such as residential homes.14 
An assessment of the prevalence of symptoms in cognitively impaired nursing 
home patients and an insight into possible factors infl uencing these symptoms are 
indispensable for accurately planning both the short-term and long-term effi cient 
use of staff in healthcare facilities against reasonable costs. Moreover, such an 
assessment could provide valuable information on psychosocial and pharmacological 
interventions to improve the quality of life of these patients. The objective of 
this study was: (a) to determine the prevalence of neuropsychiatric symptoms in 
cognitively impaired nursing home patients and (b) to provide an overview of possible 
predictors of these symptoms based on a review of the literature. 
Methods
A computerized search in MEDLINE and PsycInfo was carried out for English-
language citations of ‘prevalence or predictors or correlates’ of ‘neuropsychiatric 
symptoms’ in ‘dementia or Alzheimer or cognitively impaired’ patients (included 
MESH-terms) between 1966 and August 2005. We also performed a search using 
related terms such as aggression, agitation, anxiety, apathy, depression, disinhibition, 
euphoria, hallucinations, irritability, misidentifi cations, negativism, psychosis, 
restlessness, and wandering. The reference lists of the articles identifi ed were also used 
to identify other articles. 
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We screened all retrieved titles and abstracts by hand. The inclusion criteria were 
(a) studies of institutionalized patients in nursing homes, chronic or long-term care 
facilities, or dementia special care units; and (b) studies of patients with dementia 
based on a chart diagnosis or using the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV) or other criteria, or cognitively impaired 
patients, as operationalized by Mini-Mental State Examination (MMSE) scores <24. 
Excluded were articles that considered (a) patients on social care, assisted living care 
or residential care; and (b) cognitively impaired patients with other diagnoses, such as 
delirium, psychiatric or other neurological disorders.
Studies that considered the infl uence of predictors in a population specifi cally selected 
on high symptom rates were not considered in the present review on prevalence. 
Neuropsychiatric symptoms were defi ned using a variety of terms. Since there is no 
solid, widely accepted classifi cation of these symptoms, we categorized them into 
(a) psychosis, including delusions, and hallucinations; (b) mood disorders, including 
depression as syndrome, depressed mood as a symptom, anxiety, crying, apathy; and 
(c) agitation and aggression, including verbal and physical aggression, irritability, 
disinhibition, wandering, restlessness, and repetitive or aberrant motor behaviour/
mannerisms, self-injurious behaviour. 
Results
Based on a preliminary assessment of 548 retrieved abstracts, we chose 81 articles 
which met or seemingly met the inclusion criteria. After the full text of each 
abstract had been evaluated, only 25 were judged to have met these inclusion 
criteria. Prevalence rates were discussed in 19 of these papers,15-33 and predictors 
in 18.15, 16, 18-20, 22-25, 27, 29, 32, 34-39 The infl uence of predictors in a selected population of 
patients with high prevalence rates of the specifi c behaviour of interest was studied 
in 5 articles.34-36, 38, 39
Patient Population
In 2 articles, the study cohort consisted of patients residing in chronic or long-
term care facilities;27, 28 all of the remaining articles dealt with patients residing in 
nursing homes, with 4 of these involving patients admitted into dementia special 
care units.16, 17, 19, 34 In 7 studies, there was evidence of a diagnosis of dementia based 
on DSM-III-R/DSM-IV,25, 30, 32, 33 or other criteria18, 26, 31 (table 1). In 5 other studies 
a further classifi cation of dementia into Alzheimer’s dementia, vascular dementia, 
mixed type dementia, and other dementias according to standard criteria15, 17, 28, 29, 37 
or neuropathological examination27 was available. In 7 other studies the diagnosis of 
dementia was based on consensus between physicians,16, 39 was based on a chart or 
clinical diagnosis,35, 38 or was not specifi ed at all.19, 22, 23 The remaining 4 studies dealt 
with cognitively impaired patients as assessed by MMSE <24.21, 24, 34, 36  
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Table 1. 
Patient characteristics and study design of 19 studies estimating the prevalence of 
neuropsychiatric symptoms in cognitively impaired nursing home patients
Author, Country Multi Number Diagnosis Criteria Mean MMSE Study design/ aim
Year  centre of patients   (SD) [range] 
Drachman, USA 1 36 53%AD,  Clinical diagnosis 6.6 (13) [0-45] Reliability COBRA scale in
1992     19%VaD/mix,   (stand. MMSE) community-dwelling  and
     28% other   institutionalized patients
Wagner, USA 70 614 Dementia Clinical diagnosis 7.8 (6.1) [0-23]  Prevalence and predictors of  
1995        behaviour in patients newly   
        admitted on special care units
McCann, USA 2 177 AD NINCDS-ADRDA 8.9 (5.9) Concordance between 
1997        direct observation and staff   
        rating of behaviour in AD
Cohen, USA 3 286 Dementia GDS, MMSE 13.6 (4.6) black/  Differences in predictors of
1998       15.7 (5.3) white depression, agitation and   
        psychosis in black and white   
        patients
Sloan, USA 53 951 Cognitively  MDS-Cog 4.9 (1.3) [2.7-6.8] Point prevalence agitation
1998     impaired  (MDS-Cog) and environmental correlates
Kolanowski, USA 4 84 Dementia MMSE 5.0 (6.3) Relation between physical
1999        aggression and personality   
        to refi ne the need-driven   
        dementia-compromised 
        behaviour model
Wood, USA 1 69 Cognitively  MMSE 6.7 [0-17] Validity NPI-NH, comparing
2000     impaired   responses of certifi ed nurses’   
        aides and licensed vocational   
        nurses
Schreiner,  Japan 6 392 Dementia NR NR Prevalence of agitation and
2000/2001 1)        aggression in Japanese   
        nursing homes
Brodaty, Australia 11 484 Cognitively  AMTS NR Prevalence and predictors of
2001     impaired   behaviour in Australian   
        nursing homes
Margallo, UK 3 231 Dementia AGECAT 7.0 (7.0) Differences in prevalences
2001 2)        between social and nursing   
        home care, relationship with   
        cognition and psychotropic   
        drugs
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Author, Country Multi Number Diagnosis Criteria Mean MMSE Study design/ aim
Year  centre of patients   (SD) [range] 
Payne, USA 1 201 60% AD, 12%  NIN(C)DS-ADRDA/ NR Incidence, prevalence and
2002     VaD, 8% mix,  AIREN  persistence of depression
     20% other   in newly admitted patients
Suh, Korea 2 257 52% AD,  DSM-IV NR Validation of Korean
2004     48% VaD   version of the CMAI 
Pitkala, Finland 7 160 Dementia DSM-IV NR Differences in prevalences of
2004 2)        behaviour in nursing home   
        and acute geriatric wards
McCarthy, USA Several 1883  Dementia ICD-9 NR Prevalences of mental illness,
2004 2)        differences in behaviour in   
        patients with and without   
        dementia
de Jonghe- The 1 110 Dementia DSM-IV 80% severe Prevalence of SIB, construct
Rouleau,  Netherlands      cognitive validity, relation with other
2005       impairment symptoms, cognition, 
        psychotropic drugs and   
        restraints
Note: 
AD = Alzheimer’s dementia, Mix = Mixed type of dementia, VaD = vascular dementia; AGECAT = computer 
based diagnostic system formulation 8 diagnostic clusters (organic, schizofrenic/paranoia, mania, depression, 
obsessionality, hypochondriasis, phobia, anxiety), AMTS = Abbreviated Mental Test Scale, DSM = diagnostic and 
statistical manual of mental disorders, GDS = global deterioration scale, ICD-9 = International Classifi cation of 
Diseases (9th version), MDS-Cog = Minimal Dataset-Cognition Scale, MMSE = Mini-Mental State Examination, 
NINCDS-ADRDA = National Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer’s Disease and Related Disorders Association, NINDS-AIREN = National Institute of Neurological 
Disorders and Stroke and the Association Internationale pour la Recherche et l’Enseignement en Neurosciences; 
NR = Not reported; COBRA = Caretaker Obstreperous-Behaviour Rating Assessment, CMAI = Cohen-Mansfi eld 
Agitation Inventory, NPI-NH = Neuropsychiatric Inventory – Nursing home version, SIB = self-injurious behaviour, 
1) Articles of Schreiner were combined (addressed same patients population)
2) Only a subgroup of nursing home patients was presented
3) Only a subgroup of dementia patients was presented
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Prevalence
The 19 studies addressing the prevalence of neuropsychiatric symptoms were very 
different with respect to patient population, design/aim of the study, and the rating 
scale used (table 1); the patients participating in these studies not only differed with 
regard to their diagnosis (Alzheimer’s dementia, vascular dementia, or unspecifi ed 
dementia), but had different levels of cognitive impairment as well, with mean MMSE 
scores ranging from 5.020 to 15.7.18 Mean age ranged from 78 years31 to 87 years.21 
The majority of these patients were female, with the proportion ranging from 66%27  
to 83%32, except for a study of military veterans (94% male).31  The prevalence rates 
of neuropsychiatric symptoms are presented in 19 studies, but only 10 of these were 
primarily designed to assess the prevalence (and predictors) of newly admitted16, 28, 33 
or long-stay22, 23, 24, 32 patients in nursing homes or long-term care facilities or to assess 
cultural differences18 or differences in prevalence between care settings26, 30 in a cross-
sectional design. 
A variety of rating scales were used to assess different symptoms, with only 3 
inventories used in more than 1 study: the Behavioural Pathology in Alzheimer’s 
disease rating scale (BEHAVE-AD),18, 24 Neuropsychiatric Inventory- Nursing Home 
version (NPI-NH),21, 26 and Cohen-Mansfi eld Agitation Inventory (CMAI)17, 22, 23, 29
(Table 2.). Five studies estimated the (overall) prevalence of any one neuropsychiatric 
symptom in nursing home patients, which was found to range from 82% to > 90%16, 
24, 26, 30; a low prevalence (38%) of any one symptom was found in one study that used 
a Clinical Interview Schedule, in which symptoms were only observed or reported 
during a semi-structured interview.33
Table 2. 
Prevalence Estimates of Neuropsychiatric Symptoms in Cognitively Impaired Nursing Home 
Patients in 19 studies
Author,  Assessment Prevalence Psychosis Depression, Agitation
Year Instrument (All)  anxiety, apathy
Drachman,  COBRA  36 delusions,  64 aggression  (33 verbal/25 physical), 
1992    13 hallucinations  67 motor behaviour (22 wandering)
Wagner,  MBPC-NH >90 49 delusions, 37 depressed mood, 71 wandering, 61 restlessness
1995   39 hallucinations 48 anxiety, 41 apathy
McCann,  CMAI    37 verbal, 25 physical aggression,  
1997     47 wandering, 32 aberrant motor behaviour  
Cohen, CSDD, CMAI,   23 psychosis 23 possible depression, 
1998 BEHAVE-AD   4 major depression 
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Author,  Assessment Prevalence Psychosis Depression, Agitation
Year Instrument (All)  anxiety, apathy
Sloan, RSOC (direct     10 agitation (4 aberrant motor behaviour,
1998 observation)    6 wandering), 0 aggression
Kolanowski,  RAS    44 physical aggression
1999 
Wood, NPI-NH  17 delusions, 74 depressed mood, 77 aggression/agitation, 67 irritability,
2000   19 hallucinations 46 anxiety, 84 apathy 30 disinhibition, 51 aberrant motor behaviour
Schreiner,  CMAI    45 aggression (39 verbal / 25physical), 
2000/2001      37 wandering, 38 restlessness
Brodaty BEHAVE-AD 92 54 delusions,  44 depressed mood, 53 agitation, 77 aggression
2001   33 hallucinations 69 anxiety
   (60 psychosis) 
Menon,  PGDRS,  1 psychosis 21 depressed mood 10 verbal, 11 physical aggression
2001 CSDD
Evers, DSM-IIIR   29 major depression
2002 
Payne, CSDD   20 depressed mood
2002   
Wancata,  CIS 38 3 delusions, 8 depressed mood, 6 aggression
2003   1 hallucinations 7 anxiety
Suh, CMAI    82 aggression /agitation (39 physical),
2004      82 motor behaviour (28 wandering)
Pitkala, Nurse  88 36 delusions 4 major depression,  28 agitation, 18 aggression, 17 wandering
2004 questionnaire  (56 psychosis) 51 depressed mood,
    51 anxiety, 17 apathy 
McCarthy, ICD-9, PAI   4 major depression 22 verbal, 19 physical aggression,
2004      61 inappropriate behaviour
de Jonghe- Nurse rating    22 self-injurious behaviour
Rouleau,  scale
2005    
Note: 
All data are presented as percentages; BEHAVE-AD = Behavioural Pathology in Alzheimer’s disease rating 
scale, CMAI = Cohen-Mansfi eld Agitation Inventory, CIS = Clinical Interview Schedule, COBRA = Caretaker 
Obstreperous-Behaviour Rating Assessment, CSDD = Cornell Scale for depression in dementia, 
MBPC-NH = Memory and Behaviour problems Checklist- Nursing home version, NPI-NH = Neuropsychiatric 
Inventory- Nursing Home version, PAI = Patient Assessment Instrument, PGDRS = Psychogeriatric Dependency 
Rating Scale, RAS = Ryden Aggression Scale, restl = restlessness, RSOC = Resident and Staff Observation 
Checklist.
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Psychosis
Prevalences of psychosis reported in 3 studies varied from 23 to 60%.18, 24, 30 Only 
Menon et al25 reported a remarkably low prevalence of psychosis (1%), defi ned 
as the presence of hallucinations or delusions measured with the Psychogeriatric 
Dependency Rating Scale (PGDRS). Some studies described psychotic symptoms 
(i.e., delusions or hallucinations) separately. Delusions were present in 16 to 54%15, 
16, 21, 24, 26, 30 of the patients, whereas hallucinations were reported in 5 to 39% of the 
patients.15, 16, 21, 24, 26 Visual and auditory hallucinations were reported in 21% and 16% 
of the patients, respectively.30 Low prevalences of delusions and hallucinations – 3% 
and 1%, respectively – were recorded when symptoms were observed during a semi-
structured interview.33 
Mood disorders, anxiety, apathy
In the study of Evers et al,27 29% of the demented patients were judged to suffer from 
a major depression, whereas Cohen et al18 found prevalences for possible depression 
of 19% and 34% for black and white patients, respectively. Using the more strict 
DSM-IV criteria for probable major depression, Cohen et al18 found much lower 
frequencies for both groups (3% and 9%, respectively). The overall percentages of 
major depression in the total group was 4%, which is similar to that found in two 
other studies.30, 31 
Several studies described the prevalence of depressive symptoms rather than the 
frequency of major or minor depression. Prevalences of dysphoria or depressed mood 
ranged from 8% to 74%16, 21, 24-26, 28, 30, 33. Crying occurred in 22% of the demented 
patients.16 Prevalences of anxiety ranged from 7% to 69%.16, 21, 24, 26, 30, 33 Euphoria, a 
mood symptom less well studied, occurred in 3 to 7% of the demented patients.26, 33 
The prevalence of apathy varied from 17% to 84%16, 21, 26, 30 with major difference in 
prevalence between the 2 Neuropsychiatric Inventory (NPI) studies.
Agitation and Aggression
The overall prevalence of agitated or aggressive behaviours was found to range from 
48% to 82%, depending on the rating scale used to assess a wide range of symptoms.21, 
26, 29 Agitation (aggression not included) was prevalent in 28% and 53% of the 
respective patients of 2 studies.24, 30 With respect to the different manifestations of 
agitation, frequencies of 18% and 30% were reported for disinhibition,21, 26 31% and 
67% for irritability,21, 26 38% and 61% for restlessness,16, 22 17 to 71% for wandering,15-17, 
22, 29, 30 and 32 to 51% for aberrant motor behaviour.17, 21, 26 In some studies, symptoms 
such as wandering, pacing, hyperkinesias, and repetitive sorting were grouped as 
motor abnormalities, which occurred in 67% and 82% of the patients.15, 29 Frequencies 
of aggression showed a considerable degree of variation, from 6 to 77%.15, 23, 30, 33 
When aggression was specifi ed as either verbal or physical aggressive behaviour, the 
frequencies ranged from 10% to 39%15, 17, 23, 25, 31 and from 11% to 44% 15, 17, 20, 23, 25, 29, 31 
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respectively. Self-injurious behaviour, a symptom very rarely studied, was found to be 
prevalent in 22% of the patients in 1 study.32 Low prevalences of agitation, aberrant 
motor behaviour, and wandering of 10% or less were found in 1 study.19
Predictors
Patient Demographics
Age. In 2 studies a signifi cant effect of age on neuropsychiatric symptoms was found; 
younger patients were more aggressive,24 restless,16 and depressed,16 whereas older 
patients were more suspicious.16 Other studies failed to demonstrate a signifi cant 
effect of age on the prevalence of such symptoms as aggression or agitation15, 22, 23
Gender. In most studies, agitated behaviour, such as physically nonagressive 
behaviour,35 (physically) aggressive behaviour,23, 24 verbal aggression,25 or vocal 
agitation,35 was more prevalent in male patients; the 3 exceptions were studies 
showing that agitation and aggression in general15, 39 and verbal agitation38 appeared 
to be more prevalent in female patients. One study found a relationship between 
male gender and depressed mood24, whereas another study was unable to fi nd this 
association.27
Race. Cohen et al18  reported a lower prevalence of depression and lower levels of 
agitation in black patients with dementia than in white patients, with no interracial 
differences between African Americans and African Carribeans. Evers et al27 did not 
fi nd an effect of race on the prevalence of depression.
Marital status. In 2 studies, nursing home patients who had lived alone before 
admission showed a higher prevalence of psychosis18 and physical aggression25 than 
those who were married. However, in another study physical aggression appeared to 
be more common in married patients.35 
Dementia-related factors
Dementia type. Because dementia type was established only in a minority of the 
nursing home studies reviewed here, little evidence is available on the infl uence of 
different types of dementia on neuropsychiatric symptoms. There was some evidence 
of more aggression and agitation or physically non-aggressive behaviour and hiding/
hoarding behaviour in patients with Alzheimer’s dementia than in those with vascular 
dementia or other dementing disorders.15, 29
(Global) disease severity. Some studies discussed the relationship between 
neuropsychiatric symptoms and dementia stage, the latter considered to be a mixture 
of cognition, language disability and activities of daily living (ADL). During the 
deterioration of cognitive function that occurs with progressive dementia, these 
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domains can not easily be disentangled and hence will be discussed together. 
Almost all neuropsychiatric symptoms were found to be related to a more 
pronounced cognitive or ADL dysfunction. Signifi cant correlations were found 
between cognitive dysfunction and the presence of suspicious behaviour,16 agitation in 
general,37 physically agitated or vocally or verbally agitated/aggressive behaviour,35, 38 
physical or verbal aggression,25 repetitive questioning,16 and between ADL dysfunction 
and the presence of delusions,24 depression,25 anxiety,24 agitation,19 verbally agitated 
behaviour,38 (physical) aggression,23-25 or immobility and self-injurious behaviour.32 
In black patients, cognitive dysfunction seemed to be correlated with the presence 
of agitation and psychosis, but this was not true for white patients.18 Other studies 
were unable to demonstrate a signifi cant relationship between the presence of 
cognitive dysfunction and physical aggression15, 34 and between ADL dysfunction and 
the presence of psychosis,18 depression,18 agitation,18, 35 and physically non-aggressive 
behaviour.38
Although, in general, symptoms were more frequent as the disease progressed, only 
depression was associated with less severe stages of the dementia.27 
Comorbidity. Two studies found that the number of physical disorders registered 
in the minimum data set was a predictor of agitation,18, 19 but not of depression or 
psychosis.18 An inverse relationship was found between the number of medical chart 
diagnoses and the prevalence of physically non-aggressive behaviour.38 In another 
study, a relationship between the number of medical diagnoses obtained from the 
participant’s charts and physically and vocally agitated (disruptive) behaviour could 
not be demonstrated.35
Premorbid personality
Only 1 study investigated the relationship between premorbid personality and 
neuropsychiatric symptoms, and it failed to show a signifi cant correlation between 
physical aggression and premorbid personality.20
 
Psychoactive medication
Higher rates of aggression were found in antipsychotic and anxiolytic drug users,36 
and lower rates of aggression were found in antidepressant users.36 Self-injurious 
behaviour was associated with prescribed benzodiazepines but not with anti-
psychotics or anti-depressants.32 
Environmental factors
To determine the infl uence of environmental factors, more direct observational 
methods were used, such as a structured time-sampling technique with a 5-min 
paper-and-pencil recording,17 computer-assisted real-time observational systems,34, 
39 or agitated behaviours mapping instruments (ABMI),38 all of which enabled a 
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more continuous recording of behaviours. These techniques enables to investigate 
not only diurnal variations, such as a late-day peak in pacing and verbal or physically 
aggressive behaviour,37 but also antecedents directly preceding agitated behaviour. For 
example, it was shown that agitated behaviour was preceded by staff verbal and touch 
interactions.39 Physically aggressive behaviour was shown to be preceded by verbal 
aggression or the non-compliance of residents toward staff or defi ance toward any 
staff ’s request to the client. Physical aggression also occurred in response to intrusion 
into the resident’s own personal space, especially in the context of bathing, toileting, 
grooming, dressing, or during redirection of the resident.34
Physical restraints. Two studies showed that the use of physical restraints was 
a predictor of physically aggressive behaviour36 or self-injurious behaviour,32 
independent from the use of psychoactive medication. In another large study in 53 
Alzheimer’s disease special care units, it was found that the proportion of the residents 
restrained was a predictor of the mean agitation level at a care unit, independent from 
other variables such as ADL dependency and the number of diagnoses per resident.19 
Social environment. Only 1 study could be retrieved from the literature in which 
neuropsychiatric symptoms were directly compared between community-dwelling 
and nursing home patients with dementia.15 Whereas in the former setting patients 
showed more delusions, hallucinations, and mechanical/motor abnormalities, in the 
latter setting patients had more aggressive behaviour. 
Within the setting of nursing homes or other long-term care facilities, 6 articles 
investigated neuropsychiatric symptoms in relationship to the social environment.18, 19, 
38 size of the living group19 or institution,24 or type of care delivered to the patient.36, 
37 Whereas large nursing homes in general24 or large units in particular19 were related 
to higher levels of agitation in the patient19 or other neuropsychiatric symptoms,24 
the presence of social support – as measured with the number of visitors or telephone 
calls per week18, 38 or frequency of communication with staff or other residents38 
– seemed to coincide with a lower prevalence psychoses (in black patients)18, verbal  
agitation38 or disruptiveness of agitation.38 The relative importance of the therapeutic 
(psychosocial) environment was supported by a positive association between low 
(mean) agitation rates at a special care unit and favorable scores on measures of 
physical environment and staff treatment activities, such as general design, space, 
lighting, noise, maintenance, resident rooms, the quality of the staff interaction with 
residents, and the proportion of residents engaged in planned activities.19 In this study 
no difference in prevalence of agitation could be shown between patients in dementia 
special care units and those in traditional care units. Finally, it was shown that residents 
on secured units were more physically aggressive (but also more cognitively impaired) 
than patients not on secured units.36
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Discussion
This review of the literature clearly shows that neuropsychiatric symptoms in 
cognitively impaired nursing home patients are very common, with more than 
5 out of 6 institutionalized patients suffering from 1 or more symptoms. The 
ranges in prevalences were considerable, from 3 to 54% for delusions, 1 to 39% for 
hallucinations, 8 to 74% for depressed mood, 7 to 69% for anxiety, 17 to 84% for 
apathy, 48 to 82% for aggression or agitation, and 11 to 44% for physical aggression. 
The prevalence of neuropsychiatric symptoms was associated with factors such as 
dementia type and global severity and can be modifi ed with factors related to the 
interaction of the patient with others or with the (physical) environment. In addition, 
patients with neuropsychiatric symptoms were administered more psychoactive 
medication and were more often physically restrained than those without symptoms.
There was considerable variation in the frequencies of neuropsychiatric symptoms 
reported in different studies. This large variability may be based on the degree of 
uncertainty with respect to defi ning dementia itself, its type and/or severity or 
on variations in the methodology used to evaluate neuropsychiatric symptoms. 
Consequently, only a few studies dealt with patients with accurately diagnosed 
dementia. Moreover, the adoption of different inventories, with different ratings or 
symptom defi nitions, probably infl uenced the prevalence outcome as well and makes 
pooling of symptom frequencies in different studies impossible.
Prevalence rates of neuropsychiatric symptoms, especially agitation, in residents of 
nursing homes are high and probably higher than in patients living in other types 
of care facilities, such as residential care/assisted living facilities,40 social care,24 or in 
community-dwelling patients,15 probably attributable to a selection effect. Behavioural 
problems, such as agitation and global severity of the disease, are the main reasons 
for patients to be admitted to a nursing home. Moreover, it is also during the 
subsequent progression of the disease in long-stay patients that behavioural symptoms 
are expected to occur more frequently. An additional exacerbating factor is that 
nursing home patients usually spend a considerable portion of their daytime hours 
in overcrowded communal living rooms in which agitated and aggressive behaviour 
is likely to be enhanced further by the behaviour of other patients. In this review 
we have shown that more and more studies have concluded that the psychosocial 
environment in nursing homes is a signifi cant factor in determining the prevalence 
of neuropsychiatric symptoms. For assessing the infl uence of this psychosocial 
environment on neuropsychiatric symptoms, commonly used (global) rating scales 
are not adequate as they have not been designed to study and describe in detail a 
resident’s behaviour during the day and the preceding behaviours. For that purpose 
dementia care mapping or continuous observation techniques (by video taping 
caregiving activities) seem to be more accurate and reproducible.17 
Insight into the prevalence of neuropsychiatric symptoms, especially into its 
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exacerbating or modifying factors, has important practical consequences. Both 
the numbers of patients showing resistance to (morning) care and of those with 
wandering in the afternoon should be important factors in determining the number 
of staff to be employed during the day. As to less-predictable behaviours, such as 
physical aggression, more detailed knowledge of the derailing factors and the exact 
circumstances in which this form of aggression occurs (or diminishes) in each 
individual patient is indispensable and should be conveyed to the staff in order that 
they can adequately deal with these stressful events in the daily practice of caregiving. 
With that objective,  the continuing education of inadequately trained staff (by means 
of practical experience under supervision or other techniques such as role playing or 
video-interaction techniques) should also be encouraged. 
Because dementia is not curable, most biological and disease-related predictors cannot 
be removed or treated, and because psychoactive medication has only limited effect 
on neuropsychiatric symptoms,41 both psychosocial interventions42 and those made in 
the patient’s social and physical environment should be used more often as a means to 
adapt the current personal living space and to design (small-scale) facilities for use in 
the near future. Consequently, more research is needed on the effects of manipulating 
the physical and social environments in nursing homes. A better understanding of 
these effects would facilitate the development of appropriate services for nursing 
home residents as a means of minimizing behavioural problems and increasing the 
quality of life.
References
 1. Pot A. Caregiver perspectives; a longitudinal study on the psychological distress of  
  informal caregivers of demented elderly. Amsterdam: VU, 1996.
 2. Coen RF, Swanwick GR, O’Boyle CA, et al. Behaviour disturbance and other 
  predictors of carer burden in Alzheimer’s disease. Int J Geriatr Psychiatry 
  1997;12:331-336.
 3. Clyburn LD, Stones MJ, Hadjisstavropoulos T, et al. Predicting caregiver burden and 
  depression in Alzheimer’s disease. J Gerontol Series B, Psycholoc Sci & Soc Sci 
  2000;55:S2-S13.
 4. Knopman DS, Kitto J, Deinard S, et al. Longitudinal study of death and 
  institutionalization in patients with primary degenerative dementia. J Am Geriatr 
  Soc 1988;36:108-112.
 5. Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home 
  placement with Alzheimer’s disease. Am J Psychiatry 1990;147:1049-1051.
 6. Haupt M, Kurz A. Predictors of nursing home placement in patients with Alzheimer’s  
  disease. Int J Geriatr Psychiatry 1993;8:741-746.
31
Prevalence and predictors of neuropsychiatric symptoms
 7. De Vugt ME, Stevens F, Aalten P, et al. A prospective study of the effects of behavioural  
  symptoms on the institutionalisation of patients with dementia. Int Psychogeriatr  
  2005;17:577-589.
 8. Everitt DE, Fields DR, Soumerai SS, et al. Resident behavior and staff distress in the  
  nursing home. J Am Geriatr Soc 1991;39:792-798.
 9. Sourial R, McCusker J, Cole M, et al. Agitation in demented patients in an acute care  
  hospital: prevalence, disruptiveness, and staff burden. Int Psychogeriatr 2001;13:183-197.
 10. Hagen BF, Armstrong-Esther C, Quail P, et al. Neuroleptic and benzodiazepine use in  
  long-term care in urban and rural Alberta: characteristics and results of an education  
  intervention to ensure appropriate use. Int Psychogeriatr 2005;17:631-652.
 11. Ruths S, Straand J, Nygaard HA. Psychotropic drug use in nursing home - diagnostic  
  indications and variations between institutions. Eur J Clin Pharmacol 2001;57:523-528.
 12. Strumpf NE, Evans LK. Physical restraints of the hospitalized elderly: perceptions of  
  patients and nurses. Nurs Res 1988;37:132-137.
 13. O’Brien JA, Shomphe LA, Caro JJ. Behavioral and psychological symptoms in dementia 
  in nursing home residents: the economic implications. Int Psychogeriatr 2000;12
  (suppl. 1):51-57.
 14. Health Council of the Netherlands. Dementia. The Hague, 2002, publication 
  no. 2002/04.
 15. Drachman DA, Swearer JM, O’Donnell BF, et al. The caretaker obstreperous-behavior  
  rating assessment (COBRA) scale. J Am Geriatr Soc 1992;40:463-480.
 16. Wagner AW, Teri L, Orr-Rainey N. Behavior problems of residents with dementia in  
  special care units. Alz Dis Assoc Dis 1995;9:121-127.
 17. McCann JJ, Gilley DW, Hebert LE, et al. Concordance between direct observation and  
  staff rating of behavior in nursing home residents with Alzheimer’s disease. J Gerontol B 
  Psychol Sci Soc Sci 1997;52:63-72.
 18. Cohen CI, Hyland K, Magai C. Interracial and intraracial differences in    
  neuropsychiatric symptoms, sociodemography and treatment amongst nursing home  
  patients in dementia. Gerontologist 1998;38:353-361.
 19. Sloane PD, Mitchell CM, Preisser JS, et al. Environmental correlates of resident   
  agitation in Alzheimer disease special care units. J Am Geriatr Soc 1998;46:862-869.
 20. Kolanowski AM, Garr M. The relation of premorbid factors to aggressive physical   
  behavior in dementia. J Neurosci Nurs 1999;31:278-284.
 21. Wood S, Cummings JL, Hsu MA, et al. The use of the Neuropsychiatric Inventory in  
  nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry  
  2000;8:75-83.
 22. Schreiner A, Shiotain H, Yamamoto E. Agitated behavior in elderly nursing home   
  residents with dementia in Japan. J Gerontol B Psychol Sci Soc Sci 2000;55:180-187.
 23. Schreiner AS. Aggressive behaviors among demented nursing home residents in Japan.  
  Int J Geriatr Psychiatry 2001;16:209-215.
32
C H A P T E R  2
 24. Brodaty H, Draper B, Saab D, et al. Psychosis, depression and behavioural disturbances  
  in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry  
  2001;16:504-512.
 25. Menon AS, Gruber-Baldini AL, Hebel JR, et al. Relationship between aggressive   
  behaviors and depression among nursing home residents with dementia. Int J Geriatr  
  Psychiatry 2001;16:139-146.
 26. Margallo M, Swann A, O’Brien J, et al. Prevalence of the pharmacological and   
  psychological symptoms amongst dementia sufferers living in care environments. Int J  
  Geriatr Psychiatry 2001;16:39-44.
 27. Evers MM, Samuels SC, Lantz M, et al. The prevalence, diagnosis and treatment of   
  depression in dementia patients  in chronic care facilities in the last six months of life.  
  Int J Geriatr Psychiatry 2002;17:464-472.
 28. Payne JL, Sheppard JM, Steinberg M, et al. Incidence, prevalence, and outcomes of   
  depression in residents of a long-term care facility with dementia. Int J Geriatr   
  Psychiatry 2002;17:247-253.
 29. Suh GH. Agitated behaviours among institutionalized elderly with dementia: validation  
  of the Korean version of the Cohen-Mansfi eld Agitation Inventory. Int J Geriatr   
  Psychiatry 2004;19:378-385.
 30. Pitkala KH, Laurila JV, Strandberg TE, et al. Behavioral symptoms and the   
  administration of psychotropic drugs to aged patients with dementia in nursing homes  
  and in acute geriatric wards. Int Psychogeriatr 2004;16:61-74.
 31. McCarthy JF, Blow FC, Kales HC. Disruptive behaviors in veterans affairs nursing   
  home residents: how different are residents with serious mental illness? J Am Geriatr  
  Soc 2004;52:2031-2038.
 32. de Jonghe-Rouleau AP, Pot AM, de Jonghe JF. Self-injurious behaviour in nursing   
  home residents with dementia. Int J Geriatr Psychiatry 2005;20:651-657.
 33. Wancata J, Benda N, Meise U, et al. Non-cognitive symptoms of dementia in nursing  
  homes: frequency, course and consequences. Soc Psychiatry Psychiatr Epidemiol   
  2003;38:637-643.
 34. Bridges-Parlet S, Knopman DS, Thompson T. A descriptive study of physically   
  aggressive behavior in dementia by direct observation. J Am Geriatr Soc 
  1994;42:192-197.
 35. Beck C, Frank L, Chumbler NR, et al. Correlates of disruptive behavior in severely  
  cognitively impaired nursing home residents. Gerontologist 1998;38:189-198.
 36. Ryden MB, Feldt KS, Oh HL, et al. Relationships between aggressive behavior in   
  cognitively impaired nursing home reisidents and use of restraints, psychoactive drugs,  
  and secured units. Arch Psychiatr Nurs 1999;13:170-178.
 37. McCann JJ, Gilley DW, Bienias JL, et al. Temporal patterns of negative and positive   
  behavior among nursing home residents with Alzheimer’s disease. Psychol Aging   
  2004;19:336-345.
33
Prevalence and predictors of neuropsychiatric symptoms
 38. Cohen-Mansfi eld J, Libin A. Verbal and physical non-aggressive agitated behaviors 
  in elderly persons with dementia: robustness of syndromes. J Psychiatr Res   
  2005;39:325-332.
 39. Burgio LD, Butler FR, Roth DL, et al. Agitation in nursing home residents: the role of  
  gender and social context. Int Psychogeriatr 2000;12:495-511.
 40. Gruber-Baldini AL, Boustani M, Sloane PD, et al. Behavioral symptoms in residential  
  care/assisted living facilities: prevalence, risk factors, and medication management. J Am  
  Geriatr Soc 2004;52:1610-1617.
 41. Zuidema SU, van Iersel MB, Koopmans RTCM, et al. Effi cacy and adverse reactions of  
  antipsychotics for neuropsychiatric symptoms in dementia: a systematic review. Ned  
  Tijdschr Geneeskd 2006;150:1565-1573.
 42. Livingston G, Johnston K, Katona C, et al. Systematic review of psychological   
  approaches to the management of neuropsychiatric symptoms of dementia. Am J   
  Psychiatry 2005;162:1996-2021.
34
Effi cacy and adverse reactions of anti-
psychotics for neuropsychiatric symptoms 
in dementia: a systematic review
C H A P T E R  3
Sytse U. Zuidema
Marianne B. van Iersel
Raymond T.C.M. Koopmans
Frans R.J. Verhey
Marcel G.M. Olde Rikkert
Ned Tijdschr Geneesk 2006; 150: 1565-1573
Abstract
Aim of this study 
To assess the effi cacy and adverse events of antipsychotics in the treatment of 
neuropsychiatric symptoms associated with dementia and to verify the evidence 
warning against the cerebrovascular adverse events of atypical antipsychotics.
Design
Systematic review.
Methods 
A selection of double-blind randomised studies with intention-to-treat analysis in 
Medline, Cinahl, PsycInfo, EMBASE and Cochrane (1980-2005) that researched the 
effi cacy and adverse events of antipsychotics against neuropsychiatric disorders in 
dementia. These studies were assessed for quality in a standardised manner.
Results 
Of the 950 articles found, 14 publications were selected on the effect of haloperidol, 
risperidone, olanzapine, quetiapine, tiapride, loxapine and perphenazine. Haloperidol, 
risperidone and olanzapine proved to be more effi cacious against aggression and 
psychosis than placebo in seven out of ten cases. However, a direct comparison 
between typical and atypical antipsychotics revealed no statistically signifi cant 
difference. The most frequent adverse events were extrapyramidal symptoms and 
drowsiness. These adverse events were less severe with low-dose risperidone than 
with haloperidol and olanzapine, but risperidone and olanzapine were shown in two 
studies to be associated with a higher risk for cerebrovascular adverse events.
Conclusion
Typical and atypical antipsychotics show a comparable effi cacy, and only risperidone 
– predominantly at lower doses – seems to have fewer (extrapyramidal) adverse events. 
The profi le of the adverse events has been inadequately described in the published 
research and, consequently, the warnings for an increased mortality cannot be 
confi rmed. 
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Introduction
Dementia is often complicated by manifestations of agitation, psychosis, apathy and 
depression. In the international literature these symptoms have been grouped together 
under the combined heading of neuropsychiatric symptoms. Such neuropsychiatric 
symptoms occur frequently, are highly taxing for the patient and her/his partner and 
oftentimes lead to an earlier admission in a nursing home. The treatment of such 
neuropsychiatric symptoms, especially those of agitation/aggression and psychosis, 
consists of pharmacological and psychosocial intervention strategies. Antipsychotics 
form one of the most important pharmacological therapies, but their use can result 
in major adverse events, such as extrapyramidal symptoms, drowsiness, orthostatic 
hypotensia and an increased proneness to falling. Atypical antipsychotics have been 
reported to cause fewer extrapyramidal adverse events 1,2 – while still being considered 
to be as effi cacious as typical antipsychotics. However, the American Food and 
Drug Administration (FDA), the UK government and the European Registration 
Authority (EMEA) released a warning stating that there is a relationship between 
atypical antipsychotics and an increased risk of stroke and mortality.3-5  A great deal of 
attention has been paid to these topics, including an article published by van Marum 
and Jansen.6 
In the present systematic review, we will conduct an in-depth assessment of (a) the 
evidence of warnings for these and other adverse events, and (b) the proposed equal 
effi cacy of typical (such as haloperidol) and atypical antipsychotics (such as olanzapine 
and risperidone).
Methods 
Search strategy
A search of the relevant literature was carried out in the databases of Medline, 
PsycInfo, Cinahl, EMBASE, and the Cochrane Trial Register from 1980 to 2005 
using general search terms and the following medical subject headings: (1) dementia; 
(2) antipsychotics; (3) randomised, controlled trial; (4) neuropsychiatric symptoms and 
related terms. Publications prior to 1980 were not taken into account because the 
criteria used for diagnosing dementia prior to 1980 were substantially different from 
those currently in use. 
Selection
One author (M.B.v.I.) made a selection from all of the titles and abstracts mined 
from the databases using the following criteria for inclusion: (1) randomised, double-
blind studies in which an antipsychotic was compared to another antipsychotic 
or to a placebo; (2) effects on neuropsychiatric symptoms or adverse events as the 
primary result of medication; (3) the cohort consisted of patients with dementia; (4) 
administration was oral. The publications which met these criteria were subsequently 
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studied in detail by two of the authors (M.B.v.I., S.U.Z.), who applied the following 
criteria for exclusion: (1) there was no ‘intention-to-treat’; (2) dementia was not 
diagnosed according to internationally accepted criteria currently in use (Diagnostic 
Statistical Manual-IV), National Institute for Neurological Disorders and Stroke and 
the Association International pour la Recherche et l’Enseignement en Neurosciences 
(NINDS-AIREN), National Institute for Neurological and Communicative 
Diseases and Stroke and the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA). 
Methodological Assessment
The same researchers made a mutually independent assessment of the methodological 
quality of these articles included in the review using an assessment form for the 
therapeutical studies.4 This assessment form has been applied in numerous meta-
analyses and consists of 12 methodological criteria; for each of these criteria, a 
maximum number of points can be scored (the combined maximum amounts to 100 
points), so that the higher the score, the better the quality of the study in question. 
Effi cacy Assessment
The assessment of effi cacy was expanded with a responder-analysis when deemed 
possible. Numbers Needed to Treat (NNT) and Numbers Needed to Harm (NNH) 
were calculated as measures of the number of patients that have to be treated with the 
medication researched as compared to placebo in order to obtain one added successful 
treatment (responder) or one extra adverse event. By using this approach, we were 
able to transform the results of these studies so that they became relatively comparable.
Results
About 950 publications were found, of which 70 articles were selected on the 
grounds of the criteria for inclusion. After applying the criteria for exclusion, we were 
left with 14 articles considered to be appropriate.8-21  Of the 56 excluded articles, 22 
were excluded because they had been published before 1980, three were excluded 
because the antipsychotics had been administered only intramuscularly and 31 were 
not taken into account because of various combinations of the other exclusion 
criteria.
Quality assessment
Table 1 shows the quality assessment of the 14 studies available, presented in rank 
order of quality. The number of quality points assigned to the different studies varied 
from 49 to 85. No one study satisfi ed all criteria, and each study showed various 
methodological limitations.
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Table 1.
Assessment of methodological quality of 14 randomized controlled trials on the effi cacy of 
antipsychotics for neuropsychiatric symptoms in dementia, published between 1980 and 2005 
First author, publication year A B C D E F G H I J K L Total
Maximum score 8 5 10 12 10 8 7 12 8 5 5 10 100
De Deyn 11, 1999 7 5 10 8 4 6 0 12 7 5 5 10 85
Katz 14,  1999 5 5 10 8 4 6 0 12 7 5 5 10 77
Brodaty 10, 2003 6 5 10 10 8 6 0 4 7 5 5 10 76
Teri 8, 2000 6 5 6 6 4 6 7 10 2 5 5 10 72
Street 15, 2000 6 5 6 6 4 6 7 6 7 3 5 10 71
Devanand 13, 1998 4 5 4 6 8 4 7 12 8 3 0 10 71
Verhey 20, 2005 6 5 6 6 4 6 0 6 8 5 0 10 64
Ballard 19, 2005 4 5 6 5 10 6 0 6 8 5 0 10 64
De Deyn 12, 2004 3 5 10 6 4 8 0 6 7 3 0 10 62
Deberdt 21, 2005 3 5 10 4 4 4 0 4 7 5 5 10 61
Allain 9, 2000 5 5 10 2 6 6 0 4 7 3 5 8 61
Pollock 16, 2002 5 5 4 4 8 8 7 0 7 3 0 8 59
Auchus 18, 1997 2 5 2 8 8 6 7 0 7 3 0 10 58
Carlyle 17, 1993 3 5 4 2 8 6 0 4 3 3 5 6 49
Notes: 
A. Homogeneity of the study population, B. Treatment allocation randomized and blinded, C. Group size, 
D. Prognostic comparability at baseline, E. Loss-to-follow up (% drop-out and loss-to-follow-up not leading to 
bias), F. Adequate description of intervention (both active drug and placebo), G. Co-intervention (comedication 
and rescue medication) described and comparable between study groups, H. Patient, therapist and observer 
blinded, I. Adequate outcome measures (and measurements were carried out blinded), J. Duration of follow-up 
and timing comparable for each group, K. Adequate description of side effects, L. Data presentation and statistical 
analysis
 
Interventions
Of the 12 placebo-controlled studies, fi ve evaluated the effect of haloperidol, four that 
of risperidone, three that of olanzapine, one that of tiapride, one that of perphenazine 
and one that of quetiapine. In two non-placebo controlled studies haloperidol was 
compared to loxapine and olanzapine. The time frame of the studies in question 
varied from 2.5 to 26 weeks. 
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Patients
We found a large heterogeneity in terms of the composition of the patient groups 
between the included studies (see Table 2). The average age of the patients in 
the study cohorts of the studies ranged from 72 to 84 years. The patients had a 
moderate to severe cognitive impairment, characterised by a mean Mini Mental State 
Examination score varying from 5.5 to 15.2 (the maximum is 30, representing no 
cognitive impairment) and a diagnosis of Alzheimer’s dementia (36-100%), vascular 
dementia (0-31%) or a mixture of both (0-16%).
Table 2. 
Characteristics of patient groups of 14 randomized controlled doubleblind trial on the effi cacy 
of antipsychotics for neuropsychiatric symptoms in dementia, 1980-2005 *(see table 3 for the 
study outcomes)
Author, Intervention and N Duration Wash out Mean age  Gender Dementie Mean Setting
publication  and daily study  of inter- period of (SD) [range] (%female) type MMSE
year dosage (mg)  vention previous    (SD)
   (weeks) medication     [range]
    (days)   
De Deyn, 11  risperidone 1.1† 115 12 <14 81.3 [56-97] 56% 67%AD, 8.4 (7.7) Nursing home
1999 haloperidol 1.2† 115     26%VaD,  
 placebo 114     7%mix
Katz, 14 risperidone 0.5 146 12 3-7 82.7 (7.2) 68% 73%AD, 6.6 (6.3) Nursing home
1999 risperidone 1 148     15%VaD,  
 risperidone 2 162     12%mix
 placebo 161     6.6 (6.3) 
Brodaty, 10  risperidone 0.95† 167 12 <7 83.0 (7.2) 72% 58%AD, 5.5 (5.7) Nursing home
2003 placebo 170     29%VaD,   
       13%mixed
Teri, 8 haloperidol 1.8† 34 16 14 82.8 (6.6) 55% 100%AD 13.0 (7) Community
2000 trazodone 200† 37
 BMT 41
 placebo 36
Street, 15  olanzapine 5 55 6 3-14 82.8 (6.6) 61% 100%AD 6.7 (6.6) Nursing home
2000 olanzapine 10 49       
 olanzapine 15 51
 placebo 47
Devanand 13 haloperidol 2.65† 20 4 7 72.1 (9.6) 65% 100%AD 15.2 (4.6) Community
1998 haloperidol 0.71† 20
 placebo 20
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Author, Intervention and N Duration Wash out Mean age  Gender Dementie Mean Setting
publication  and daily study  of inter- period of (SD) [range] (%female) type MMSE
year dosage (mg)  vention previous    (SD)
   (weeks) medication     [range]
    (days)   
Ballard, 19  quetiapine 50-100 31 26 NR 83.8 (7.7) 80% 100%AD - Residential
2005 rivastigmine 9-12 31       care
 placebo 31
De Deyn, 12  olanzapine 1.0 129 10 <14 76.6 (10.4) 75% 100%AD 13.7 (5.1) Nursing home
2004 olanzapine 2.5 134       
 olanzapine 5.0 125
 olanzapine 7.5 132
 placebo 129
Deberdt, 21  olanzapine 5.2† 204 19 3-14 78.3 (7) 66% 81% AD, 14.4 (5.6) Community/
2005 risperidone 1.0† 196     6% VaD,  resident care/
 placebo 94     13% mix  nursing home
Allain, 9 haloperidol 3.5† 101 3 NR 79.6 (7.6) 64% AD, VaD, NR Nursing home/
2000 tiapride 175† 102     mix, %NOS  hospital
 placebo 103
Pollock, 16 perphenazine 6.5 33 2.5 3-5 80.1 (8.2) 65% 72%AD, 7.7 (6.7) Hospital
2002 citalopram 20 31     7%VaD,
 placebo 21     2%mix, 
       19%NOS
Auchus, 18 haloperidol 3 5 6 14 76 (8) 67% 100%AD 15.2 (4.6) Community
1997 fl uoxetine 20 5
 placebo 5
Carlyle, 17 haloperidol 7† 20 4 2-7 79 [65-91] 45% AD, mix,  NR Hospital
1993 loxapine 36† 20     %NOS
Notes: 
AD = Alzheimer dementia, mix = features of Alzheimer dementia and vascular dementia, MMSE = Mini Mental 
State Examination, NOS = not otherwise specifi ed, SD = standard deviation, VaD = vascular dementia. * Studies 
are listed in rank order of quality (see table 1), † = mean daily dose
Effi cacy
In four studies, specifi c symptoms were used as the primary measure of outcome, 
such as irritability,9 agitation,9 aggression 9, 10, 17 and psychosis;12 in the other studies a 
global clinical assessment 8 or the total score on a specifi c assessment scale was used. 
Very diverse instruments were used as the secondary measure of outcome to measure 
behaviour, cognition, functional condition and global impression.
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Haloperidol, risperidone and olanzapine were found to have signifi cantly favourable 
effects on the Behavioural Pathology in the Alzheimer’s Disease Rating Scale 
(BEHAVE-AD) and Neuropsychiatric Inventory- Nursing Home version (NPI-NH) 
scores (Table 3). In addition a dose of 1.2–3 mg haloperidol proved to be signifi cantly 
more effi cacious than placebo in treating psychosis and agitation 13, irritability 9 and 
aggression.9, 11 Risperidone, in a daily dose of 1.1 mg, proved to be more effi cacious 
than placebo in treating aggression,10, 11, 14 and it was reported to be effi cacious in
treating psychosis in two studies,10, 14 but not in a third one.11 In one study, risperidone 
was reported to be ineffi cacious against motor agitation;10 the other two studies 
did not provide any specifi c information on this subject.11, 14 Olanzapine was 
effi cacious for treating agitation and aggression in two studies,12, 15 but in only one 
of these studies was it also effi cacious for treating delusions and hallucinations.15 The 
remaining six studies did not reveal any difference in terms of effi cacy between 1.8 8 
or 3 18 mg haloperidol and placebo, between 1.0 mg risperidone or 5.2 mg olanzapine 
and  placebo,21 between 7 mg haloperidol and loxapine,17 between 1.8 mg haloperidol 
and 4.7 mg olanzapine,20 between 50-100 mg quetiapine and placebo 19 and between 
6.5 mg perphenazine and placebo.16 
Responders
The number of responders varied from 30 to 70% of the patients in the intervention 
group and from 30 to 66% of those in the placebo group (see Table 3). Six studies 
did not defi ne responders at all.10, 12, 16, 18-20 In two studies, the number of responders 
to haloperidol,8 risperidone 21 or olanzapine 21 was not higher than that to placebo; 
in the remaining studies, the number of responders to usual doses of antipsychotics 
proved to be larger than that to placebo, with the NNTs for haloperidol being 3–6,
9, 11, 13 for risperidone 6–8 14 and for olanzapine 3–5.15 In the only direct comparison 
between typical and atypical antipsychotics, risperidone did not give a signifi cantly 
higher number of responders than haloperidol.11
Adverse events
Haloperidol as well as olanzapine and risperidone caused extrapyramidal adverse 
events, with a large overlap between the NNHs of the three medications (haloperidol: 
4–9; olanzapine: 6–15; risperidone: 7–13) (see Table 3). Only a dose of about 1 mg 
risperidone daily did not cause more extrapyramidal adverse events than placebo,10, 
11, 14 although more extrapyramidal adverse events were reported with haloperidol 
in doses of 1.2 mg 12 and 1.8 mg 8 and  with olanzapine.15, 21 In one study, 1 mg 
risperidone was found to cause more gait disorders than placebo,21 but this dose of 
risperidone did cause less somnolence than olanzapine (NNH risperidone: 10–13 
11, 14, 21; NNT olanzapine: 3–7 15, 21). In a direct comparison between risperidone and 
haloperidol, we were unable to determine any difference in terms of extrapyramidal 
adverse events (NNH not signifi cant) and somnolence (NNH not signifi cant).11
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Table 3. 
Primary and secundary endpoints and responder analysis of the effi cacy and adverse events in 
14 randomized controlled trials of antipsychotics for neuropsychiatric symptoms in dementia, 
published between 1980 and 2005 (see table 2 for characteristics of patient groups) *,†
Haloperidol 11 as well as quetiapine 19 were associated with an accelerated cognitive 
decline, not only compared to placebo but also relative to both risperidone and 
rivastigmine.
Data on the number of cerebrovascular adverse events were incomplete in these 
studies. Two studies reported a signifi cantly larger number of strokes with either 
risperidone use (NNH, with 95% Confi dence Interval (CI) of 14 [8–41] 10 and 50 
[25–2500]21) or olanzapine use (NNH, with 95% CI of 40 [22–280] 21) than with 
placebo.10 In so far as has been reported in the available studies, the number of deaths 
as a result of a cerebrovascular events did not differ between patients administered 
placebo and those receiving haloperidol,9  risperidone10, 21  or olanzapine.21 In 
addition, there were no differences in the number of deaths (also due to other causes) 
between patients receiving placebo and those receiving haloperidol,9  risperidone10, 14, 
21 or olanzapine.12, 21
Discussion
There are very few published double-blind and placebo-controlled studies into the 
effects of antipsychotics for neuropsychiatric symptoms in dementia that also have 
an acceptably large number of patients. In addition, the methodological quality of 
the studies we assessed is highly variable. Haloperidol, risperidone and olanzapine 
have been tested numerous times in extensive trials (> 50 patients per group) of 
a reasonably acceptable quality.9-12, 14, 15, 21 There has not been enough research on 
quetiapine, loxapine and perphenazine and, with particular reference to the latter two 
antipsychotics, those studies carried out were of moderate quality.
The results of most of the more extensive and large-scale investigations have revealed 
that haloperidol, risperidone and olanzapine are effective in treating aggression and 
psychosis. These typical and atypical antipsychotics do not seem to differ greatly from 
each other in terms of effi cacy, with comparable NNTs of 3–6 and 3–8, respectively. 
Extrapyramidal symptoms and somnolence are seen with all these types of medication 
and, based on the results of the studies reviewed herein, the NNHs for risperidone 
were higher than those for haloperidol and olanzapine. This apparent advantage 
of risperidone seems to be limited to a daily dose of approximately 1 mg. A direct 
comparison of risperidone and haloperidol did not reveal any difference between 
them in terms of effi cacy and the profi le of adverse events.
While an increased risk for stroke has been reported in two studies on risperidone10, 21
and one on olanzapine,21 two retrospective studies on olanzapine, risperidone and 
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 Primary endpoint Effect Secondary endpoint Effect
 (responders defi nition)  
De Deyn, 11  BEHAVE-AD ris = pla BEHAVE-AD aggression, CGI, ris > pla
1999 total score hal > pla CMAI aggression hal > pla
 (>30% decrease)   (except for BEHAVE-AD   
    psychosis)
Katz, 14 BEHAVE-AD ris‡ > pla BEHAVE-AD psychosis and ris ‡ > pla
1999 total score (>50% decrease)  aggression, CGI, CMAI aggression
Brodaty, 10  CMAI aggression score ris > pla CMAI subscales, BEHAVE-AD ris > pla
2003 (NR)  total and psychosis, CGI (except CMAI physically 
    non-aggressive behavior)
Teri, 8 CGI-C hal = pla BRSD, RMBPC, CMAI, hal = pla
2000 (% improvement)  SCB, ABID
Street, 15 NPI-NH FxS delusions+ ola§ > pla NPI-NH, BPRS, MMSE ola║ > pla
2000 hallucinations+agitation/aggression   (except for MMSE, 
 (>50% decrease)    NPI depression)
Devanand 13 BPRS psychosis score,  hal ¶ > pla MMSE, Blessed functional hal = pla
1998 BSSD agitation,   activities
 SADS psychose (>25% afname) ** 
Verhey, 20 CMAI total score (NR) hal = ola NPI, CGI, MMSE hal = ola
2005 
Ballard, 19  CMAI total score (NR) que = pla SIB que < pla
2005 
De Deyn, 12  NPI-NH FxS score psychosis ola††= pla NPI-NH, BPRS ola > pla 
2004 (NR)   (NPI agression/anxiety, 
    positive symptom BPRS) 
Deberdt, 21  NPI FxS psychosis ola = ris = pla NPI, CMAI, PDS, CSDD, MMSE ola = ris = pla
2005 (30% decrease)
Allain, 9 MOSES irritability/ hal > pla MOSES (other subscales) hal = tia = pla
2000 aggressiveness subscale 
 (>25% decrease) 
Pollock, 16  NBRS total score, agitation, per = pla None -
2002 psychosis score (NR) 
Auchus, 18 CMAI total score hal = pla BEHAVE-AD, CSI hal = pla
1997 (NR) 
Carlyle, 17 aggression frequency total score hal = lox None -
1993 (decrease)
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 Responder analysis NNT [95% BI] EPS/abnormal gait Somnolence
 % responders vs placebo NNH [95% BI] vs placebo NNH [95 % BI] vs placebo
De Deyn, 11  ris: 54% NS ris 1.1mg: NS ris 1.1mg: 13 [6.7-137]
1999 hal: 63%  6.3 [3.4-30] hal 1.2mg: 9.0 [4.9-67] hal 1.2mg: 8.2 [5.0-23]
 pla: 47%
 (hal vs ris: NS)  (hal vs ris NS) (hal vs ris: NS)
Katz, 14 ris: 0.5mg NR ris 0.5mg : NS ris 0.5mg : NS
1999 ris 1mg : 45%  8.3 [4.4-85] ris 1mg : NS ris 1mg : 11 [6.1-63]
 ris 2mg : 50%  5.9 [3.6-16] ris 2mg: 7.2 [4.7-16] ris 2mg : 5.0 [3.6-8.4]
 pla : 33% 
Brodaty, 10  NR  ris 0.95mg: NS ris 0.95mg: 8.9 [4.8-70]
2003
Teri, 8 hal: 32% NS hal 1.8mg: 4.2 [2.4-18] hal 1.8mg: NS
2000 tra: 41%  NS tra 200mg: NS tra 200mg: NS
 BMT: 32%  NS BMT: NS BMT: NS
 pla: 31% 
Street, 15 ola 5mg: 66% 3.3 [2.1-9.0] ola 5mg : 5.7 [3.5-16] ola 5mg : 5.4 [3.1-19]
2000 ola 10mg: 57%   4.6 [2.4-52] ola 10mg : 8.4 [4.5-71] ola 10mg : 5.1 [3.0-18]
 ola 15mg: 43% NS ola 15mg : 6.4 [3.7-23] ola 15mg : 3.4 [2.3-6.8]
 pla : 37%  
Devanand 13 hal 2.7mg: 60% 3.3 [1.7-167] hal 2.7mg: 5.0 [2.6-41] -
1998 hal 0.7mg: 30% NS hal 0.7mg: NS
 pla:  30% 
Verhey, 20 NR  hal 1.75 vs ola 4.71mg: NS hal 1.75mg vs ola 4.71mg:NS
2005 
Ballard, 19  NR  - -
2005 
De Deyn, 12  NR  - -
2004
Deberdt, 21  ola : 62% NS ola : 15 [8.3-15] ola : 6.8 [4.4-15]
2005 ris : 64% NS ris : 13 [7.6-40] ris : 9.7 [5.5-40]
 pla : 66%   
Allain, 9 hal: 69% 4.9 [3.0-14] hal 3.5mg: 5.9 [3.5-20] hal 3.5mg: NS
2000 tia: 63% 7.0 [3.6-143] tia 175mg: NS tia 175mg: NS
 pla: 49%   
Pollock, 16  NR  - -
2002 
Auchus, 18 NR  - -
1997 
Carlyle, 17 hal: 55%  - -
1993 lox: 70%
 (hal vs lox: NS)
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Notes: 
CI = confi dence interval, EPS = extrapyrimidal symptoms, NR = not reported, NS = not signifi cant (when the 95% 
confi dence interval includes infi nity (∞), the active drug is not signifi cantly more effi cacious than placebo or any 
other drug), NNH = number needed to harm, NNT = number needed to treat, 
* Interventions: BMT = behavioural management techniques, hal = haloperidol, lox = loxapine, ola = olanzapine, 
per = perphenazine, pla = placebo, que = quetiapine, ris = risperidone,  tra = trazodone, tia = tiapride 
† Assessment instruments: ABID = Agitated Behaviour Inventory for Dementia, BEHAVE-AD = Behavioural 
Pathology in Alzheimer’s Disease Rating Scale, BPRS = Brief Psychiatric Ratring Scale, BRSD = Behaviour Rating 
Scale for Dementia, BSSD = Behavioural Syndrom Scale for Dementia, CGI(C) = Clinical Global Impression of 
Change, CMAI = Cohen Mansfi eld Agitation Inventory, CSDD = Cornell Scale for Depression in Dementia, 
CSI = Caregiver Stress Inventory, MOSES = Multidimensional Observation Scale for Elderly Subjects, NBRS = 
NeuroBehaviour Rating Scale, NPI(-NH) (FxS) = Neuropsychiatric Inventory (-Nursing Home version)(Frequency 
X Severity score), PDS = Progressive Deterioration Scale, RMBPC = Revised Memory and Behaviour Problem 
Checklist, SADS = Schedule for Affective Disorders and Schizophrenia, SCB = Screen for Caregiver Burden, SIB = 
Severe Impairment Battery 
‡ For risperidone 1mg and 2mg, § For olanzapine 5mg and 10mg (not for 15mg), ║ olanzapine 5mg and not for 
10mg and 15mg, ¶  Haloperidol standard dose only; ** other primary endpoints: BSSD agitation score showed 
a signifi cant NNT for haloperidol 2.7mg only and SADS psychose score did not show signifi cant NNT for 0.7mg 
or 2.7mg, †† only effi cacious for olanzapine 7.5mg (Last Observation Carried Forward analyses) and not for 
olanzapine 1.0mg, 2.5mg en 5.0mg
quetiapine in patients with dementia did not fi nd any such increased risk.22, 23 These 
warnings of cerebrovascular adverse events with olanzapine as well as risperidone are 
based on an amalgamation of data sets from various registration studies that have only 
been published in part. Due to the absence of well-designed, large-scale investigations, 
a class-effect on cerebrovascular morbidity and mortality cannot be defi nitively 
excluded.6 The presence of such a class-effect does seem likely on the basis of data 
from a recent meta-analysis.24
It is very important to be careful in interpreting the outcome of the various studies, 
notably because of the heterogeneity of the patient populations and the high and 
selective quantity of drop-outs, predominantly from adverse events. Another important 
limitation to obtaining valid data is the fact that various studies on this topic remain 
unpublished,24 with the possibility that there is a publication bias. 
Although a description of the effi cacy and the adverse events in terms of NNTs and 
NNHs is the most commonly used approach for formulating a clinically relevant 
measure of outcome, the responder criteria vary between the different studies. For this 
reason we decided not to attempt a statistical pooling (meta-analysis) of the results. 
To date,  no unequivocal responder criteria are available for antipsychotics used in 
treating neuropsychiatric symptoms; consequently, the heterogeneity in the research 
results will remain for the time being, and extreme alertness is advised with respect to 
differences in defi nitions when interpreting NNTs and NNHs.
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In summary, it can be stated that a large number of investigations have presented a 
credible case for the effi cacy of haloperidol, risperidone and olanzapine in treating 
neuropsychiatric symptoms in dementia and that atypical and classic types of 
medication are equally effi cacious. In the case of equal effi cacy, a choice will have to 
be made based on the profi le of adverse events, which has, in the studies assessed here, 
generally been described both too concisely and incompletely. The importance of the 
formal warnings could not properly be assessed on the grounds of the investigations 
published. In principle, however, the atypical medications olanzapine and risperidone 
are contra-indicated in the case of cardiovascular comorbidity. Given the obscurity 
that surrounds potentially severe adverse events – even after our assessment of all 
of the relevant published studies – we strongly advocate imposing an obligation on 
pharmaceutical companies to be forthcoming about all of the data on adverse events. 
We suggest that they should be obliged to publish these data after receiving warnings 
from the regulatory authorities on severe adverse events of one (or more) of their 
medications.
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Abstract 
Objective  
To estimate the prevalence of neuropsychiatric symptoms of dementia patients in 
Dutch nursing homes. 
Methods 
Cross-sectional study in a large sample of 1322 demented patients living in 59 
dementia special care units (SCUs) in the Netherlands. Symptoms were observed by 
licensed vocational nurses during regular care-giving in a two-week observational 
period prior to assessment. Neuropsychiatric symptoms were assessed using the 
Neuropsychiatric Inventory- Nursing home version (NPI-NH; frequency × severity 
score ≥ 4) and the Cohen-Mansfi eld Agitation Inventory (CMAI; symptoms 
occurring at least once a week). 
Results
More than 80% of these patients suffered from at least one clinically signifi cant 
symptom, as defi ned with the NPI-NH frequency × severity score ≥ 4. Measured 
with the NPH-NH agitation/aggression, apathy and irritability were the most 
frequently observed behaviours, with prevalences of 30-35%. Using the CMAI, 
85% of the patients showed at least one symptom of agitation, of which general 
restlessness was observed most frequently (44%). Other frequently observed symptoms 
with prevalence rates of 30% were cursing or verbal aggression, constant request for 
attention, negativism, repetitious sentences, mannerisms, pacing, and complaining. 
Physically aggressive symptoms such as hitting, kicking, biting occurred less often 
(less than 13%).
Conclusions  
Prevalence rates of neuropsychiatric symptoms in Dutch nursing home patients with 
dementia residing in SCUs are high, especially agitation and apathy. Insight into the 
prevalence rates of individual symptoms in patients with dementia has important 
practical consequences for the accurate planning of staff allotment and stresses the 
need for patient oriented care.  
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Introduction
Dementia is an incurable disease with substantial effects on cognition, activities of 
daily living and behaviour, resulting in a considerable loss in the quality-of-life of 
both patients and caregivers. Neuropsychiatric symptoms are a particularly heavy 
burden for the caregiver, 1, 2 and these are the main reason for institutionalization. 3-5 
In the Netherlands, 30,000 dementia patients currently reside in nursing homes,6 
which is approximately 20% of all persons with dementia. Figures on the prevalence 
of neuropsychiatric symptoms are badly needed because of its consequences for 
the psychosocial and pharmacological interventions that are necessary to improve 
the quality of life of these patients. Furthermore these fi gures can assist in the 
development of caregiving plans that can provide appropriate care against reasonable 
costs.
Many authors have estimated the prevalence of neuropsychiatric symptoms – usually 
referred to as agitation/psychosis, depression/apathy – in demented patients.7 
The majority of these studies involved community-dwelling patients or patients 
temporarily admitted to hospitals or research clinics. Only recently have several studies 
addressed the neuropsychiatric symptoms of nursing home patients, being prevalent 
in more than 80% of the patients.8-11 Agitation/aggression occurred in 48–83% of the 
patients, with 11–44% of these showing physical aggression.8-12, 13 , 14-19 
Apathy was prevalent in 17–41%,8-11 delusions and hallucinations in 12–49% and 
5–39%, respectively,8-12 and depressive symptoms were seen in 10–51%.8-11, 16, 20-22 
The reported prevalence rates of specifi c symptoms varied because studies not 
only differed with respect to the assessment scales used and the population studied, 
but prevalence rates also seemed to differ between countries. To date, data on 
the prevalence of neuropsychiatric symptoms in demented patients are available 
from many countries. However, no fi gures are available on the prevalence of 
neuropsychiatric symptoms in large groups of Dutch nursing home patients with 
dementia. Nursing homes in the Netherlands differ from their counterparts in other 
countries in that the staff includes specially trained nursing home physicians (one 
full-time doctor per 100 patients), physical therapists, occupational therapists, speech 
therapists, pastoral workers, dietarians, psychologists, social workers and, occasionally, 
music therapists and psychomotor therapists, all of whom are employed by the nursing 
home.23, 24 Care for people with dementia is generally provided in special care units 
(SCUs), where patients usually live in small groups of about 6–12 persons. 
The objective of this study was to determine the prevalence of neuropsychiatric 
symptoms in general – and aggression and agitation in particular –  in a large sample 
of patients residing in dementia SCUs in Dutch nursing homes. 
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Methods
Study design, selection of patients and ethical considerations
This was a cross-sectional cohort study. All of the 72 nursing homes providing the 
specialist training program for nursing home physicians in cooperation with the 
Department of Nursing Home Medicine of the Radboud University Nijmegen 
Medical Centre  (the Netherlands) were asked to participate in the study. The 25 
nursing homes that ultimately agreed to participate are situated in the eastern, 
northern and southern part of the Netherlands. Of the total amount of 117 dementia 
SCUs in the 25 nursing homes, 59 SCUs (50%) participated in this study. The 
managing director of these institutions selected the dementia SCUs to be assessed. 
The participating SCUs did not differ with respect to admission policy towards 
patients with neuropsychiatric symptoms or dementia stage/care level of non-
participating SCUs. Although 5 SCUs are especially built for demented patients 
with high levels of neuropsychiatric symptoms, neuropsychiatric symptoms are not a 
prerequisite to be admitted on the other 54 SCUs. 
Patients were considered for inclusion provided they (1) met the Diagnostic and 
Statistical Manual of Mental Disorders fourth edition (DSM-IV) criteria 25 for 
dementia and (2) resided in the nursing home more than four weeks . Terminally ill 
patients were excluded. 
The study was undertaken in accordance with the Declaration of Helsinki and 
the guidelines on Good Clinical Practice. Approval of the regional research ethics 
committee was obtained. Informed consent was acquired from a primary family 
member or legal guardian of the patients. 
Data collection and assessments
The assessments took place within a 4-week period in 2003. All licensed vocational 
nurses, who had been specifi cally assigned to individual patients, were trained and 
instructed to observe symptoms during a two-week period. At the end of the 
two-week observation period the vocational nurses were interviewed by trained 
nurse-assistants. The interviews were structured, following guidelines provided by a 
written manual, with the aim of eliciting specifi c observations of all neuropsychiatric 
symptoms. The interviewers were trained by two researchers (SZ, ED) during a two-
hour session prior to the study. 
Neuropsychiatric symptoms were assessed with the Neuropsychiatric Inventory-
Nursing Home version (NPI-NH), a scale originally developed by Cummings 26, 
27 as a means to assess neuropsychiatric symptoms in demented outpatients. The 
nursing home version was developed for the use of professional caregivers within 
institutions and proved to be valid and reliable for trained nursing staff.28, 29 The NPI-
NH is the only nursing home instrument for assessing neuropsychiatric symptoms 
that has been translated into Dutch.30 The NPI-NH includes 12 neuropsychiatric 
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symptoms: delusions, hallucinations, agitation, depression, anxiety, euphoria/elation, 
apathy/indifference, disinhibition, irritability, aberrant motor behaviour, night-
time disturbances and appetite/eating change. Both the frequency (F) and severity 
(S) of each symptom are rated on a four- (1–4) and three-point (1–3) Likert scale, 
respectively. A separate score can be calculated for each symptom by multiplying the 
frequency and severity scores (FxS score), resulting values ranging from zero to 12 for 
each symptom. 
Agitation and aggression were assessed using the Cohen Mansfi eld Agitation 
Inventory (CMAI). This instrument, originally developed by Cohen-Mansfi eld,31 is 
designed to assess 29 agitated or aggressive behaviours and has been extensively used 
for assessment purposes in nursing homes. The original CMAI has been validated by 
Miller 32 and is the only instrument specifi cally addressing agitation or aggression that 
has been translated into Dutch. The Dutch CMAI (CMAI-D) has been validated.33 
The frequency of each symptom is rated on a seven-point scale (1–7) ranging from 
‘never’ to ‘several times an hour’. 
To describe the severity of the dementia the psychologist (or nursing home physician) 
assessed the disease stage using the Global Deterioration Scale,34 which consists of a 
seven-point scale (1–7) ranging from no global impairment (1) to very severe global 
impairment (7). Baseline characteristics, such as age, sex, marital status and time of 
institutionalization, were retrieved from the patients’ charts. Finally, data on the actual 
use of psychoactive medication on the day of assessment were registered. Psychoactive 
medications were classifi ed using the Anatomical Therapeutical Chemical-
classifi cation 35 and grouped into antipsychotics, anxiolytics, hypnotics/sedatives, 
antidepressants, anti-epileptics and miscellaneous (e.g. cholinesterase inhibitors). 
Analysis
In this study, clinically relevant neuropsychiatric symptoms measured with the NPI-
NH were defi ned by a F × S score for each individual symptom, with a score of ≥ 4 
taken as being likely to represent patients with clinically signifi cant behaviour.9, 28 
Agitation measured with the CMAI was defi ned as behaviour occurring at least once 
a week or more (frequency score ≥ 3). 
Results
One proxy gave no informed consent, and this patient was subsequently excluded; all 
other eligible (n=1322) patients were included.  The mean age of these patients was 
83.0 years, and the female to male ratio was 4:1(table 1).  At the time of the study, all 
of the participants had lived in the nursing home an average of 20 months. This mean 
age (95% Confi dence Interval, 95%CI) of 83.0 years (82.6–83.4) was slightly higher 
and the percentage of males (20%) was lower than national fi gures derived from the 
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(total) number of patients in SCUs of nursing homes in the Netherlands (81.8 years 
and 25% male).36 The majority of the patients were in Global Deterioration Scale 
(GDS) stage 6. Some kind of psychoactive medication was prescribed in more than 
60% of the patients, mostly antipsychotics (37%) or antidepressants (27%).
Table 1. 
Characteristics of the 1,322 Nursing Home Patients with Dementia Participating in the Study
Age (years)
 mean ± SD 83.0 ± 8.1
 Range 36–102
Sex
  (% male) 20
Marital status
 Married (%) 20
 Widow/Widower (%) 67
 Divorced (%) 5
 Unmarried (%) 9
Duration of institutionalization (months)
 Mean 20
 Range 1–119
Global Deterioration Scale (GDS)
 GDS 3 (%) 0.2
 GDS 4 (%) 3
 GDS 5 (%) 18
 GDS 6 (%) 51
 GDS 7 (%) 28
Psychoactive medication use (total, %)  65
 Antipsychotic drugs (%) 37
 Antidepressant drugs (%) 27
 Anxiolytic drugs (%) 16
 Hypnotics/sedatives (%) 15
 Antiepileptic drugs (%) 6
 Cholinesterase inhibitors or nootropil (%) 1
Note: 
All percentage values are presented as percentages of the total group
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Of the patients assessed, 81% had clinically relevant neuropsychiatric symptoms, with 
a NPI-NH FxS score ≥ 4 for at least one symptom. A majority of the patients (61%) 
had multiple symptoms, with 18% scoring ≥ 4 on two items, 14% scoring ≥ 4 on 
three items, 11% on four items and 19% on more than four items. Apathy, irritability, 
aberrant motor behaviour and agitation/aggression were the most prevalent 
neuropsychiatric symptoms, with rates of about 30% (fi gure 1). Psychotic symptoms, 
such as delusions and hallucinations, appeared to occur in 15 and 8%, of the patients, 
respectively, while depression and anxiety occurred in 20% of the patients.
Figure 1. 
Delusions
Hallucinations
Agitation
Depression
Anxiety
Euphoria
Apathy
Disinhibition
Irritability
Aberrant motor behavior
Night time disturbances
Eating change
Neuropsychiatric Inventory- Nursing home version (NPI-NH) prevalence rates of neuropsychiatric symptoms in 
1,322 nursing home patients (Frequency × Severity symptom score ≥ 4). The numbers in the fi gure refer to 
percentages.
Some type of agitated behaviour, as measured by the CMAI, was shown by 85% of 
the patients (table 2); of these, 74% had two symptoms or more, and 63% had three 
symptoms or more. The median (range) number of symptoms was 4 (0–23). The most 
prevalent item was general restlessness, which occurred in 44% of the patients. Other 
frequently occurring symptoms were cursing or verbal aggression, constant request for 
attention, repeating sentences, mannerisms, negativism and pacing, all with prevalence 
rates of about 30%. Physical aggression, such as hitting, kicking and biting, was 
prevalent in 13%, 7% and 8% of the patients, respectively.  
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Table 2. 
CMAI prevalence rates (%) in 1,322 nursing home patients, occurring at least once a week.
General restlessness 44
Cursing or verbal aggression 33
Constant request for attention 32
Negativism 31
Repetitious sentences/ questions 30
Pacing 29
Performing repetitious mannerisms 28
Complaining 26
Grabbing 24
Making strange noises 20
Inappropriate robbing/ disrobing 18
Handling things inappropriately 18
Get to different place 16
Hitting 13
Screaming 13
Hoarding things 12
Hiding things 10
Pushing 9
Scratching 8
Spitting 8
Kicking 7
Hurting oneself or others 5
Tearing things 5
Throwing things 4
Biting 3
Eating inappropriate substances 3
Verbal sexual advances 2
Physical sexual advances 2
Intentional falling 1 
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Discussion
The results of this study reveal that behavioural problems were very common among 
this large sample of Dutch nursing home patients with dementia. More than 80% of 
the study population had at least one clinically relevant symptom, while the majority 
of the patients had multiple symptoms. To date, fi ve studies have used the NPI-NH 9, 11 
and CMAI to estimate the prevalence of neuropsychiatric symptoms in nursing home 
patients with cognitive impairment.11, 15, 17, 19 In the present study, the overall prevalence 
rates on any one symptom, as measured with the NPI-NH and CMAI (81 and 85%, 
respectively), were very similar to those reported in earlier studies – 84% 9 and 85% 11 
using the NPI; and 82% 15, 83% 11, 19 using the CMAI. Also, the prevalence rates of 
individual symptoms assessed with the NPI-NH and CMAI were generally in line 
with those found in the earlier studies.9, 11, 15, 17, 19
To the best of our knowledge, the present study is the largest one of its kind to be 
carried out on the prevalence of neuropsychiatric symptoms in demented nursing 
home patients. The cohort population comprised 4.4% of all demented nursing home 
patients in the Netherlands. This study, however, may have some limitations with 
respect to the validity of generalizing the data to the nursing home population at a 
national level. Although there does not seem to have been a selection by the nursing 
home itself for any one specifi c SCU, the age and sex distribution of our patient 
sample differ slightly of those of the national nursing home population. A sampling 
error may occur, since only 25 of the 72 nursing homes asked to participate in the 
study complied with our request and no data on the reason for non-participation of 
the other 47 nursing homes were available. Moreover, no national data are available 
on the distribution of dementia stage and the use of psychoactive medication, which 
are both known to affect the neuropsychiatric symptom rates. 37-39 Consequently, there 
may be unknown differences between the distribution of the dementia stage and 
psychoactive medication use in our study cohort and demented patients in SCUs in 
other parts of the Netherlands, thereby making extrapolation to the Dutch national 
nursing home situation diffi cult.
In contrast to our expectations, the prevalence rates of neuropsychiatric symptoms 
in the Dutch special care setting, which differs from other comparable care settings 
throughout the world, was not lower than those elsewhere. This could be due to the 
tendency that patients with dementia prefer to live at home as long as possible and 
consequently nursing home admission is postponed. Neuropsychiatric symptoms 
are often the main reason for admission and may even be exacerbated by the typical 
nursing home environment, in which patients usually spend a considerable portion 
of their daytime hours in overcrowded communal living rooms. In the Dutch 
special care setting, patients’ neuropsychiatric symptoms may also more likely to be 
accepted, which may result in a reduced number of patients with high prevalence of 
neuropsychiatric symptoms being transferred to geriatric or psychiatric hospitals. 
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The homogeneity of prevalence estimates of neuropsychiatric symptoms – 85% 
– that has been reported by both the present and numerous other studies suggests 
that symptoms are both ubiquitous in dementia and relatively independent of 
the care setting. One should therefore be cautious to consider the prevalence of 
neuropsychiatric symptoms as an indicator of quality of care, since certain amount of 
symptoms present could be more or less accepted and may not be infl uenced by any 
intervention. 
In the present study, psychotropic medication use was high, and comparable with 
in other nursing home settings.9, 10, 40, 41 Since psychotropic medication has limited 
effi cacy,42, 43 and considerable side effects 43, 44 with a possible negative infl uence on the 
patient’s well-being,41 it would be worthwhile to reduce the amount of prescription 
of psychotropics and put more effort in psychosocial interventions.
Insight into the prevalence rates of individual symptoms in patients with dementia 
has important practical consequences for the accurate planning of staff allotment.  
Both the numbers of patients showing resistance to (morning) care and of those 
with wandering in the afternoon should be important factors to be taken into 
consideration when determining the number of staff to be employed during the day. 
This stresses the need for tailored person-centred care. To accomplish this, a detailed 
knowledge of the derailing factors and exact circumstances in which the symptoms 
occur is indispensable.  The staff should be made aware that neuropsychiatric 
symptoms can be considered to be a consequence of a patient’s failing mechanism to 
cope with or adapt to their disease.45 Also, a better understanding of the infl uence of 
physical (large or small SCUs) and psychosocial conditions on the development of 
neuropsychiatric symptoms could contribute to the reduction of symptoms and an 
improvement in the quality of life.
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Abstract
Background/Aims 
To examine the infl uence of dementia stage and psychoactive medication use on the 
factor structure of the Neuropsychiatric Inventory-Nursing Home version (NPI-NH) 
in Dutch nursing home patients. 
Methods 
The NPI-NH was administered to a large sample of 1,437 patients with mild to 
severe dementia receiving nursing home care. Exploratory factor analysis was used to 
examine behavioural dimensions underlying neuropsychiatric symptoms indicated by 
the NPI-NH across dementia stages (as assessed with the Global Deterioration Scale 
-GDS) and in patients with or without psychoactive medication prescribed.
Results  
In GDS stage 4/5, 6 and 7, a 4- or 5-factor solution was found, with factors referred 
to as agitation/aggression, depression, psychosis, psychomotor agitation and apathy. 
These symptom clusters were replicated in the group of drug-naive patients, but only 
partially in the group of patients on psychoactive medication.
Conclusion  
The factor structure of the NPI-NH in nursing home patients is consistent with the 
clinical taxonomy of symptoms, is relatively stable across dementia stages, and is only 
moderately infl uenced by psychoactive medication use. The division of depression and 
apathy into separate behavioural dimensions – also in patients with severe dementia – 
may have important therapeutic consequences. 
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Introduction
Neuropsychiatric symptoms are highly prevalent in dementia.1-3 Individual 
neuropsychiatric symptoms have been observed in variable frequencies across stages 
and subtypes of dementia,4 thereby refl ecting different biological correlates and 
psychosocial determinants.5 Systematic assessment of neuropsychiatric symptoms is 
important not only for reasons of timely diagnosis and choice of treatment options, 
but also from a taxonomy perspective, i.e. whether these psychiatric symptoms are 
associated with dementia. In an attempt to redirect research and clinical attention to 
the so-called non-cognitive symptoms of dementia, the International Psychogeriatric 
Association introduced the concept of Behavioural and Psychological Symptoms in 
Dementia (BPSD).6 However, others in the fi eld have stated that neuropsychiatric 
symptoms are too heterogeneous to be considered within the context of one unifying 
concept.5
For practical purposes, e.g. in clinical trials, symptoms are often grouped together in 
clusters or ‘syndromes’.7-9 The European Alzheimer’s Disease Consortium (EADC) 
has proposed grouping neuropsychiatric symptoms into hyperactive (agitated) 
behaviours, affective behaviours, psychosis and apathy.10, 11 Others have proposed 
splitting hyperactive behaviour into (physical) aggression/agitation and psychomotor 
agitation.12 However, the underlying relationships or behavioural dimensions of these 
symptoms may differ between various types and stages of dementia and between 
residential settings. Consequently, both for clinical and research purposes it is 
important to determine whether these underlying behavioural dimensions are robust 
and invariant in different patient samples. 
The Neuropsychiatric Inventory (NPI)13 is a well-known informant-based rating 
scale for assessing neuropsychiatric symptoms in dementia. It measures a wide range 
of neuropsychiatric symptoms and it has been validated for use in epidemiological 14 
and intervention studies.7-9 Few studies using the NPI were done in nursing home 
patients at different stages of dementia.  
Several authors used factor analysis to explore the behavioural dimensions that 
underlie different neuropsychiatric symptoms15-24 and others examined different 
clusters of patients using latent class analysis.25 In most studies 3-5 syndromes were 
identifi ed with various terminologies assigned to each syndrome. Intrinsic differences 
in the populations studied and in the severity and type of dementia assessed in these 
patients may have infl uenced these analyses, resulting in a great diversity of results 
with respect to the taxonomy of neuropsychiatric symptoms. To date, studies have 
been conducted in outpatient departments,18-20 memory clinics16 and/or Alzheimer 
units15 within a general hospital and in psychiatric hospitals,16, 22 other hospital 
settings21 or a mixed setting of outpatients and nursing home patients23 or on a 
special care unit for temporarily admitted patients.24 However, no data are exclusively 
available on chronic nursing home patients with different stages of cognitive 
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deterioration. The prevalence rates of neuropsychiatric symptoms are particularly high 
in this type of setting, since these symptoms may have been the primary reason for 
the patient to have been placed in an institution initially.26 Moreover, some behaviours 
(especially agitation and aggression) are likely to be infl uenced by social interaction, in 
the large groups with which patients residing in a nursing home must interact during 
the day 27 and/or during care deliver situations.28
In all NPI factor-analytic studies, psychoactive medication use was allowed, 
but not separately analysed.15-24 Psychoactive medication is meant to reduce 
neuropsychiatric symptoms, but some symptoms could more likely respond to these 
drugs than others.12 This selective response could affect the prevalence rate of some 
neuropsychiatric symptoms (more than others) and therefore infl uence the factor 
structure. 
The objective of this study was to explore the stability of the different behavioural 
dimensions that may underlie neuropsychiatric symptoms in dementia patients 
across different stages of cognitive deterioration, and in patients with or without 
psychoactive medication. To our knowledge, this is one of the few studies that has 
evaluated symptom associations in a large sample of nursing home patients with 
dementia.
Methods
Study design and subjects
This study is part of a cross-sectional cohort study evaluating the prevalence and 
correlates of neuropsychiatric symptoms in Dutch nursing home patients with 
dementia.29 Patients were recruited from 27 nursing homes in the Eastern, Northern 
and Southern parts of The Netherlands. Patients of 59 dementia special care units 
and 13 units for outreaching nursing home care situated in residential homes were 
included in the study. Nursing home care in The Netherlands is not restricted to the 
nursing home setting but is also provided in residential homes. This complementary 
outreaching nursing home type of care is provided by members of multidisciplinary 
nursing home teams (i.e. nurses, nursing home physician, physical therapists, 
occupational therapists and a psychologist) to demented patients still residing in a 
residential home, with the aim of postponing the admission of a patient to a nursing 
home.30 
Patients were considered for inclusion provided: (1) they met the criteria for dementia 
established by the Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
(DSM-IV)31, and (2) they had resided in the nursing home for more than 4 weeks. 
Terminally ill patients were excluded. The presence of neuropsychiatric symptoms 
was not a prerequisite to be included in the study. The study was undertaken in 
accordance with the Declaration of Helsinki and the guidelines for Good Clinical 
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Practice. The local Research Ethics Committee approved of the study. Family members 
or legal guardians of the patient gave informed consent. All eligible patients with an 
informed consent were included.
The study cohort comprised 1,437 patients (male:female, 1:4), most of whom were 
over 80 years of age (Table 1). The median length of residence in the nursing home at 
the time of the study was 18 months. Psychoactive medication was prescribed to 65% 
of the patients, antipsychotics to 37%, antidepressants to 27% and both anxiolytic drugs 
and hypnotics/sedatives to 15%. The majority of patients (77%) had severe or very 
severe cognitive deterioration (Global Deterioration Scale (GDS) stage 6 or 7). GDS 
scores refl ect different stages of dementia on a seven-point scale in which stage 1
indicates no cognitive decline and stage 7, very severe cognitive decline (severe 
dementia). 32 
Table 1. 
Patient characteristics of 1,437 nursing home patients with dementia
Age, years
 Median 83
 Range 37–102
Gender, male  276 (19)
Duration of residence in institution, months
 Median 18
 Range 1–191
Global Deterioration Scale (GDS)
 GDS stage 4, mild dementia 59 (4)
 GDS stage 5, moderate dementia 282 (20)
 GDS stage 6, moderately severe dementia 728 (51)
 GDS stage 7, severe dementia 368 (26)
Psychoactive medication use a  925 (65)
 Antipsychotic drugs 532 (37)
 Antidepressant drugs 390 (27)
 Anxiolytic drugs 222 (16)
 Hypnotics/sedatives 214 (15)
 Antiepileptic drugs 84 (6)
 Cholinesterase inhibitors, nootropics 15 (1) b
Notes: 
Figures in parentheses indicate percentages. All percentage values are percentages of the total group, a Total 
number of patients on psychoactive therapy, b Cholinesterase inhibitors are not prescribed in Dutch nursing homes
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Procedures
Licensed vocational nurses, each of whom had been specifi cally assigned to individual 
patients for care management purposes, were instructed to observe ‘their’ patients’ 
neuropsychiatric symptoms during a 2-week period. At the end of the 2-week 
observation period vocational nurses were interviewed by trained nurse assistants 
who had been trained by two researchers during a 2-hour session prior to the 
study. Supervision of the interviewers was provided by a psychologist or nursing 
home physician. The interviews were structured in that they followed guidelines 
laid down in a written manual that were aimed at eliciting specifi c observations of 
neuropsychiatric symptoms.
Neuropsychiatric symptoms were assessed with the Dutch translation of the 
Neuropsychiatric Inventory-Nursing Home version (NPI-NH).33 This scale was 
originally developed by Cummings et al.13 and Cummings 34 as a means to assess 
neuropsychiatric symptoms in demented outpatients. The nursing home version 
was developed for the use of professional caregivers within institutions and has 
been translated into Dutch;33 it has proven to be a valid and reliable assessment tool 
for trained nursing staff.14, 22 The NPI-NH consists of an assessment rating on 12 
neuropsychiatric symptoms: delusions, hallucinations, agitation, depression/dysphoria, 
anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability/lability, 
aberrant motor behaviour, night-time disturbances and appetite/eating change. Both 
the frequency (F) and severity (S) of each symptom are rated on a 4- and 3-point 
Likert scale, respectively. A specifi c and distinct score can be calculated for each 
symptom by multiplying the frequency and severity scores, resulting in a score range 
of 0-12. A total score can be calculated by summing the 12 F x S scores, yielding a 
range from 0 to 144. Clinically relevant neuropsychiatric symptoms were defi ned 
by an F x S score ≥ 4 as being likely to represent patients with clinically signifi cant 
behaviour. 14,35 
Data analysis
The factor structure of the NPI-NH was evaluated using exploratory factor analysis 
(SPSS 9.0.1; SPSS Inc., Chicago, Ill.). Separate analyses were performed for patients 
in GDS stages 4/5, 6 and 7; and for groups of patients with or without prescribed 
psychoactive medication. In the fi rst analysis, factors with eigenvalues >1 (a measure 
of the percentage of variance) were extracted and orthogonally rotated to achieve 
simple structure (Varimax). In the second analysis, oblique rotation of the factors was 
applied (Direct Oblimin), as we expected signifi cant correlations between NPI-NH 
factors. Items with factor loadings (a measure of the degree of correlation) higher 
than or equal to 0.4 were considered to be relevant. 
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Results
Prevalence rates (for NPI items with an F x S score ≥ 4) and mean F x S scores of 
neuropsychiatric symptoms are given in table 2. High prevalence rates were shown for 
apathy, agitation, irritability and aberrant motor behavior (about 30%). Euphoria and 
hallucinations are the lowest occurring symptoms (about 7%). 
Table 2. 
F x S scores and prevalence of individual neuropsychiatric symptoms in 1,437 Dutch nursing 
home patients with dementia, measured with the Dutch version of the NPI-NH
NPI-NH symptoms F x S score Prevalence
  mean ± SD (F x S score ≥ 4)
A. Delusions 1.17 ± 2.70 14.4
B. Hallucinations 0.64 ± 1.94 7.7
C. Agitation/aggression 2.59 ± 3.64 31.0
D. Depressed mood 1.76 ± 3.19 20.1
E. Anxiety 1.80 ± 3.26 20.9
F. Euphoria 0.61 ± 2.05 7.2
G. Apathy 3.20 ± 4.42 34.2
H. Disinhibition 1.69 ± 3.27 19.7
I. Irritability 2.70 ± 3.60 33.3
J. Aberrant motor behaviour 2.51 ± 4.09 28.4
K. Night-time behaviour 1.02 ± 2.50 12.1
L. Eating change 1.97 ± 3.67 23.4 
Factor analysis
The factor analyses of patients in GDS stage 4/5, 6 and 7 and of patients with 
or without prescribed psychoactive medication are presented in tables 3 and 4, 
respectively. Medication use was not independent of dementia stage and was highest 
in GDS stage 6. In GDS stage 6, 71% used one or more psychoactive drugs, compared 
to 60% in GDS stage 4/5 and 56% in GDS stage 7 (χ2, p < 0.0005).
Factor analysis of GDS stage 4/5 data showed a 4-factor solution that explained 57% 
of common variance (Table 3). Factor 1 consists of agitation, disinhibition, irritability 
and delusions and was named ‘agitation/aggression’; factor 2 (‘mood/psychosis/ 
psychomotor agitation’) consists of depression, anxiety, delusions, hallucinations, 
aberrant motor behaviour, and night-time behaviour; factor 3 (‘apathy’) includes 
apathy and eating disorders; and factor 4 euphoria. 
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 Table 3. 
Results of the factor solution analysis of the NPI-NH (F×S score) in 1,437 Dutch nursing 
home patients with dementia in GDS stages 4/5, 6 and 7. 
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Table 4.
Results of the factor solution analysis of the NPI-NH (F×S score) in 1,437 Dutch nursing 
home patients with dementia with or without psychoactive medication. 
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For GDS stage 6 a 5-factor solution was found that explained 61% of the variance, 
with a factor ‘agitation/aggression’ for agitation, disinhibition, irritability (and 
euphoria); a factor ‘depression’ for depression and anxiety; a factor ‘psychosis’ for 
delusions and hallucinations; a factor ‘psychomotor agitation’ for aberrant motor 
behaviour and night-time behaviour; and a factor ‘apathy’ for apathy and eating 
disorders. For GDS stage 7, a 5-factor solution was found (explaining 61% of the 
variance) also with a factor ‘agitation/aggresion’ including agitation and irritability, 
a factor ‘psychosis’ including delusions, hallucinations and disinhibition, a factor 
‘depression’ including depression and anxiety, a factor ‘apathy’ including apathy and 
aberrant motor behaviour and a factor for night-time behaviour and eating disorders.
The factor structure of patients in drug-naive patients was somewhat different from 
that of those patients using psychoactive medication (table 4). In the drug-naive 
patients the same 5-factor solution was found with factors for agitation/aggression, 
psychosis, depression, apathy and psychomotor agitation as in GDS stage 6. Only 
euphoria loaded on the psychomotor agitation cluster instead of the agitation/
aggression cluster. In patients using one or more psychoactive drugs, a 4-factor 
solution was revealed, in which symptoms in the factors apathy and psychomotor 
agitation clustered together. Night-time behaviour also loaded on the psychosis 
cluster.  
Results after oblique rotation of factors were very similar to those described after 
orthogonal rotation; in different GDS stages and with or without psychoactive 
medication the same number of factors were found and the same combination of 
symptoms loaded to each factor, except for GDS stage 7 where disinhibition loaded 
on the ‘psychosis’ factor.
Discussion
This study shows that neuropsychiatric symptoms in nursing home patients with 
dementia were related. While some associations between individual symptoms – as 
measured with the NPI-NH – were infl uenced by dementia severity, the behavioural 
dimensions or ‘syndromes’ underlying neuropsychiatric symptoms, i.e. agitation/ 
aggression, psychosis, depression, psychomotor agitation and apathy were not. 
The stability of the factor structure has been replicated by others.19, 23 With respect to 
the 5 factors, the cluster agitation in this study generally corroborates the fi ndings of 3 
other studies 21-23, the cluster psychosis is consistent with that found in 6 other studies 
16, 19, 21-24 and the cluster depression is consistent with the results of 3 other studies.15, 
23, 24 Psychomotor agitation (a combination of aberrant motor behaviour and night-
time disturbances) is only replicated by 2 studies.14, 22 Apathy as a single symptom or 
together with eating disorders or disinhibition has never been replicated by any other 
study. 
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Our fi nding that apathy and depression belong to different underlying dimensions is 
supported by 2 studies using the NPI.16, 21 In two other studies, however, apathy and 
depression belong to the same underlying behavioural dimension.19, 23 A possible 
explanation for the confl icting results may be that the clustering of apathy and 
depression depends on the severity of cognitive deterioration. Apathy and not 
depression appeared to be associated with cognitive dysfunction.36 Depression tends to 
occur more frequently during the earlier stages of dementia,2 while the prevalence of 
depressive symptoms or major depression is relatively low in more severely demented 
patient samples,2, 37, 38 perhaps due to the patient’s loss of awareness of deterioration 
or his inability to communicate these symptoms; in contrast, apathy is more prevalent 
in the latter group.37 The shift from depression towards apathy in the severe stages 
of the disease may (partially) explain why apathy and depression are based on two 
distinct behavioural dimensions in this study (with patients with moderate to severe 
dementia) as well as in the study by Hollingworth et al. (in the subgroup of patients 
with GDS 5-7)23, while in patients with relatively mild stages of dementia,19, 23 apathy 
and depression are part of the same cluster. In addition, the relationship between 
depression and apathy may change over the course of dementia: while it may be part 
of an affective disorder in the early stages, apathy may develop into a phenomenon in 
its own right with a separate, probably more neurobiological pathogenesis in advanced 
stages due to frontal lobe (or widespread cortical) dysfunction.39
Aberrant motor behaviour was associated with night-time disturbances in severe 
cognitive deterioration (GDS stage 6). Aberrant motor behaviour comprises 
symptoms like pacing, constant opening/closing wardrobes, repeatedly dressing 
or undressing and picking/fi ddling or other repetitive behaviour. This fi nding is 
consistent with the cluster concept psychomotor agitation, described by Lawlor and 
Bhriain.12 
The 5 clusters (underlying behavioural dimensions), i.e. agitation/aggression, 
psychosis, depression, psychomotor agitation and apathy, were also found in a 
subgroup of drug-naive patients. However, in the group of patients on psychotropic 
medication, symptoms of the cluster ‘apathy’ and ‘psychomotor agitation’ were 
grouped together. Possibly, adverse events of psychoactive medication such as 
somnolence or extrapyramidal symptoms have been misinterpreted as apathy and 
psychomotor agitation, respectively. Moreover, the correlation between symptoms 
could change – and the factor structure accordingly – because of a selective reduction 
of prevalence and severity of some behavioural symptoms by the effect of the 
psychoactive medication.
To the best of our knowledge the present study is the largest factor-analytic study 
of patients with severe dementia. The sample covers 4.4% of all demented patients 
that receive nursing home care in the Netherlands. The study cohort was a relatively 
homogeneous and representative sample of patients without a priori behavioural 
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problems receiving nursing home care, not only in dementia special care units within 
nursing homes but also in residential homes through outreach care programmes. 
Special care was taken to ensure the reliability of the data through special training 
and supervision of the interviewers and the requirement that registered nurses make 
the assessments, thereby ensuring that the best qualifi ed person was available for each 
patient. 
There are a number of limitations to this study. (1) We did not have reliable data 
on dementia subtype. Some authors found similarities across diagnoses of dementia 
subtypes,1 others did not.40-43 However, the latter fi ndings would not necessarily 
imply that the correlation between symptoms would be affected by dementia subtype. 
In fact, in a separate analysis of patients with Alzheimer’s disease the same factor 
structure was found.19 (2) We have tried to distinguish neuropsychiatric symptoms in 
different stages of dementia from adverse reactions of psychoactive medication, and 
have tried to test whether the effect of medication could (selectively) have infl uenced 
the correlation between symptoms, by performing a separate analysis in drug-
naive patients and in patients with prescribed psychotropic medication. However, 
psychoactive medication use is not independent of dementia stage (medication was 
most frequently described in GDS stage 6). (3) We used the NPI as a measure of 
neuropsychiatric symptoms. The NPI is a rating scale with established validity which 
has been used on many diverse patient cohorts. Therefore, although it is possible 
that some symptoms were diffi cult to assess in the moderate to severe dementia 
patients, the procedure used in this study can be considered to be a valid measure of 
neuropsychiatric symptoms. 
Our fi ndings may have two important implications for clinicians as well as researchers 
interested in the taxonomy of neuropsychiatric symptoms in dementia. First, the 
results of this study imply that the severity of dementia only partially infl uences the 
correlation between individual symptoms, but that the clusters of the neuropsychiatric 
symptoms, i.e. agitation/aggression, psychosis, depression, psychomotor agitation and 
apathy (as proposed by Lawlor and Bhriain12), are valid and stable across dementia 
stage. Even in severe dementia, when some behaviours dealing with patients’ inner 
experience (depression, anxiety, delusions, hallucinations) are more diffi cult to observe, 
different factors can clearly be distinguished. Our fi ndings are in accordance with 
the results of pharmacological studies, which have shown that treatments have a 
consistent effect on behavioural problems in dementia when studying behavioural 
sub-syndromes,7, 12 but not when studying individual symptoms. Symptom clusters 
can therefore be used to study populations with further deterioration of the disease, 
e.g. in longitudinal research involving clinical trials. However, one would be cautious 
about interpreting clusters at the level of individual symptoms. Second, the fi nding 
that apathy and depression are distinct ‘syndromes’ may have important therapeutic 
consequences. Clearly apathy without depressive symptoms should not be treated 
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with antidepressants because of the risk of adverse reactions. Also depression should 
not be mistaken for apathy because of the treatment options for depression. We 
emphasize that the timely diagnosis of depression and the correct diagnosis of 
depression as opposed to apathy are of major importance also in patients with severe 
cognitive dysfunction. 
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Abstract 
Background/aims 
To establish the construct validity of the Dutch version of the Cohen-Mansfi eld 
Agitation Inventory (CMAI-D) in institutionalized patients with dementia. 
Methods  
The CMAI-D was administered in a large sample of 1437 patients with moderate 
to severe dementia, receiving nursing home or outreaching nursing home care. 
Exploratory factor analysis was used to examine the behavioural dimensions 
underlying CMAI-D observations. 
Results
A restricted three factor solution showed three factors, i.e. physical aggression, 
physically non-aggressive behaviour and verbally agitated behaviour, with prevalences 
of 62%, 67%, and 62% respectively. An unrestricted factor solution revealed three 
additional behavioural dimensions:  hiding/hoarding, vocal agitation and a factor of 
miscellaneous items (i.e. repetitious mannerisms, spitting), which occurred respectively 
in 30%, 28% , and 35% of the patients. 
Conclusion 
The three factor solution of physical aggression, physically non-aggressive behaviour 
and verbally agitated behaviour corroborates earlier fi ndings in other patient samples 
and therefore establishes the constructed validity in institutionalized patients with 
severe dementia. The robustness of these fi ndings across different care settings suggests 
that agitated behaviours have a common basis. In addition, unrestricted factor analysis 
showed three other important independent behavioural symptoms in dementia, 
but are in fact too small to be used as a subscale. These fi ndings might add to the 
taxonomy of agitation and aggression in dementia.
C H A P T E R  6
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Introduction
Agitation is a common neuropsychiatric phenomenon of dementia. The estimated 
prevalence of agitation in nursing home patients with dementia ranges from 45 to 83 
%.1-8 Disruptive or agitated behaviours can be very distressing to patients, carers and 
nursing home staff alike.9, 10 It may lead to institutionalization,11 the (excessive) use of 
psychotropic medication 12 and physical restraints.13 Some debate exists on whether 
agitation or aggression in dementia is a unitary concept or not and on which aspects 
of agitation research we should focus on when designing intervention trials so as to 
maximize outcome effects. 
The debate somewhat centers around the ‘lumping or splitting’ of different symptoms. 
Agitation in dementia can be defi ned as inappropriate verbal, vocal or motor 
activity 14 and includes a variety of different (physically and verbally) behaviours, 
such as hitting, kicking, wandering, general restlessness, complaining or hoarding. 
Furthermore, agitation may vary according to dementia type (e.g., it is highly 
prevalent in frontal-temporal dementia)15-17, severity of dementia 18, 19 and the physical 
environment and social interaction within institutions. 20-23 
The Cohen-Mansfi eld Agitation Inventory (CMAI), is a 29-items nurse based rating 
scale and it has been used in different studies evaluating the prevalence of agitation in 
nursing home patients and therapeutic effects of psychoactive medication.24-28 
Factor analysis studies in different countries have shown that CMAI symptoms 
refl ect three or four behavioural dimensions.5, 29-34 However, some studies included 
a heterogeneous sample of patients with or without dementia.5, 29, 32-34 In both the 
original and other studies three factors were found: i.e. physical aggression, physically 
non-aggressive behaviour and verbally agitated behaviour.30, 31, 33 Recent studies 
have proposed a four factor model, adding hoarding/ hiding as another independent 
behavioural dimension.5, 29 Some behavioural changes such as repetitive behaviours or 
vocalizations and screaming may be more typical of severe dementia in nursing home 
patients 35 and they may refl ect an behavioural dimension of agitation that is different 
from those found in other patient samples.24-26 
Three studies have evaluated the construct validity of the CMAI in institutionalized 
patients residing in nursing homes.30, 31 In the Netherlands, nursing home care can also 
be given in residential homes by means of complementary outreaching nursing home 
care. This type of shared care is delivered by family physicians, nurses and nursing 
home physicians to patients in residential homes, in order to prevent or postpone 
nursing home admission.36 To our knowledge, this is the fi rst study to explore 
different behavioural dimensions that may underlie agitation in institutionalized 
patients with dementia receiving nursing home care or complementary outreaching 
nursing home care in a representative sample without a prior behavioural problems. 
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Methods
Study design and subjects
This cross-sectional cohort study is part of a study evaluating the prevalence and 
correlates of neuropsychiatric symptoms in Dutch nursing home patients with 
dementia. Patients were recruited from 27 nursing homes in the Eastern, Northern 
and Southern parts of the Netherlands. The nursing homes supplied 59 dementia 
special care units and 13 units providing programs for outreaching nursing home care 
situated in homes for the elderly. Patients were considered for inclusion provided (1) 
they met Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-
IV) criteria 37 for dementia, (2) their cognitive decline was judged to be moderate to 
very severe, as defi ned by the Global Deterioration Scale stages 4-7,38 (3) and they 
had resided in the institution for more than four weeks. Terminally ill patients were 
excluded. Presence of agitated behaviour or other behavioural changes was not a 
prerequisite to be included in the study. 
The study was undertaken in accordance with the Declaration of Helsinki and the 
guidelines on Good Clinical Practice. The local Research Ethics Committee approved 
of the study. Eligible patients were only included after informed consent of the 
patients or legal guardian was obtained.
Procedures
Licensed vocational nurses were instructed to observe patients’ behaviour during a 
two week period. These nurses were all specifi cally assigned to individual patients for 
managing the care process. At the end of the two week observation period vocational 
nurses were interviewed by trained nurse-assistants. The structured interviews were 
based on a written manual and aimed to elicit specifi c observations of agitated 
behaviours. Prior to the study interviewers were trained by two researchers during 
a two-hour session. Nursing home psychologists or resident physicians supervised 
the interviewers on a regular basis. Agitation was measured with the 29-items CMAI 
Dutch version (CMAI-D). CMAI-D items are rated on a 7-point scale (1-7) ranging 
from ‘never’ to ‘several times an hour’. The CMAI has well-established (test-retest and 
interrater) reliability,31, 39 and (concurrent) validity 31 in both community samples 39 
and in nursing homes patients.31 Preliminary data supports construct validity of the 
CMAI-D in a mixed sample of demented and elderly psychiatric patients.34 
The nursing home psychologist or resident physician assessed dementia severity on 
the Global Deterioration Scale, which is a well-known severity measure of dementia 
and scores ranges from no dementia (stage 1) to very severe dementia (stage 7).38 
Baseline characteristics, such as age, sex, marital status, time of institutionalization and 
psychoactive medications used were retrieved from patients’ charts. 
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Data analysis
Construct validity of the CMAI-D was evaluated using exploratory factor analysis 
(SPSS 9.0.1). Items with a prevalence < 10% were excluded from analysis. Initially, 
factors with eigenvalues > 1 were extracted and orthogonally rotated to achieve 
simple structure (Varimax). Secondly, the number of extracted factors was limited 
based on inspection of the factor scree-plot.  Limiting the number of factors extracted 
was considered useful, because a large number of factors with very few items would 
not refl ect to be clinically meaningful entities/ behavioural syndromes. It has been 
recommended that the number of items loading on any given factor should be at 
least three or more.40 In a second analysis, oblique rotation of factors was used (Direct 
Oblimin), as we expected agitation symptoms to be associated in dementia.
Items with factor loadings higher or equal than 0.4 were considered relevant. The 
highest factor loading of a particular item determined to which factor the item was 
assigned. Of each factor, both the variance explained and the overall factor prevalence 
– defi ned as at least one item present within a factor – was given. Prevalence of 
individual items of the CMAI were described elsewhere.8
Results
Patient characteristics
The study population consisted of 1,437 patients. The (median) age of the patients 
was 83 years, the female - male ratio was 4:1 and the median length of stay in the 
nursing home was 18 months (Table 1.). The majority of patients had severe to very 
severe cognitive decline (GDS stage 6 or 7). Psychoactive medication was prescribed 
to 65% of the patients, with prescriptions of antipsychotics in 37%, antidepressants in 
27% and both anxiolytic drugs and hypnotics/sedatives in 15% of the patients. Very 
few patients were prescribed acetylcholinesterase inhibitors.
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Table 1. 
Patients characteristics of 1,437 nursing home patients with dementia
Age, years
 Median 83
 Range 37-102
Gender,  male  276 (19)
Duration of institutionalization, months
 Median 18
 Range 1-191
Global Deterioration Scale (GDS)
 GDS stage 4, mild dementia 59 (4)
 GDS stage 5, moderate dementia 282 (20)
 GDS stage 6, moderately severe dementia 728 (51)
 GDS stage 7, severe dementia 368 (26)
Psychoactive medication use  925 (65)
 Antipsychotic drugs 532 (37)
 Antidepressant drugs 390 (27)
 Anxiolytic drugs 222 (16)
 Hypnotics/sedatives 214 (15)
 Antiepileptic drugs 84 (6)
 Cholinesterase inhibitors, nootropics 15 (1)
Note: 
Figures in parentheses indicate percentages. All percentage values are percentages of the total group
Factor analysis
The prevalence of nine behavourial symptoms was less than 10% (i.e. kicking, 
throwing things, biting, intentional falling, eating or drinking inappropriate substances, 
hurt self or others, tearing things or destroying property, verbal sexual advances and 
physical sexual advances). These symptoms were therefore excluded from subsequent 
analyses.
Factor analysis of the remaining 20 items revealed an initial six factor solution 
(table 2), explaining 60% of variance. The initial six factor solution included the 
three factors also found in other studies, i.e. physical aggression (hitting, pushing, 
cursing, scratching), verbally agitated behaviour (complaining, constant unwarranted 
request for attention, negativism, repetitive sentences or questions), physically non-
aggressive behaviour (pace/aimless wandering, trying to get to a different place, 
general restlessness), and additionally three other factors which were labeled ‘hiding/
hoarding’ (hoarding things, hiding things, handling things inappropriately), ‘vocal 
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agitation’ (strange noises, screaming), and a miscellaneous factor (performing repetitious 
mannerisms, spitting). Handling things inappropriately, grabbing onto people and 
general restlessness, loaded on the miscellaneous factor (>0.40) also. 
Table 2: 
Results of initial factor structure of CMAI in 1,437 Dutch nursing home patients with dementia
   Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6
   Physically  Verbally Physically Hiding/ Perseverative Vocal agitation
   aggressive  agitated nonaggressive hoarding behaviour
   behaviour  behaviour behaviour
 7. Hitting (including self) 0.80
 10. Pushing 0.74
 4.  Cursing/ verbal aggression 0.60
 15.  Scratching 0.55
 9.  Grabbing 0.50    (0.40)
 18.  Complaining  0.79
 5.  Constant unwarr.req.attention help  0.76
 6.  Repetitive sentences or questions  0.67
 19.  Negativism  0.66
 1.  Pace, aimless wandering   0.79
 16.  Trying to get to a different place   0.77
 29.  General restlessness   0.60  (0.44)
 24.  Hoarding things    0.83
 23.  Hiding things    0.82
 22.  Handling things inappropriately    0.50 (0.44)
 26.  Repetitious mannerisms     0.71
 3.  Spitting (including at meals)     0.44
 12.  Strange noises      0.81
 13.  Screaming      0.78 
Explained variance 12% 12% 11% 10% 8% 7%
Prevalence (any item) 54.2% 61.6% 57.2% 30.4% 34.7% 28.1%
Notes: 
Factor loadings > 0.40 presented (‘inappropriate dressing or disrobing’ failed to load on any factor). 
Inspection of the factor scree-plot suggested limitation of the number of factors to 
be examined to three. Results of this three factor model are presented in table 3, 
explaining 42% of the variance. 
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Table 3: 
Results of limited 3- factor solution analysis of CMAI in 1,437 Dutch nursing home patients 
with dementia
   Factor 1 Factor 2 Factor 3
   Physically  Physically Verbally
   nonaggressive  aggressive agitated
   behaviour behaviour behaviour
 1.  Pace, aimless wandering 0.69
 23. Hiding things 0.65
 24.  Hoarding things 0.64
 16.  Trying to get to a different place 0.61
 22.  Handling things inappropriately 0.60
 29.  General restlessness 0.59
 2.  Inappropriate dressing or disrobing 0.57
 7.  Hitting (including self)  0.75
 10.  Pushing  0.63
 15.  Scratching  0.60
 4.  Cursing or verbal aggression  0.58
 9.  Grabbing  0.55
 13.  Screaming  0.48
 3.  Spitting (including at meals)  0.47
 12.  Strange noises  0.41
 5.  Constant unwarr.req.attention help   0.78
 18.  Complaining   0.75
 6.  Repetitive sentences or questions   0.68
 19.  Negativism   0.63 
Explained variance 15% 14% 13%
Prevalence (any item) 66.6% 62.4% 61.6%
Factor loadings > 0.40 presented (‘performing repetitious mannerisms’ failed to load on any factor). 
Items loading on the fi rst factor (15% explained variance) were pacing, hiding, 
hoarding, trying to get to a different place, handling things inappropriately, general 
restlessness, inappropriate robbing/disrobing. The factor was labeled physically non-
aggressive behaviour.  Items loading on the second factor (14% explained variance) 
were hitting, pushing, scratching, cursing, grabbing, screaming, spitting, and strange 
noises. This factor was labeled physical aggression. 
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Items loading on the third factor (13% explained variance) were constant 
unwarranted request for attention or help, complaining, repetitive sentences or 
questions, negativism. The third factor was labeled verbally agitated behaviour. 
Repetitious mannerisms did not load on any of the factors. 
Factor analysis with oblique rotated factors produced very similar results to the 
previous analyses.
The overall prevalence of any item of the three factors physical aggression, physically 
non-aggressive behaviour and verbally agitated behaviour in the initial six factor 
and fi nal three factor solution ranged from 54-62% and 62%-67% respectively. The 
prevalence of hoarding/ hiding, vocal agitation and the miscellaneous cluster was 
lower, i.e. 30%, 35% and 28% respectively.
Discussion
This study explored construct validity of CMAI-D ratings in a large sample of nursing 
home patients with moderate to severe dementia. Three underlying behavioural 
dimensions were found. 
The present fi ndings corroborate those of others. Previous studies have shown that 
agitation as measured with the CMAI consists of physically aggressive behaviour, 
physically non-aggressive behaviour and verbally agitated behaviour.30, 31, 33, 34 In this 
study 20 out of 29 items were factor analyzed. Of the 20 items, 18, 20, 15 and 17 
items loaded on similar factors found in previous studies. 30, 31, 33, 34 These studies have 
been done in different settings, i.e. nursing homes,30, 31 hospitals 33 or psychiatric 
observation clinic for older persons 34 with 33, 34 or without 30, 31 a confi rmed diagnosis 
of dementia. In three studies agitated patients were included only.31, 32 Also in the 
other CMAI-D study, agitation was probably highly prevalent in patients admitted 
to a psychiatric hospital;34 in the other two studies agitation was not an inclusion 
criterion.30, 33 
The present study is, to our knowledge, the largest factor analytic study in patients 
with dementia. The sample covered 4.4% of all demented patients that received 
nursing home care in the Netherlands. It has been carried out in a relatively 
homogeneous and representative sample of patients without a priori behavioural 
problems receiving nursing home care, not only in dementia special care units 
within nursing homes, but also in residential homes by means of outreaching care. 
Special care was taken to ensure reliability of the data, with respect to training and 
supervision of the interviewers and the requirements of the licensed nurses, so that 
the best informant was available for each patient. In this sample of patients with severe 
dementia, the factor structure was similar compared to what was found by others. 
These robust fi ndings support construct validity of the CMAI-D across different 
settings and severity of dementia. 
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In our initial unrestricted factor model, we were able to fi nd three additional 
dimensions of agitated behaviour. Our large database enabled us to detect additional 
clusters containing less frequent items which might not have been found in other 
studies. The additional three factors are important, not so much as to add to the 
construct validity of the CMAI-D, but as they add to the taxonomy of agitation. 
(1) The fi rst additional factor hiding/hoarding has also been found by two other 
studies in demented nursing home patients5, 29 Although hoarding is associated with 
other manifestations of agitation,41 it can occur without other physically non-
aggressive behaviours. Since hiding and hoarding behaviour is associated with mild 
cognitive deterioration and less ADL impairment,41 because it requires relatively 
intact ambulatory function, it can be separated from other physically non-aggressive 
behaviours, such as general restlessness, occurring in more advanced dementia. 
Hoarding may also have a distinct underlying mechanism as opposed to other 
physically non-aggressive behaviours in dementia and may be related to complex 
compulsive behaviours as have been described as a temporal variant of frontotemporal 
dementia 42 or to imitation and/or utilization behaviour.43
(2) Vocal agitation or vocally disruptive behaviour is typical verbally agitated 
behaviour in severe dementia with declining communicative abilities and might be 
considered as an indirect request for help, in patients with discomfort or other unmet 
needs.44 The exact mechanisms inducing vocal agitation are yet unknown,45 but might 
be explained by interruption of the frontal subcortical circuits.35 Vocal agitation has 
also been associated with severe cognitive impairment 46 or severe dementia with 
total dissolution of speech,35 depression,47, 48 psychosis,48 under-treated pain 46, 48 or 
environmental factors such as noise levels, or over/understimulation.48, 49 There may 
be different types of disruptive vocalizations.44 However, the two CMAI items (i.e. 
strange noises and screaming) are incomplete to assess different types of disruptive 
vocalizations.  
(3) The cluster of miscellaneous symptoms contained ‘performing repetitious 
mannerisms’, ‘spitting’, and (possibly) ‘handling things inappropriately’, ‘grabbing onto 
people’ and ‘general restlessness’. These symptoms may be regarded as stereotyped and 
perseverative, or hyperoral behaviour typical of frontal lobe degeneration, as opposed 
to complex ritualistic behaviour in the early stages of this disease.50-52
A closer look of the factor structure of the CMAI revealed different symptom clusters 
of agitation and aggression. This might add to understanding specifi c end-stage 
phenomena, such as vocal agitation and executive dysfunction in dementia, such 
as hoarding and stereotypical repetitive behaviour. The three additional dimensions 
found included too small a number of symptoms to construct separate CMAI 
subscales,40 but this study gives rise to the discussion to extent the CMAI-D with 
specifi c items on these dimensions. Until this issue has been settled, these symptoms 
can be measured more reliably with other assessment scales such as the stereotypic 
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and ritualistic behaviours subscale as an addendum to the NPI 52, 53 or the typology of 
vocalizations.44 
The robust fi ndings of three behavioural dimensions underlying agitation in this large 
study of Dutch nursing home patients with moderate to severe dementia support 
construct validity of the CMAI-D. Implications are, that given the similar results 
found in different studies in several countries and across different care settings, agitated 
behaviour in dementia may have a strong common (biological) basis. Our initial 6 
factor model that comprises the original three factors, not only support the construct 
validity of the CMAI-D, but it also suggests that aggressive or agitated behaviour and 
its underlying mechanisms should be further explored. 
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Abstract 
Background/aims
To assess the infl uence of disease-related predictors on neuropsychiatric symptoms in 
nursing home patients with dementia. 
Methods
Agitation and other neuropsychiatric symptoms were assessed in a large sample of 
1319 Dutch nursing home patients using the Cohen-Mansfi eld Agitation Inventory 
(CMAI) and the Neuropsychiatric Inventory–Nursing Home version (NPI-NH). 
The infl uence of gender and severity of cognitive decline, assessed with the Global 
Deterioration Scale (GDS), was investigated using logistic regression analysis and 
subsequently corrected for possible confounders, such as age of the patient, duration 
of institutionalization and psychoactive medication use. 
 
Results
While physically aggressive behaviour was more common in patients with very severe 
cognitive deterioration (GDS stage 7), disinhibition, irritability, physically non-
aggressive and verbally agitated behaviour were more common in patients in GDS 
stage 5 or 6.  Physically aggressive behaviour was more common in men, whereas 
female patients demonstrated more verbally agitated behaviour. With respect to 
other neuropsychiatric symptoms, delusions and depression were also more common 
in patients in GDS stage 5 and 6, while prevalences of anxiety and apathy further 
increased in severely demented patients (GDS stage 7). Apathy was more prevalent in 
male patients, while depression and anxiety were more common in female patients 
Conclusion 
In this large sample of nursing home patients, agitation and other neuropsychiatric 
symptoms were associated with the severity of dementia, with most symptoms 
occurring in patients showing (moderately) severe cognitive decline. Only physical 
aggression, anxiety and apathy were more common in patients with very severe 
cognitive decline (GDS stage 7). Disease-related factors and gender were important 
predictors of neuropsychiatric symptoms in this patient cohort. More research is 
needed to explore the environmental correlates of neuropsychiatric symptoms in 
nursing homes. 
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Introduction
Neuropsychiatric symptoms are ubiquitous in dementia and are important predictors 
of institutionalization.1, 2 The prevalence of neuropsychiatric symptoms in nursing 
homes has been estimated to be between 72 and 92%.3-7 Agitation in particular is 
regarded as one of the most troublesome behavioural changes in dementia. To date, 
only a few studies have examined correlates of agitation, 8, 9 and our understanding of 
the factors that contribute signifi cantly to this and other neuropsychiatric symptoms 
in nursing home patients with dementia is still quite limited. In general terms, these 
factors may be disease related, such as dementia type or severity, psychological in 
nature or related to the nursing home environment. 
With respect to disease-related factors, some studies in nursing home patients with 
dementia have established the relationship between (increased) cognitive and 
global deterioration associated with dementia and agitation or aggression,7, 10, 11, 12, 13 
psychosis,7 or apathy.7 There is also some evidence that gender is an important 
predictor of agitation in nursing home patients, with men tending to show more 
physically non-aggressive behaviour,11 physically aggressive behaviour 14 or vocal 
agitation 11 than women, whereas the results on verbally aggressive/agitated behaviour 
are confl icting.10, 12 
The prevalence of neuropsychiatric symptoms may also be infl uenced by the use of 
psychoactive medication, such as antipsychotics, which are frequently prescribed to 
patients with agitation, psychosis and anxiety.7 Such medication may confound the 
effect of other predictors on these symptoms.
To date, no data on predictors of agitation are available on Dutch nursing home 
patients with dementia. Nursing homes in The Netherlands differ from their 
counterparts in other countries in that the staff comprise not only nursing personnel 
but also specially trained nursing home physicians, physical therapists, psychologists 
and social workers,15, 16 all of whom are employed by the nursing home. Moreover, 
care is provided in dementia special care units (SCUs), where patients usually live in 
small groups of about 6-12 persons. 
It is relevant to investigate the importance of disease-related predictors on 
neuropsychiatric symptoms in an institutional setting in which such behaviour 
may not only be infl uenced by disease-related factors but also by nursing home 
environment characteristics. The objective of this study was, therefore, to assess the 
infl uence of the severity of dementia and gender on neuropsychiatric symptoms in 
nursing home patients with dementia corrected for possible confounders.
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Methods
Study design and subjects
This cross-sectional cohort study is part of the WAAL Behaviour in Dementia 
(WAALBED)-study evaluating the prevalence and correlates of neuropsychiatric 
symptoms in Dutch nursing home patients with dementia. Patients were recruited 
from 26 nursing homes in different parts of the Netherlands, and these nursing homes 
provided a total of 59 dementia SCUs. Patients were considered for inclusion in the 
study when (1) they met Diagnostic and Statistical Manual of Mental Disorders fourth 
edition (DSM-IV) criteria 17 for dementia, (2) their cognitive decline was staged 
as moderate to very severe, as defi ned by Global Deterioration Scale (GDS) stages 
4–7 18 (3) and they had resided in the institution for more than 4 weeks. Terminally 
ill patients were excluded. The presence of neuropsychiatric symptoms was not a 
prerequisite to be included in the study. Detailed information of the study method has 
been published elsewhere. 3
The study was undertaken in accordance with the Declaration of Helsinki and the 
guidelines on Good Clinical Practice. The local Research Ethics Committee approved 
the study. Eligible patients were only included after the informed consent of the 
patients or legal guardian was obtained.
Data collection and assessments
Data were collected between February 2003 and October 2003. To rule out any 
longitudinal effects, the assessments took place within a 4-week period. All licensed 
vocational nurses assigned to individual patients were instructed to observe symptoms 
during a 2-week observation period. At the end of this 2-week period, the vocational 
nurses were interviewed by trained nurse-assistants who had received special training 
from two researchers in a 2-h session prior to the study. The interviews were 
structured, following guidelines provided by a written manual, and had the aim of 
eliciting specifi c observations of all neuropsychiatric symptoms. Supervision of the 
interviewers was provided by a psychologist or a nursing home physician. 
Agitation and aggression were measured using the Cohen Mansfi eld Agitation 
Inventory (CMAI). This instrument, originally developed by Cohen-Mansfi eld et 
al.,19 is designed to assess 29 agitated or aggressive behaviours and has been extensively 
used for assessment purposes in nursing homes. The CMAI has been validated by 
Miller et al.20 and subsequently translated into Dutch and validated by de Jonghe.21 
The frequency of each symptom is rated on a seven-point scale (1–7) ranging from 
‘never’ to ‘several times an hour’.  The CMAI has a well-established (test–retest and 
interrater) reliability 20, 22 and (concurrent) validity 20 in both community samples 
22 and nursing home patients.20 Preliminary data support the construct validity of 
the CMAI-D in a mixed sample of demented and elderly psychiatric patients.21 For 
the study reported here, symptoms were clustered in three behavioural dimensions 
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– physically aggressive, physically non-aggressive and verbally agitated behaviour. 
The clusters were obtained using factor analysis of the CMAI-D in a larger but 
partly overlapping population of dementia patients receiving nursing home care in 
nursing homes and outreaching nursing home care projects.23 The items within each 
cluster are comparable with those reported by others.20, 21, 24, 25 Aggressive or agitated 
behaviour within each cluster was considered to be relevant when one or more items 
occurred at least once a week (any individual items score ≥ 3). 
Other neuropsychiatric symptoms were assessed with the Neuropsychiatric 
Inventory–Nursing Home version (NPI-NH). Cummings originally developed the 
NPI as a means to assess neuropsychiatric symptoms in demented outpatients.26, 27 
The nursing home version was developed for the use of professional caregivers within 
institutions and has been translated into Dutch by Kat and de Jonghe;28 it has proven 
to be a valid and reliable assessment instrument for trained nursing staff.29, 30 
The NPI-NH includes 12 neuropsychiatric symptoms: delusions, hallucinations, 
agitation, depression/dysphoria, anxiety, euphoria/elation, apathy/indifference, 
disinhibition, irritability/lability, aberrant motor behaviour, night-time disturbances 
and appetite/eating change. Both the frequency (F) and severity (S) of each symptom 
are rated on a four- (1–4) and three-point (1–3) Likert scale, respectively. A separate 
score can be calculated for each symptom by multiplying the frequency and severity 
scores, resulting in values ranging from zero to 12 for each symptom. We considered 
neuropsychiatric symptoms with an F × S score ≥ 4 to be clinically relevant, which is 
in accordance with previous studies.31, 32 
To describe the severity of the dementia, the psychologist (or nursing home physician) 
used the Global Deterioration Scale (GDS),18 which consists of a seven-point scale 
(1–7) ranging from no cognitive decline (1) to very severe cognitive decline (7). 
GDS scores of 4, 5 and 6 denote moderate, moderately severe and severe cognitive 
decline, respectively. Baseline characteristics, such as age, sex, marital status and time 
of institutionalization, were retrieved from patients’ charts. Data on the actual regular 
use of psychoactive medication on the day of assessment were registered. Psychoactive 
medications were classifi ed using the Anatomical Therapeutical Chemical-
classifi cation 33 and grouped into antipsychotics, anxiolytics, hypnotics/sedatives, 
antidepressants, anti-epileptics and miscellaneous (e.g. cholinesterase inhibitors). 
Analysis
Data on prevalences are presented on subgroups of male and female patients and/
or with different severities of cognitive decline (GDS stages 4–7). Differences in 
prevalences of agitation and other neuropsychiatric symptoms by gender and GDS 
were tested using chi-square statistics. A p-value of < 0.05 was considered to be 
statistically signifi cant. The infl uence of predictors on neuropsychiatric symptoms 
were also simultaneously assessed in a logistic regression analysis. Dependent variables 
98
C H A P T E R  7
were presence or absence of agitated behaviour on the CMAI clusters and the 
presence or absence of individual symptoms on the NPI-NH (F × S cut-off score 
< or ≥ 4).  Independent variables entered in the model were gender and dementia 
severity. The infl uence of both gender and dementia severity on neuropsychiatric 
symptoms was corrected for possible confounders, such as age of patient, duration of 
institutionalization and psychoactive medication use. Age was categorized in 5-year 
intervals, and duration of institutionalization in intervals of 6 months – 1 year.  
Antipsychotics, anxiolytics, hypnotics, antidepressants and antiepileptics were 
simultaneously entered as dichotomous variables. Interaction terms were also entered 
in the model to make allowance for possible effect modifi cation, but were left out of 
the fi nal analysis when they did not appear to reach statistical signifi cance (p < 0.05).
Results
Patient characteristics
The (median) age of the study population (1319 patients) at enrollment was 83 years, 
the female/male ratio was 4:1 and  the median length of stay in the nursing home 
was 18 months (Table 1). The majority of patients had been assessed to have severe to 
very severe cognitive decline (GDS stage 6 or 7). Psychoactive medication had been 
prescribed to 65% of the patients in the form of antipsychotics (in 37% of patients), 
antidepressants (27%) and both anxiolytic drugs and hypnotics/sedatives (15%). Very 
few patients (<1%) used cholinesterase inhibitors.
Prevalences of agitation and other neuropsychiatric symptoms
Prevalences of physically aggressive, non-aggressive and verbally agitated behaviour 
were 56%, 62% and 56%, respectively (Table 2). Prevalences of agitation as measured 
with the NPI-NH were 31% for agitation, 20% for disinhibition, 29% for aberrant 
motor behaviour and 34% for irritability. Prevalences of other neuropsychiatric 
symptoms ranged from 8% to 34% (delusions, 15%; hallucinations, 8%; depression, 
20%; anxiety, 21%; apathy, 34%) (see also Chapter 4 for detailed description of the 
prevalence rates)3. 
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Table 1. 
Patient characteristics of 1,319 nursing home patients with dementia
Age, years
 Median 83.0
 Standard Deviation 8.1
 Range 36–102
Gender,  male  266 (20)
Duration of institutionalization, months
 Median 20
 Range 1–191
Global Deterioration Scale (GDS)
 GDS stage 4, moderate cognitive decline 38 (3)
 GDS stage 5, moderately severe cognitive decline 234 (18)
 GDS stage 6, severe cognitive decline 681 (51)
 GDS stage 7, very severe cognitive decline 366 (28)
Total psychoactive medication use   857 (65)
 Antipsychotic drugs 488 (37)
 Antidepressant drugs 356 (27)
 Anxiolytic drugs 211 (16)
 Hypnotics/sedatives 198 (15)
 Antiepileptic drugs 79 (6)
 Cholinesterase inhibitors, nootropics 13 (1)
Figures in parentheses indicate percentages. All percentage values are percentages of the total group
Infl uence of  dementia severity
Prevalences of physically aggressive behaviour signifi cantly increased from GDS stage 
4 to GDS stage 7. (Table 2). Physically non-aggressive behaviour and verbally agitated 
behaviour were highly prevalent in GDS stages 5 and 6. Disinhibition, irritability 
and aberrant motor behaviour also showed different prevalences at various stages 
of cognitive decline, with the highest prevalences of disinhibition and irritability 
in patients with GDS stages 5 and 6 and the highest prevelances of aberrant motor 
behaviour in patients with GDS stage 6. The prevalences of agitation, as measured 
with the NPI-NH, and anxiety were not signifi cantly different between GDS stages. 
Delusions and depression were highly frequent in patients with GDS stage 5 and 6. 
Hallucinations and apathy showed increasing prevalences with further cognitive 
decline, with the highest prevalences occurring in patients with GDS stage 7. 
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 Table 2: 
Prevalence (%) of agitation and other neuropsychiatric symptoms by gender and cognitive decline 
(GDS) in nursing home patients with dementia
 Males Females p-value 3) GDS 4 GDS 5 GDS 6 GDS 7 p-value 3) Overall
 (n=266) (n=1053)  (n=38) (n=234) (n=681) (n=366)  (n=1319)
CMAI 1)
Physically aggressive 61.3 54.5 0.047 (*) 26.3 42.3 58.6 62.6 0.000 (*) 55.9
Physically non-aggressive 62.8 61.3 0.647 44.7 62.0 69.5 48.4 0.000 (*) 61.6
Verbally agitated behaviour 51.1 56.7 0.103 50.0 66.7 65.3 30.9 0.000 (*) 55.6
NPI-NH agitation 2)
Agitation 33.1 30.9 0.492 15.8 27.8 33.6 31.0 0.062 31.3
Disinhibition 22.6 19.1 0.207 13.2 21.4 24.5 10.7 0.000 (*) 19.8
Irritabilility 33.6 33.5 0.977 23.7 40.2 38.6 20.8 0.000 (*) 33.5
Aberrant motor behaviour 27.8 29.4 0.618 10.5 15.8 34.9 28.7 0.000 (*) 29.1
NPI-NH other items 2)
Delusions 15.4 14.3 0.657 7.9 17.1 19.2 4.9 0.000 (*) 14.6
Hallucinations 9.4 7.2 0.232 0.0 3.8 8.5 9.3 0.018 (*) 7.7
Depression 13.5 21.5 0.004 (*) 18.4 23.1 23.5 11.2 0.000 (*) 19.9
Anxiety 15.4 21.8 0.020 (*) 10.5 16.3 22.0 21.6 0.104 20.5
Apathy 39.8 32.2 0.018 (*) 18.4 20.1 31.3 48.6 0.000 (*) 33.7
Notes: 
GDS, Global Deterioration Scale; CMAI, Cohen-Mansfi eld Agitation Inventory; NPI-NH, Neuropsychiatric 
Inventory-Nursing home version,1) Any-item occurring once a week or more,2) NPI-NH frequency (F) × Severity (S) 
score ≥ 4,3) (*) indicates p < 0.05 (Chi-square statistics)
Infl uence of gender
Physically aggressive behaviour was more common in male patients (Table 2). No 
gender differences were found for physically non-aggressive behaviour or for the 
NPI-NH items on agitation. Depression and anxiety were more frequent in female 
patients and apathy in male patients. 
Logistic regression analyses
The logistic regression analyses (Table 3) confi rmed the existence of signifi cant 
differences between GDS stages for all symptoms described in the univariate analyses, 
with the exception for hallucinations. Anxiety also appeared to be signifi cantly 
infl uenced by dementia severity in the logistic regression analysis, with the highest 
prevalences appearing in patients with GDS stage 7. The gender differences in the 
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univariate analyses were confi rmed by the results of the logistic regression analyses. 
Verbally agitated behaviour, which was not signifi cantly different between both 
sexes in the univariate model, appeared to be more common in female patients 
in the logistic regression analysis. The infl uence of dementia severity and gender 
on the neuropsychiatric symptoms were corrected for age of patient, duration of 
institutionalization and psychoactive medication use.
Table 3: 
Results of logistic regression analysis of the infl uence of GDS and gender on agitation and other 
neuropsychiatric symptoms in nursing home patients with dementia 1)
 GDS  (GDS 7=reference)  Gender
 GDS stage 4 GDS stage 5 GDS stage 6 male vs. female
CMAI 2)
Physically aggressive 0.2 [0.1–0.6]* 0.5 [0.3–0.7]* 0.8 [0.6–1.1] 1.4 [1.0–1.8]*
Physically non-aggressive 0.7 [0.3–1.4] 1.5 [1.0–2.2]* 2.0 [1.5–2.7]* 0.9 [0.7–1.3]
Verbally agitated behaviour 2.0 [0.98–4.1] 3.8 [2.6–5.6]* 3.4 [2.5–4.6]* 0.7 [0.5–0.97]*
NPI-NH agitation 3)
Agitation 0.4 [0.2–1.1] 1.0 [0.7–1.5] 1.1 [0.8–1.5] 1.0 [0.8–14]
Disinhibition 1.2 [0.4–3.2] 2.2 [1.4–3.6]* 2.5 [1.7–3.7]* 1.1 [0.8–1.6]
Irritabilility 1.3 [0.6–2.9] 3.1 [2.0–4.6]* 2.4 [1.7–3.3]* 0.9 [0.7–1.2]
Aberrant motor behaviour 0.3 [0.1–0.8]* 0.5 [0.3–0.7]* 1.3 [0.95–1.8] 0.8 [0.6–1.1]
NPI-NH other items 3)
Delusions 1.5 [0.4–5.6] 3.8 [2.0–7.0]* 3.8 [2.2–6.5]* 1.1 [0.7–1.6]
Hallucinations - 4) 0.5 [0.2–1.1] 0.9 [0.6–1.5] 1.3 [0.8–2.1]
Depression 1.1 [0.4–2.9] 1.8 [1.1–2.9]* 1.9 [1.3–2.8]* 0.5 [0.3–0.8]*
Anxiety 0.3 [0.1–0.9]* 0.6 [0.4–0.9]* 0.9 [0.6–1.3] 0.5 [0.4–0.8]*
Apathy 0.2 [0.1–0.6]* 0.3 [0.2–0.5]* 0.5 [0.4–0.7]* 1.5 [1.1–2.0]*
 
Notes: 
GDS = Global Deterioration Scale, CMAI = Cohen-Mansfi eld Agitation Inventory, NPI-NH = Neuropsychiatric 
Inventory- Nursing home version, *OR = 1 not included (p < 0.05), 1) After correction for psychoactive medication 
use, duration of institutionalization and age. Interaction terms were allowed but did not appear to be signifi cant 
(p > 0.05) and therefore were left out of the fi nal analysis, 2) Any-item occurring at least once a week ,3) NPI-NH 
Frequency (F) x Severity (S) score ≥ 4, 4) Prevalence = 0
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 Discussion
The results of this study show that prevalences of neuropsychiatric symptoms were 
high and that they were infl uenced by the severity of the dementia and the gender 
of the patient. Apathy, hallucinations, anxiety and physical aggressive behaviour 
showed the highest prevalences in patients with very severe cognitive decline. Other 
symptoms, such as physically non-aggressive behaviour, verbally agitated behaviour, 
disinhibition, irritability, delusion and depression were most prevalent in patients with 
GDS stage 5 or 6. 
The fi nding of a prevalence peak in patients with a (moderately) severe cognitive 
deterioration is in contrast with results from other nursing home studies in which 
agitation in general,7, 13 physically non-aggressive or vocally/verbally agitated 
behaviour,11, 12 physically non-aggressive or vocally/verbally agitated behaviour,11, 12 
physical or verbal aggression,10 aberrant motor behaviour,7 delusions 7 and 
disinhibition 7 were found to increase with further cognitive (MMSE) 10-13 or global 
deterioration (Clinal Dementia Rating Scale).7 Only the positive correlation between 
decreasing prevalences of depression and increasing severity of the dementia in the 
present study is consistent with the results of two studies in patients residing in 
nursing homes and social care facilities 6 and in a Dutch population of community 
dwelling patients with dementia.34 This discrepancy between the results of previous 
studies and those of our study may be related to the differences in dementia severity. 
Although we cannot directly compare our GDS data with the cognitive and 
global disease measurements used in the other studies, our population included a 
reasonable percentage (23%) of patients with severe dementia (very severe cognitive 
deterioration). As the disease progresses, any exploration of the patient’s inner 
experiences becomes more problematic due to the increasing loss of cognitive and 
communicative abilities. At severe to very severe stages of the disease, the symptoms 
can only be indirectly observed as overt behaviour, such as physically aggressive 
behaviour and apathy. Consequently, delusions, depression and verbally agitated 
behaviour (such as complaining, constant request for attention) become less frequent. 
The concomitant functional impairment at the more severe stages of the disease may 
also explain the less appearance of physical non-aggressive behaviour (wandering, 
hiding/hoarding things, trying to get to a different place).
The gender differences in prevalence rates found in this study are consistent with 
those reported in other nursing home studies on patients with dementia in terms 
of physically aggressive behaviour 5, 14 and verbally agitated behaviour,12 but they 
differ for verbally agitated behaviour 10 and depressed mood.5 In contrast to the 
present study, in which we found no gender differences for physically non-aggressive 
behaviour, two other studies have reported that this behaviour occurs more often in 
males.5, 14 Only in a recent Norwegian nursing home study was gender not a predictor 
of any neuropsychiatric symptoms.7
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The results have important clinical implications. Firstly, the concomitant decrease of 
the prevalence of depression and increase of the prevalence of apathy during cognitive 
deterioration support existing evidence that depression and apathy are two distinct 
syndromes 35 with different neurobiological underpinnings,36, 37 which should be treated 
differently. We propose that apathy as a syndrome related to the global deterioration of 
dementia should receive more attention from both researchers and physicians. In contrast 
to depression, there is no broadly accepted pharmacological therapy for apathy. Evidence 
of the effi cacy of cholinesterase inhibitors 38 or methylphenidate 39 for treating apathy is 
limited. Therefore, the use of effi cacious psychosocial interventions, such as snoezelen 40, 41 
or music therapy,42 should be encouraged. Patients with apathy also benefi t from personal 
attention from the activity therapist.43 
Secondly, the fi nding that physically aggressive, physically non-aggressive and verbally 
agitated behaviour were in different ways predicted by gender and dementia severity 
supports the view that agitation is not a unitary concept, but should be distinguished 
into three separate entities,25 possibly with different effi cacies for antipsychotics.44 Further 
research on this particular issue is required. 
One of the major strengths of our study is the large and representative sample, which 
enabled us to perform logistic regression analyses with reasonably large (sub)groups. 
This type of analysis is more appropriate than univariate statistical testing 6, 7, 10 or linear 
regression models/correlations used in other studies,11-13 since logistic regression analysis 
has the power to correct for possible confounders and is not based on linear assumptions 
of the relation between symptoms and dementia stage. Moreover, we did not only use the 
NPI-NH, but also the three symptom-clusters of the CMAI for the assessment of agitation, 
which appeared to be helpful in fi nding differences between stages of the disease. 
The limitations include methodological concerns about the use of the GDS to refl ect 
dementia severity. The GDS is a global measure used to assess severity of dementia for 
primary degenerative dementia. One could argue that assessing the severity of dementia 
using, for example, MMSE in combination with a functional assessment would be a 
superior approach. Furthermore, GDS also includes neuropsychiatric symptoms (delusions, 
anxiety and aggression), especially in GDS stage 6. This could be a possible source of bias. 
Another limitation concerns psychotropic medication use, which (while effective) may 
have decreased prevalence rates and weakened the relationship between the symptoms and 
other predictors, such as dementia severity. However, we found a strong and signifi cant 
relationship between severity and symptoms, even after a correction for the use of different 
groups of psychoactive medication. We did not perform a sub-analysis on drug-naive 
patients since that would require removing more than 65% of the patients from the study, 
so that the remaining sample does not represent the reality of nursing home practice. 
In conclusion, in this large representative sample of nursing home patients neuropsychiatric 
symptoms are ubiquitous in dementia and predicted by dementia severity and gender. 
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Most symptoms are associated with patients with mild-to-moderate dementia; only 
(physical) aggression, anxiety, apathy and hallucinations are more common in patients 
with severe dementia. This relationship is statistically independent of psychoactive 
medication use, age of the patient and duration of institutionalization. In this specifi c 
institutional setting, where neuropsychiatric symptoms of agitation are also supposed 
to be infl uenced by environmental factors, the relationship between neuropsychiatric 
symptoms and dementia severity and gender is evident. There is an urgent need for 
more research on the environmental correlates of neuropsychiatric symptoms in 
nursing homes.
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Abstract 
Purpose 
To estimate the infl uence of environmental correlates of neuropsychiatric symptoms 
in Dutch nursing home patients with dementia.
Methods 
Patients with dementia residing in 56 Dementia Special Care Units (SCUs) (n = 
1,289) were assessed using the Neuropsychiatric Inventory–Nursing Home version 
(NPI–NH) and the Cohen-Mansfi eld Agitation Inventory (CMAI).  Potential 
correlates of the neuropsychiatric symptoms studied were gender and age of 
patient, dementia severity as measured with the Global Deterioration Scale (GDS), 
psychoactive medication use, the number of patients per unit or per living room, staff 
size/ patient ratio, time spent on care activities and presence of an walking circuit. 
Multilevel logistic regression analysis was used to estimate the relative contribution of 
the different factors in explaining neuropsychiatric symptoms variability. 
Results 
The prevalence of neuropsychiatric symptoms differed between nursing home units, 
even after correcting for patient-related factors such as cognition and psychoactive 
medication.  Differences in symptoms between SCUs accounted for 3.9% (psychosis) 
to 14.3% (apathy) of the total variance in neuropsychiatric symptoms. Patient-
related factors explained 7–21% of the total variance of neuropsychiatric symptoms. 
Environmental correlates, such as staff size, number of patients per unit or per living 
room or presence of an walking circuit in the SCU did not predict neuropsychiatric 
symptoms (<1% of the total variance). Only in SCUs of which the staff spent more 
time on care activities did the patients show lower levels of apathy. 
Conclusion 
We conclude that there is a substantial variation in the level of neuropsychiatric 
symptoms between SCUs. Although we failed to predict neuropsychiatric symptoms 
using the environmental correlates reported in this study, the large difference between 
SCUs − even after correcting for well-known patient factors (such as dementia stage) 
− suggests that other factors associated with the physical or psychosocial environment 
may explain the observed variation in the neuropsychiatric symptoms between SCUs 
in Dutch nursing homes.
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Introduction
Neuropsychiatric symptoms, such as agitation, psychosis, depression and apathy, are 
ubiquitous in nursing home patients with dementia, with prevalence rates of more 
than 80%.1 These symptoms can be a serious burden for nursing home staff, possibly 
leading to an increase in staff distress,2, 3 and they are associated with the use of 
physical restraints4 and psychotropic medications5, 6 that in turn have the potential to 
cause negative side effects.7
Neuropsychiatric symptoms in demented nursing home residents are associated with 
the severity of dementia.8 High prevalence rates of neuropsychiatric symptoms in 
nursing home patients may be due to a biased selection, as these symptoms are the 
main reason for institutionalization.9, 10 However, neuropsychiatric symptoms may 
also be associated with the characteristics of psychosocial/physical environment 
of the nursing home environment, such as crowded housing conditions leading to 
sensory overstimulation, for which patients with dementia are more susceptible,11, 12 
the attitudes of the staff toward challenging behaviours and/or the size of the units in 
which patients reside throughout the day.
More insight into these factors and their effects on the emergence of neuropsychiatric 
symptoms may contribute to the identifi cation of best nursing home practices. 
Studies evaluating the psychosocial and physical environment factors affecting patient 
behaviour are needed because of the important implications the results of such studies 
may have in terms of psychosocial interventions, adequate staff training and the 
development of appropriate services for nursing home residents, such as small-scale 
housing facilities. 
To date, however, only limited data are available on the infl uence of the environment 
on the prevalence of neuropsychiatric symptoms.1, 13, 14 Larger nursing homes in 
general and larger resident units in particular are associated with higher levels of 
agitation 15, 16 and less social withdrawal.17 The physical characteristics of a nursing 
home ward may have an impact on behavioural changes. Neuropsychiatric symptoms 
occurred less often in nursing homes with visual barriers on exit doors to prevent 
residents from leaving the SCU, when there was more privacy and more sensory 
comprehension.17 Also, a sensory-enriched psychosocial environment in dementia 
special care units (SCUs) is associated with a lower level of agitation.15 
Until now, no data are available on the environmental correlates of neuropsychiatric 
symptoms in Dutch nursing home patients with dementia. Care for people with 
dementia in Dutch nursing homes is provided in dementia SCUs, which differ 
considerably in terms of number of patients, staff/patient ratio and quality of care. 
We hypothesized that the prevalence and degree of the neuropsychiatric symptoms 
may differ among SCUs and that these differences may be associated with differences 
in the characteristic features and properties of the SCU, such as the physical and 
psychosocial environment. To test this hypothesis, we have used the ecological model 12 
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and Progressively Lowered Stress Threshold Model 18 as underlying theoretical models.
The aim of the study was to estimate the infl uence of the physical and psychosocial 
environment on the prevalence of neuropsychiatric symptoms in nursing home 
patients with dementia.
Methods
Study design and subjects
This cross-sectional cohort study is part of a larger study evaluating the prevalence 
and determinants of neuropsychiatric symptoms in Dutch nursing home patients with 
dementia. Patients were recruited from 26 nursing homes in the eastern, northern and 
southern parts of The Netherlands, including 59 SCUs for dementia. Patients satisfi ed 
the inclusion criteria when (1) they met Diagnostic and Statistical Manual of Mental 
Disorders fourth edition (DSM-IV) criteria 19 for dementia, (2) their cognitive decline 
was judged to be moderate to very severe, as defi ned by the Global Deterioration 
Scale (GDS) scores stages 4–7,20 (3) and they had resided in the institution for 
more than 4 weeks. Terminally ill patients were excluded. The presence of agitated 
behaviour or other behavioural changes was not a prerequisite to be included in the 
study. Detailed information on the study method and prevalence rates of individual 
symptoms has been published elsewhere.21
The study was undertaken in accordance with the Declaration of Helsinki and the 
guidelines on Good Clinical Practice. The local Research Ethics Committee approved 
of the study. Eligible patients were only included after informed consent of the 
patients or legal guardian was obtained.
Data collection and assessments
All assessments took place within a 4-week period. All licensed vocational nurses 
assigned to individual patients were instructed to observe symptoms during a 2-
week observation period. At the end of this 2-week period, the vocational nurses 
were interviewed by trained nurse-assistants who had receiving special training 
from two researchers in a 2-h session prior to the study. The interviews were 
structured, following guidelines provided by a written manual, and had the aim of 
eliciting specifi c observations of all neuropsychiatric symptoms. Supervision of the 
interviewers was provided by a psychologist or a nursing home physician. 
Neuropsychiatric symptoms were assessed using the Cohen Mansfi eld Agitation 
Inventory (CMAI) and the Neuropsychiatric Inventory Nursing home version 
(NPI–NH). The CMAI is designed to assess 29 agitated or aggressive behaviours,22 
and the frequency of each symptom is rated on a seven-point scale (1–7) ranging 
from ‘never’ to ‘several times an hour’. The CMAI has a well-established reliability,23, 
24 and validity 24 in different patient samples.23,24 The Dutch version was validated by 
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de Jonghe.25 Symptoms are clustered in three behavioural dimensions – physically 
aggressive, physically non-aggressive and verbally agitated behaviour – based on a 
factor analysis of the CMAI–D in a larger and partly overlapping sample of dementia 
patients residing in nursing homes or included in outreaching nursing home care 
projects 26 and other studies.24, 25, 27, 28 Aggressive or agitated behaviour within each 
cluster was considered to be relevant when one or more items occurred at least once 
a week (any individual items score ≥ 3). 
The NPI–NH was originally developed by Cummings 29, 30. The nursing home 
version has been adapted for use by professional caregivers in nursing home facilities 
and has proven to be valid and reliable for use by trained nursing staff.31, 32 A Dutch 
translation of the NPI has also been shown to be reliable and valid.33 The NPI–
NH includes 12 neuropsychiatric symptoms: delusions, hallucinations, agitation, 
depression/dysphoria, anxiety, euphoria/elation, apathy/indifference, disinhibition, 
irritability/lability, aberrant motor behaviour, night-time disturbances and appetite/
eating change. The frequency (F) and severity (S) of each symptom is rated on a fi ve- 
(0–4) and four-point (0–3) Likert scale, respectively. A separate score can be calculated 
for each symptom by multiplying the frequency and severity scores, resulting in values 
ranging from zero to 12 for each symptom. Neuropsychiatric symptoms with a 
F × S score ≥  4 are considered clinically relevant. NPI–NH symptoms are grouped as 
psychosis (hallucinations and/ or delusions), agitation (agitation, disinhibition and/or 
irritability), depression/anxiety and apathy.
The severity of the dementia was assessed by a psychologist or a nursing home 
physician using the Global Deterioration Scale (GDS).20 The GDS is a well-known 
dementia staging measure based on a seven-point scale (1–7) ranging from no 
cognitive decline (1) to very severe cognitive decline (7). 
The environmental correlates measured were: the presence of an walking circuit, 
number of patients per unit or per living room, staff/patient ratio and hours spent on 
direct patient care. The number of patients per living room was defi ned as the number 
of patients per unit divided by the number of living rooms at the unit. Staff/patient 
ratio is defi ned as the number of staff at each unit engaged in direct patient care (i.e. 
licensed vocational nurses, nurses’ aids, recreational therapists; volunteers or non-
professional caregivers were not included) divided by the number of patients in the 
SCU. The hours spent on direct patient care is the time spent by staff on patient care 
during the working days (in hours per patient per day) divided by the number of 
patients in the SCU. Data on SCU environmental correlates were provided by the 
head of the SCU. 
Data on the actual use of prescribed psychoactive medication on the day of assessment 
were recorded. Psychoactive medications were classifi ed using the Anatomical 
Therapeutical Chemical-classifi cation 34 and grouped into antipsychotics, anxiolytics, 
hypnotics/sedatives, antidepressants.
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Analysis 
Proportions or means were used to describe the demographic and clinical 
characteristics of the study population.  The odds of any one neuropsychiatric 
symptom being associated with patient characteristics, psychoactive medication use 
and environmental correlates were estimated using a multilevel logistic regression 
analysis approach (MLwiN, ver. 1.02.0002).35 Multilevel analysis is an extended 
logistic regression analysis which can be used in two-level structured data (e.g. patients 
are clustered within SCUs). Because we hypothesized that the behaviour between 
patients of the same SCU is not independent, the estimates at the patient level must 
be corrected for the dependency at the SCU level (within SCUs) by adding an extra 
categorical variable (i.e. SCU) that provides an additional estimation of the variance at 
the SCU level (difference between SCUs).  
Dependent variables were the presence or absence of CMAI or NPI clusters of 
symptoms. Independent (fi xed) variables were baseline characteristics (gender, age 
and marital status of patient, duration of institutionalization), disease-related factors 
(GDS), psychoactive medication use (antipsychotics, anxiolytics, antidepressant and 
hypnotics) and environmental correlates. As some SCUs were specially equipped for 
patients with troublesome behaviours and others were not, an extra (dummy) variable 
was entered into the model to label these SCUs. Age of patient and duration of 
institutionalization were entered as continuous variables. Antipsychotics, anxiolytics, 
hypnotics and antidepressants were entered as dichotomous variables. 
The Wald statistic was used to test the signifi cance of the variance at the SCU level 
(variance compared to standard error of the variance) as well as the signifi cance 
of independent variables at the patient level (estimates compared to standard error 
of the estimates). Patient factors and psychoactive medication use were entered 
stepwise (forward) into the model and left out in the fi nal analysis when they did 
not reach statistical signifi cance (p not < 0.05). In the fi nal model, non-signifi cant 
environmental correlates were also entered because of the specifi c aim of the study – 
i.e. the relationship between neuropsychiatric symptoms and environmental correlates.
To estimate the relative infl uence of fi xed factors at the patient level in relation 
to the variance at the SCU level, we assumed that the total variance consists of 
variance(fi xed) + variance(SCU level) + π2/3, where the variance(fi xed) denotes the 
variance of (fi xed) patient factors, psychoactive medication use and environmental 
correlates, variance(SCU level) denotes the variance at the SCU level (i.e. due to 
differences between SCUs) and π2/3 (=3.29) denotes the unexplained variance.36
We also evaluated whether observed symptom prevalence in any given SCU differed 
from what was to be expected based on individual patient factors. Predicted symptom 
prevalence rates were estimated for each SCU after correcting for relevant patient 
characteristics and psychoactive drug use. This was done by fi rst calculating the 
odds for symptoms based on the presence or absence of all signifi cant risk factors in 
each individual patient and then averaging results for that particular SCU.  Actual 
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(observed) SCU prevalence rates were subsequently compared with the predicted 
SCU prevalence rates (estimate and 95% confi dence interval of the standard error of 
the mean).
Results
Patient and SCU characteristics
A total of 1,322 patients residing in 59 SCUs met the inclusion criteria, but three 
SCUs were excluded from the analysis because of (an unacceptable amount of) 
missing data at the patient level (up to 50%). The study therefore comprised 56 
participating SCUs with 1289 patients. The patient cohort had a mean age of 83 
(SD: 8) years and a female/male ratio of 4:1. The GDS distribution was: stage 4, 3%; 
stage 5, 17%; stage 6, 52%; stage 7, 28%. Psychoactive medication was prescribed 
in 66% of all patients and consisted of antipsychotics (38% of total group), 
antidepressants (28%), anxiolytics (16%) and hypnotics/sedatives (15%). The median 
length of stay was 20 months (range: 1–191). 
A total of 27 of the 59 SCUs (46%) had an walking circuit. The number of patients 
within an SCU ranged from 10 to 42 patients, with 5–31 patients in each living 
room (each SCU had one to four living rooms.) The time spent on direct patient care 
ranged from 2.3 to 4.1 h per patient per day. Staff/ patient ratio ranged from 0.4 to 
0.9. Five SCUs with 76 patients (6% of the total sample) were specially equipped for 
patients with severe neuropsychiatric symptoms.
Predictors
Associations between patient factors, psychoactive medication use, environmental 
variables and neuropsychiatric symptoms are presented in Table 1. 
Patient factors
Dementia severity was a signifi cant predictor of physical aggressive behaviour 
and apathy, with higher symptom prevalence in more severe stages of dementia. 
The highest prevalence of physically non-aggressive, verbally agitated behaviour, 
agitation, disinhibition and irritability was found for patients with GDS stages 5 
and 6. Male gender predicted physical aggressive behaviour and apathy, and female 
gender predicted verbally agitated behaviour and depression/anxiety. Younger patients 
expressed more physically non-aggressive behaviour and depression/anxiety than 
older patients.  Patients who had been resident for a relatively shorter period of time 
had higher prevalence rates of depression/anxiety than those who had been there 
longer. Marital status did not predict any of the symptoms assessed.
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Table 1.  
Multilevel logistic regression analysis of patient related factors, psychoactive medication use, 
environmental correlates on neuropsychiatric symptoms in 1,289 nursing home patients with 
dementia
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Notes: 
Data are presented as odds-ratios [95% confi dence interval], *Signifi cance (p-value Wald statistics < 0.05), 1) 
Compared to Global Deterioration Scale stage 7, 2) Measure in months, 3) Patients per living room yielded the same 
results (non-signifi cant factors on each symptom), 4) SCU designed for patients with high levels of neuropsychiatric 
symptoms compared to regular SCUs 5) Time spent on direct patient care per patient (in hours each day), n = 1019 
(due to 21% missing values), staff/ patient ratio yielded the same results (non-signifi cant factor on each symptom, 
except for apathy), 6) Variable not entered in the (fi nal) analysis (p-value Wald statistics > 0.05)
 
Psychoactive medication
Antipsychotic and anxiolytic drug use was positively associated with the presence 
of all symptom clusters. However, antipsychotics were less frequently prescribed to 
patients with apathy. Antidepressants were prescribed to patients with depression/ 
anxiety. A prescription for hypnotics was not associated with any of the symptoms.
Environmental correlates
The number of patients per unit or per living room, the presence of an walking 
circuit, staff/patient ratio or the time spent on direct patient care were associated 
with neuropsychiatric symptoms. Only apathy occurred less frequently in patients 
residing in SCUs where nurses spent more time on patient care and in SCUs where 
there was more staff per patient. Patients in SCUs equipped for patients with severe 
neuropsychiatric symptoms expressed more agitation/disinhibition/irritability than 
patients in regular SCUs.
Predictability of the multilevel model
Patient factors (including psychoactive medication) explained 7.3–20.2% of the total 
variance (see Table 2). Due to the large differences between SCU symptom prevalences 
(see below), the variance of all symptom clusters at the SCU level accounted for 
3.5–14.8% of the total variance, for which only delusions/hallucinations did not reach 
statistical signifi cance (Wald statistics: p not < 0.05). The addition of the environmental 
correlates to the model improved the explained variance by less than 1.1%. Verbally 
agitated behaviour was best predicted by factors at the patient level (20%), and apathy 
had the largest variance explained at the SCU level (15%). 
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Table 2. 
Explained and unexplained variance of the multilevel model for neuropsychiatric symptoms 
predicted by patient factors, psychoactive medication use and environmental correlates in nursing 
home patients with dementia
 
 Explained variance at the patient level  Unexplained variance at the patient level
 Model with  Final model, Difference Variance at the Unexplained
 patient factors  environmental  SCU level 2) variance
 and medication  correlates
 only included 1)  
CMAI
Physically aggressive behaviour 10.6 10.9 0.3 3.7 85.4
Physically non-aggressive behaviour 11.6 12.6 1.0 6.1 81.3
Verbally agitated behaviour 20.2 20.8 0.6 7.4 71.9
NPI-NH
Agitation, disinhibition, irritabilility 7.3 8.4 1.1 7.9 83.8
Delusions, hallucinations 9.6 10.0 0.4 3.5 86.4
Depression, anxiety 13.6 14.2 0.6 9.4 76.4
Apathy 9.0 9.3 0.3 14.8 76.0
Notes: 
1) n = 1,289. Time spent on direct patient care not included; time spent on patient care in a smaller population 
(n = 1019) enhanced the explained variance on the patient level by 3.7%, 2) Variance for all symptoms are 
signifi cant (Wald test : p < 0.05), with the exception of delusions/hallucinations
Comparison of mean SCU symptom prevalence
Large differences between SCUs were found, as shown in Table 3. The average 
prevalence of physically aggressive behaviour per SCU ranged from 15% to 89%. 
Even after correction for signifi cant patient-related factors (including psychoactive 
medication use), the observed SCU prevalence rates of neuropsychiatric symptoms 
deviated in 55–79% of the cases from what was expected on the basis of patient 
factors only.
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 Discussion
The results of this study reveal that there are large differences in the prevalence of 
neuropsychiatric symptoms between nursing homes units (SCUs) for dementia 
patients, even when the model is corrected for patient-related factors such as 
cognition and psychoactive medication. In our model, the level SCU was signifi cant 
for all symptoms (except for hallucinations/delusions), indicating that neuropsychiatric 
symptoms in patients residing on the same SCU were not independent. However, 
environmental correlates used in this study cannot explain the differences in the SCU 
symptom prevalence. 
Table 3.
Observed SCU symptom prevalence and number of SCUs between and outside limits of 
expected SCU symptom prevalence
 Observed SCU symptom prevalence (%) SCUs within and outside expected limits  
    (number, % of total number of SCUs) 1)
 Mean SD range Within  Higher than Lower than
    expected  expected expected
CMAI
Physically aggressive behaviour 57 15 15–89 17 (30%) 20 (36%) 19 (34%)
Physically non-aggressive behaviour 63 15 33-100 16 (29%) 18 (32%) 22 (39%)
Verbally agitated behaviour 57 17 25-100 25 (45%) 13 (23%) 18 (32%)
NPI-NH
Agitation, disinhibition, irritabilility 50 17 10–89 18 (32%) 19 (34%) 19 (34%)
Delusions, hallucinations 19 12 0–55 17 (30%) 20 (36%) 19 (34%)
Depression, anxiety 33 17 10–82 12 (21%) 23 (41%) 21 (38%)
Apathy 33 18 0–75 14 (25%) 21 (38%) 21 (38%)
Notes: 
1) Expected on the basis of the presence or absence of signifi cant factors (patient related predictors or 
psychoactive medication use)  of each individual patient of that specifi c SCU 
We failed to establish an association between neuropsychiatric symptoms and the 
physical environment, which is in contrast with two cross-sectional studies that did 
show a relationship between agitation or other neuropsychiatric symptoms and unit 
size or nursing home size 15, 16 and an experimental study.37 One would expect that 
patients on less crowded SCUs would exhibit less agitation and that patients on 
SCUs with an walking circuit would be more likely to regulate/reduce their motor 
agitation. However, it is possible that this absence of a difference can be explained by 
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a policy to admit patients who already have a high level of agitation or wandering 
on less crowded units or units with an walking circuit. Since nursing homes in 
The Netherlands generally have more than one SCU, it is possible for patient or 
carers to choose between SCUs with different environmental features or to transfer 
patients from one SCU to another (e.g. when a patient shows excessive agitation or 
wandering). 
In contrast to what was expected, the prevalence of neuropsychiatric symptoms 
in SCUs to which patients showing a high level of neuropsychiatric symptoms 
had been admitted was not higher than that found in regular SCUs (even after 
a correction for psychoactive medication use), with the exception of NPI–NH 
agitation. We hypothesize that other co-existing mechanisms (such as a higher use 
of physical restraints or a commitment to more specialized care aimed at reducing 
or even preventing neuropsychiatric symptoms) could have leveled off the expected 
differences between regular SCUs and specialized ones. The same may be true for the 
(lack of) association between staff size and symptom prevalence, as we found that staff 
size had a signifi cant association only with apathy. Patients with apathy apparently 
benefi t from a higher number of staff members, possibly due to an increased 
opportunity for stimulation.
To our knowledge, this is the fi rst study that evaluates the complicated interaction 
between behavioural changes in dementia and Dutch nursing home features in a large 
patient sample. A major strength of the study is the rather substantial number of both 
patients and SCUs, which enabled us to achieve high statistical power to investigate 
both patient-related factors and the infl uence of differences between SCUs. In 
addition, the use of the multilevel analysis – a sophisticated statistical technique that 
has become popular over the past decade – enabled us to investigate differences 
between neuropsychiatric symptoms simultaneously at the patient and SCU level. 
By applying this technique, we were able to show that neuropsychiatric symptoms 
in different patients residing in the same SCU were related, which is suggestive of an 
interpersonal effect – i.e. the onset of neuropsychiatric symptoms depends in part on 
whether these symptoms are also present in other patients or on another common 
environmental factor related to the behaviour of all patients.
There are a number of limitations to this study. We did not categorize the dementia 
subtype, which is known to be a predictor of neuropsychiatric symptoms;38-42 
however, there is only limited evidence of this in nursing home patients.43, 44  Another 
possible limitation is the choice of environmental correlates. For practical reasons, 
we selected environmental correlates that were easy to assess instead of more refi ned 
measurement scales for the quality of the physical and psychosocial environment, 
such as the Therapeutical Environmental Screening Scale (TESS)15 or the Professional 
Environmental Assessment Procedure (PEAP),45 as these two tools have not yet been 
translated and validated in the Dutch population.  In addition to aspects related to the 
119
Environmental correlates of neuropsychiatric symptoms
quality of the physical or psychosocial environment used in these assessment scales, 
other factors may also have contributed to the substantial differences between SCUs 
(even after the correction for patient factors), such as the general attitude of the staff 
or the manner in which the staff members on a whole react to patients’ behaviour. In 
community-dwelling patients, the personality and caregiver management strategies of 
the primary caregiver is known to affect the presence of neuropsychiatric symptoms.46 
However, a good theoretical psychological model or hypothesis of staff correlates − 
translated into valid assessment scales − is not available. 
The results of this study contribute to an understanding of the importance of the 
environment on neuropsychiatric symptoms. However, the set of environmental 
correlates assessed in this study cannot explain the observed variation in 
neuropsychiatric symptom prevalence. We did not fi nd any evidence for the 
hypothesis that small-scale housing is associated with a reduction in the prevalence 
of neuropsychiatric symptoms. Since the Dutch government supports a policy of 
patients residing in small living groups of about 6–12 persons,47  there is urgent need 
for conclusive evidence on the alleged positive effects of small-scale housing on 
neuropsychiatric symptoms.
Future research should focus on the complex interactions between patients with 
dementia (with increased environmental susceptibility) and the physical and 
social environment (such as small-scale housing facilities). Further research on the 
infl uence of nursing home staff 13 – with respect to both attitude and management 
strategies – on neuropsychiatric symptoms is necessary.  A better understanding of 
such interactions could be used for future staff training to reduce neuropsychiatric 
symptoms in nursing homes and for planning a building strategy so that future 
nursing homes will meet the needs of the patients with dementia.48
We conclude that there is a substantial variation in the level of neuropsychiatric 
symptoms among SCUs. Although we failed to predict neuropsychiatric symptoms by 
the environmental correlates used in this study, the large difference between SCUs − 
even when well-known patient factors (such as dementia stage) were corrected for − 
suggests that other factors associated with the physical or psychosocial environment 
may explain the variation of neuropsychiatric symptoms between SCUs in Dutch 
nursing homes. 
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General discussion
Introduction
This chapter summarizes the main fi ndings of this thesis by addressing the research 
questions. The methodological issues of the WAALBED study are discussed, followed 
by implications for researchers, physicians and psychologists, carers, architects and 
nursing home management, and policy makers. This chapter ends with suggestions for 
future research and a general conclusion.
Summary of present fi ndings
1.  What is the prevalence of neuropsychiatric symptoms in dementia patients receiving   
 nursing home care?
Prevalences of neuropsychiatric symptoms in Dutch nursing home patients were 
high (Chapter 4). More than 80% of the patients had at least one clinically signifi cant 
symptom. Agitation/aggression and apathy were the most frequently observed 
behaviours with prevalence of 30-35%. 
Despite the fact that care for Dutch patients with dementia is provided in Dementia 
Special Care units by a multidisciplinary team, prevalence rates of neuropsychiatric 
symptoms were inside the range found in previous studies evaluating cognitively 
impaired nursing home patients in other countries (Chapter 2). Admission of 
patients with already high levels of symptoms, which are the main reason for 
institutionalization, and the policy of nursing homes not to transfer patients with 
high levels of neuropsychiatric symptoms to mental health services or hospitals in the 
Netherlands may explain why symptoms rates were not lower than in nursing homes 
in other countries.
Previous studies show a large variability in prevalence rates, which may be based on 
differences in patient population − i.e. cultural differences, variation in dementia type 
and severity −, as well as differences in assessment scales used (with different ratings or 
symptom defi nitions). 
2.  What is the effi cacy and adverse events of antipsychotic medication for neuropsychiatric  
 symptoms in patients with dementia?
Although antipsychotic medication was frequently described in nursing home patients 
with dementia in the Netherlands (Chapter 2), only limited evidence is available 
on the effi cacy of these drugs, and growing concern has risen about the safety of 
these drugs, because of the alleged risk of stroke. In the systematic review described 
in chapter 3, we concluded that the effi cacy of typical and atypical antipsychotics 
are comparable, but only low-dose risperidone seem to be associated with fewer 
(extrapyramidal) side effects and the evidence of increased risk of stroke for 
risperidone and olanzapine is too insuffi cient to confi rm the warning of an increased 
risk of mortality. However, defi nitive conclusions on the issue of stroke associated 
mortality cannot be drawn out of the limited number of studies available, with a 
chance of selective reporting (publication bias). 
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3.  What is the factor structure of the NPI-NH and CMAI in Dutch nursing home   
 patients with dementia?
Three/four behavioural dimensions underlie neuropsychiatric symptoms in nursing 
home patients as measured with the Dutch version of the NPI-NH. This fi nding is 
consistent with the clinical taxonomy of symptoms often referred to as agitation/
aggression, depression, psychosis, psychomotor agitation and apathy.1 The factor 
structure was relatively stable across dementia stages, as was the case in drug-naive 
patients, and consistent with some of the previous literature. The fi ndings may add to 
a better understanding of how symptoms are related. However, clusters found are too 
small to be used as subscales in every day clinical practice. 
The factor structure of the CMAI was consistent with the taxonomy of symptoms 
referred to as physically aggressive, physically non-aggressive and verbally agitated 
behaviour. Due to the larger amount of symptoms per factor, CMAI factor based 
subscales can be constructed and used in clinical practice. It is interesting to note 
that our initial six-factor structure represents clusters referred to as hiding/hoarding 
(which is in some literature considered as the fourth behavioural dimension 2, 3) and 
vocal agitation. These clusters represent behavioural dimensions that can clearly be 
distinguished from other agitation symptoms. However, the initial six factor solution 
may not be useful for constructing additional subscales because of the limited number 
of items per scale. Additional research into these other aspects of agitation in severely 
demented patients may be warranted.
4.  What is the infl uence of patient-related factors on the prevalence of neuropsychiatric   
 symptoms in Dutch nursing home patients with dementia?
Disease severity and gender were important predictors of neuropsychiatric symptoms. 
Some symptoms occurred more often in mild to moderate stages of dementia 
(depression, psychosis, agitation), while other symptoms were more prevalent in severe 
dementia (physical aggression, anxiety and apathy). With respect to gender, men 
showed more physically aggressive behaviour and apathy, while women showed more 
verbally agitated behaviour, depression and anxiety.
5.  What is the infl uence of factors associated with the physical and psychosocial   
 environment in the special care units on the prevalence of neuropsychiatric symptoms   
 in Dutch nursing home patients with dementia?
The substantial variation found in the prevalence/severity of neuropsychiatric 
symptoms among SCUs, even after correcting for well-known patient factors (such 
as gender and dementia stage), suggests that factors associated with the physical and 
psychosocial environment may prove to be important in explaining neuropsychiatric 
symptoms. Less apathy was observed in SCUs with higher number of staff. The other 
environmental variables measured in this study, such as staff size, number of patients 
127
General discussion
per unit or per living room, the presence of an walking circuit did not predict 
neuropsychiatric symptoms. It is possible that important correlates of neuropsychiatric 
symptoms may have been overlooked and not measured. Alternatively, it is possible 
that not individual environmental correlates, but a combination of the present and 
other correlates would reveal a signifi cant effect on neuropsychiatric symptoms. 
The lack of a signifi cant association between environmental correlates and 
neuropsychiatric symptoms might also be explained by the policy to admit or transfer 
patients with high level of agitation or wandering to a less crowded unit or a unit 
with an walking circuit. In conclusion, neuropsychiatric symptoms seem to be related 
to the environment of the dementia special care unit, but further research is necessary 
to explore what factors associated with the physical and psychosocial environment are 
responsible for the variation of neuropsychiatric symptoms between SCUs.
Methodological issues
Assessment instruments
Neuropsychiatric symptoms were measured in the WAALBED study using two 
different behavioural rating scales. The NPI-NH is a comprehensive neuropsychiatric 
rating scale and the CMAI is a specifi c rating scale for measuring agitation and 
aggression. The NPI-NH and CMAI are frequently used in nursing homes for both 
prevalence and intervention studies.4, 5 Both scales have established validity and have 
been used in many different studies of neuropsychiatric symptoms in dementia. The 
combination of both scales made it possible to measure a wide range of important 
behavioural changes in dementia. However, other neuropsychiatric symptoms have 
been observed in dementia patients, such as self injurious behaviours, 6, 7 that are 
not measured in detail by the NPI-NH and CMAI. Secondly, the NPI-NH offers 
limited possibility to assess specifi c symptoms, such as visual or auditory hallucinations 
or certain types of delusions. Thirdly, the NPI-NH measures depressed mood as a 
symptom but not depression at a syndromic level. For further assessment of psychosis, 
depression and apathy other rating scales would be more appropriate, but this was 
outside the scope of this thesis. So, content validity of the results on prevalence rates 
of neuropsychiatric symptoms is limited by the behaviours sampled in the scales used 
in this thesis.
We spent much effort in training the nurse-assistants, to ensure reliability of the 
interviews. Assessments were preceded by a two-week observational period in which 
staff members not participating in the study were asked to report neuropsychiatric 
symptoms. Reliability of neuropsychiatric prevalence rates may depend on the quality 
of such reported data. 
Apart from the technical aspects, other diffi culties with regard to assessing 
neuropsychiatric symptoms may have occurred. In patients with severe dementia, 
communicative abilities decrease and symptoms can only be directly observed as overt 
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behaviour, such as aggressive behaviour or apathy. For that reason depression, delusions 
and verbally agitated behaviour were less often observed in these cases. Moreover, it 
is possible that the beliefs and attitudes of the nursing staff towards neuropsychiatric 
symptoms could introduce bias with regard to observation and interpretation of 
symptoms. 
The NPI-NH and CMAI may be of limited use in evaluating individualized 
psychosocial treatment programs. Both scales measure the frequency and severity of 
certain symptoms, but do not assess the context in which the behaviours occur, i.e. 
the eliciting factors and consequences. These scales were designed and proven useful 
for evaluating (global) effi cacy of pharmacological interventions. To study effectiveness 
of psychosocial interventions, much more information is needed. For that purpose 
other observation techniques (such as video taping caregiving activities) or dementia 
care mapping 8 would be more appropriate.
The Global Deterioration Scale (GDS) is used to refl ect dementia severity. The GDS 
includes also neuropsychiatric symptom (delusions, anxiety and aggression) especially 
in severe cognitive deterioration (GDS 6). The consideration of neuropsychiatric 
symptoms in the GDS could be a possible source of bias when using the GDS to 
study the infl uence of dementia stage on the presence of neuropsychiatric symptoms. 
One might argue that a combination of the Mini Mental State Exam (MMSE) and 
functional assessments would have been superior.
The content validity of the measures of environmental correlates of neuropsychiatric 
symptom may be questioned. Some environmental factors were measured while 
other factors were perhaps not. The choice of the environmental correlates was 
driven by practical reasons, i.e. we used correlates that are easy to assess. More refi ned 
measurement scales for the quality of the physical and psychosocial environment, 
such as the Therapeutical Environmental Screening Scale (TESS) 9 or the Professional 
Environmental Assessment Procedure (PEAP), 10 have neither been translated nor 
validated for the Dutch population. 
Selection bias
The WAALBED study was carried out in northern, eastern and southern parts of the 
Netherlands. Only the 72 nursing homes providing the specialist training program 
for nursing home physicians in cooperation with the Department of Nursing Home 
Medicine of the Radboud University Nijmegen Medical Centre were asked to 
participate. Twenty-fi ve of them ultimately agreed to participate in the study. The 
managing director of these institutions selected the SCUs to be assessed. All these 
‘choices’ may be a source of selection bias. However, participating SCUs did not differ 
with respect to admission policy towards patients with neuropsychiatric symptoms or 
dementia stage/ care level compared to non-participating SCUs. The age and gender 
distribution of our patient sample differed only slightly from that of the national 
nursing home population. Unfortunately we cannot compare the WAALBED 
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data with the national nursing home population with respect to dementia type 
and psychoactive medication use – both factors known to affect neuropsychiatric 
symptoms, since these data are not available. This unknown source of selection bias 
hampers extrapolation of the results to the Dutch national nursing home population. 
However, the large study sample – that comprised 4.4% of all demented nursing 
home patients in the Netherlands – makes large sampling errors improbable. 
Type of dementia
No data were available on the type of dementia. The lack of an etiological diagnosis 
may obscure the results of how neuropsychiatric symptoms are interrelated and on 
the correlates of neuropsychiatric symptoms. Some neuropsychiatric symptoms are 
highly prevalent in certain types of dementia while they are observed less frequently 
in other dementias: e.g. hallucinations are prominent in Lewy Body Dementia 
and disinhibition is typical of Frontotemporal dementia. These differences are also 
clinically important in terms of treatment options and patient management. Thus an 
etiological diagnosis of the dementia syndrome is relevant. However, many Dutch 
dementia patients enter the nursing home without an etiological diagnosis established. 
In most instances the diagnosis of ‘dementia’ is all there is. We had to deal with this 
situation and considered that establishing and etiological diagnosis in this large patient 
sample was simply beyond the possibilities both in terms fi nances and available time. 
Moreover, in cases where an etiological diagnosis of dementia is feasible in the early 
stages of the disease, it becomes increasingly diffi cult in later stages. Our study sample 
included many severe dementia patients for whom it would be almost practically 
impossible to determine exact etiology of the dementia syndrome at the time they 
were included in the study. The patients in the longitudinal study on the course and 
predictors of neuropsychiatric symptoms (WAALBED-2) – also being conducted by 
the Radboud University Nijmegen Medical Centre – will be diagnosed with respect 
to their dementia type. 
Generalizability
As nursing home care for patients with dementia in the Netherlands is mainly 
provided in dementia special care units, this study included patients residing in SCUs 
only. Dutch policy is to provide dementia care in the community, so that patients 
with dementia can stay at home as long as possible. Community dwelling patients 
with neuropsychiatric symptoms are more likely to be admitted to nursing homes 
compared to those without. Because of the high quality of the multidisciplinary 
treatment in the SCUs, patients are not often transferred to psychiatric hospitals when 
neuropsychiatric symptoms deteriorate. We therefore expect that the prevalence of 
neuropsychiatric symptoms in Dutch SCUs is higher than in nursing homes in other 
countries. Accordingly, this hampers generalizability of our results.
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Implications for researchers
Conceptualization of neuropsychiatric symptoms
Our fi nding that disease related factors (Chapter 7) are associated with 
neuropsychiatric symptoms is in agreement with previous studies in community-
dwelling patients in The Netherlands11 and also with studies of community-residing 
and institutionalized dementia patients samples in other countries (see Chapter 2). 
Also, the way in which symptoms co-occur or cluster is consistent with previous 
fi ndings (Chapter 5 and 6). 
These robust trans-cultural fi ndings strongly favour a biological origin of 
neuropsychiatric symptoms. The anatomical substrate of neuropsychiatric symptoms 
has been studied with Computer Tomography (CT), Magnetic Resonance Imaging 
(MRI) or Single Photon Emission Computer Tomography (SPECT) in dementia 
patients with vascular lesions. Relationships between regional anatomical lesions/ 
hypoperfusions and neuropsychiatric symptoms have been shown for apathy as a 
syndrome (anterior cingulate),12 apathy in Alzheimer’s disease (anterior cingulate13, 14 
or thalamic areas 15 or frontal lobe 16), apathy in frontotemporal dementia (frontal 
lobe),17 major depression (orbitofrontal areas),12 depression and apathy after stroke,18 
hallucinations in Alzheimer dementia (parietal lobes),19 delusions in Alzheimer 
dementia or vascular dementia (frontal lobe),19, 20 aggression in dementia (right 
medial temporal region21 or left frontotemporal region22), disinhibition or stereotypic 
behaviour in frontotemporal dementia (temporal lobe).17 Apparently, neuropsychiatric 
symptoms are related to the way in which the damaged human brain acts on stressors. 
Acute stress might in this respect be accompanied with confusion, disorientation 
and delirium, whereas chronic stress might result in exhaustion, depression or apathy. 
Apathy can be seen as extinction of behaviour due to brain damage in specifi c or 
global areas in the brain. The increasing prevalences of apathy during increasing 
cognitive deterioration (as a result of brain damage) is in line with this idea (Chapter 7).
Alternatively, it is possible (although in our opinion less likely) that, regardless of time 
and location, dementia patients react in similar ways when confronted with cognitive 
deterioration or when admitted to a nursing home. Such a view would disfavour a 
common biological origin of neuropsychiatric symptoms. 
However, neuropsychiatric symptoms were obviously infl uenced by other factors than 
biological factors only. Even after correction of disease related factors, prevalence rates 
of neuropsychiatric symptoms varied across SCUs in The Netherlands (Chapter 8) 
as is the case in SCUs in other countries (e.g. in Australia).23 This variation in SCU 
symptom prevalence is likely to be associated with correlates of the physical and 
psychosocial environment (Chapter 8, see also implications for architects and nursing 
home management). Accordingly, the biopsychosocial model as an extension of the 
biological model, is not only valid in community-residing patients,11 but is applicable 
to nursing home patients as well.  
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Classifi cation of neuropsychiatric symptoms in general
The concept of BPSD, as originally proposed by the International Psychogeriatric 
Association (IPA), suggests clustering all behavioural (e.g. aggression and psychomotor 
agitation, psychosis) and psychological (e.g. depression) symptoms. In agreement with 
others, we showed that there is evidence for clustering symptoms into aggression, 
psychomotor agitation, psychosis, depression and apathy (Chapter 5).
The clinical relevance of classifying neuropsychiatric symptoms is recently 
acknowledged in an IPA consensus paper,24 which stated that ‘Agreement about the 
most appropriate differentiation and classifi cation of neuropsychiatric symptoms 
into syndromic groupings is needed, and would be the best way to address the issue 
of symptoms overlap’. The classifi cation of neuropsychiatric symptoms proposed in 
that paper differs from the one in the WAALBED study. The IPA consensus group 
proposed a hierarchical approach to differentiate neuropsychiatric symptoms into 
dementia-associated affective disorder (depressed or agitated) and dementia-associated 
psychotic disorder, that subscribes to the signifi cance of treatable syndromes. 
The dementia-associated affective disorder with agitation, however, suggests a 
co-occurrence of depression and agitation, which we have shown to be different 
behavioural dimensions. In the hierarchical approach of the IPA consensus paper, 
apathy is acknowledged as a syndrome distinct form depression, but − in contrast to 
our fi ndings − this paper suggests a further differentiation into apathetic syndrome 
and executive syndrome. The latter syndrome includes disinhibited behaviours such as 
hoarding, pacing or hitting.25 We feel that the clinical classifi cation of symptoms – i.e. 
aggression, psychomotor agitation, psychosis, depression and apathy – of which we 
found supportive evidence, is more applicable in every-day clinical practice. 
Classifi cation of apathy and depression
Factor analysis of the NPI-NH (Chapter 5) supports the IPA proposal that apathy and 
depression should be viewed as separate entities. In this thesis, it is also shown that 
apathy and depression have different frequencies across gender and dementia severity 
(Chapter 7). 
The fi nding that apathy was related to cognitive (i.e. executive) dysfunction (whereas 
depression is not) is also consistent with previous studies including patients with 
Alzheimer’s disease26 and other neurodegenerative diseases such as Parkinson 
Disease27 and Progressive Supranuclear Palsy.28 Apathy can be present in the absence 
of depression in dementia and in other diseases, such as Parkinson disease29, 30 and 
stroke.18 Apathy and depression may have different anatomical substrates12 and revealed 
different outcomes in neuropsychological tests.31 Depression and apathy can also 
overlap in both patients with dementia26 and stroke.18 
From a clinical point of view differentiating depression from apathy can be diffi cult, 
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because loss of interest and psychomotor retardation are features of both depression 
and apathy. These symptoms should not be considered suffi cient core features of 
minor depression.29, 32 This emphasizes the need to defi ne diagnostic criteria for 
apathy as a syndrome (as is the case for depression) in neurodegenerative diseases such 
as Alzheimer disease and Parkinson disease.33 
Differentiating depression from apathy, even in patients with severe dementia (Chapter 
5), has important clinical consequences. Depression, by contrast to apathy, can be 
treated with antidepressants. We suggest that patients with executive dysfunction 
(apathy) with depressed mood should be treated with antidepressants, where apathetic 
patients without observable mood-disturbances should not. For apathy, there is 
no broadly accepted pharmacological or psychosocial intervention. There is some 
evidence favouring the use of cholinesterase inhibitors,34 methylphenidate,35 activity 
therapy/reminiscence,36 snoezelen37, 38 or music therapy.39 Whatever intervention is 
chosen, the effects of apathy on quality of life are hardly investigated and additional 
research is warranted.
Classifi cation of agitation
By contrast to the IPA consensus paper,24 our results showed that agitation represents 
at least three underlying behavioural syndromes, i.e. physically aggressive, physically 
non-aggressive and verbally agitated behaviour (Chapter 6). The three clusters of 
agitation in the WAALBED study have also different frequencies across gender and 
severity, which supports the view that agitation is not a unitary concept but should 
be distinguished into three separate entities. This may have clinical consequences, for 
example because of the different effi cacies for antipsychotics.40 
Vocal agitation was also found as a distinct cluster − apart from the three other 
types of agitation. This type of agitated behaviour is acknowledged as a distinct 
phenomenon in the guideline about problem behaviour of the Dutch Association 
of Nursing Home Physicians (NVVA).41 Vocal agitation may be more diffi cult to 
treat than other types of agitation, such as physical aggression or wandering. Verbally 
disruptive behaviour (screaming, vocal agitation) may be associated with cognitive 
deterioration, severe impairment, worse performance of activities of daily living, pain, 
depression, impaired social functioning.42, 43 There may be different types of disruptive 
vocalizations with different aetiology.44 Especially vocalization not related to pain or 
depression but to cognitive deterioration instead may be conceptualized as repetitive 
behaviour with a separate neurobiological etiology.45 The CMAI only partially taps 
different types of disruptive vocalizations. We suggest that new assessment scales 
focussing on vocally disruptive behaviour should be developed. 
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Implications for physicians and psychologists
Antipsychotics and other psychotropic drugs are frequently used in Dutch nursing 
homes as we have shown (Chapter 4),46 This is also the case in other nursing homes 
47-52 and residential homes throughout the world.53 Psychotropic drugs are used 
(too) frequently, despite guidelines41, 54, 55 and Omnibus Budget Reconciliation 
Act (OBRA)-regulations that warn against excessive and long-term/ chronic use. 
Guidelines are not always adhered to53 and patient factors, such as the presence of 
neuropsychiatric symptoms, are often not the only reason for prescribing psychotropic 
drugs. We noticed that prescriptions rates vary greatly among nursing homes 51 and 
may be associated with nursing home facility characteristics such as low level of staff.52
Antipsychotics have only limited effi cacy in agitation and psychosis and have 
considerable sides effects such as extrapyramidal symptoms, somnolence and an 
increased risk for stroke (i.e. olanzapine and risperidone)(Chapter 3). In a recent 
meta-analysis of published and unpublished randomized controlled trials atypical 
antipsychotics were found to be associated with a (small) increased risk of death 
compared to placebo.56 The increased risk of death associated with atypical 
antipsychotic medication may also be true for conventional antipsychotics as well.57 
The evidence on the effi cacy and adverse events of atypical antipsychotic drugs was 
increased by two recent publications: (1) The results of the CATIE-AD trial showed 
that time to discontinuation due to lack of effi cacy favoured olanzapine, risperidone 
(but not quetiapine), but time to discontinuation due to intolerability favoured 
placebo;58 (2) A Cochrane review showed that risperidone appeared to be effi cacious 
for aggression and psychosis, and olanzapine for aggression only, but both drugs 
were associated with higher incidence of serious adverse cerebrovascular events and 
extrapyramidal symptoms. 59 
Psychotropic drugs, - especially antipsychotics -, may also be associated with lower 
quality of life.60 Physicians should therefore be careful in prescribing antipsychotic 
drugs in frail elderly with dementia especially in the presence of cardiovascular 
risk factors. Psychotropic medication is often prescribed as long-term treatment.51 
However, the natural history of behavioural changes in Alzheimer’s disease shows 
great individual variation 61 and some neuropsychiatric symptoms are intermittent 62, 63 
or even may occur only once.61 We advise physician to make regular attempts to taper 
or to discontinue psychotropic medication. 
Caution on psychotropic drugs may not apply to antidepressants, since these drugs 
have fewer devastating side effects than antipsychotics and depression in nursing 
homes is often underdiagnosed and undertreated, at least in patients with no or 
mild cognitive disorders.64 We feel that this is even more true in patients with severe 
dementia. Cholinesterase inhibitors are also thought to have fewer side effects, but 
are only registered for cognitive and global deterioration in patients with Alzheimer 
disease. The evidence of effi cacy of cholinesterase inhibitors for neuropsychiatric 
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symptoms in both Lewy-body dementia 65, 66 and Alzheimer’s disease 67 is weak and 
needs further study. 
In our opinion, the use of psychosocial interventions as a fi rst choice of treatment 
should be encouraged.68 Unfortunately, the evidence of the effect of psychosocial 
interventions is limited and quality of the studies is moderate. There is insuffi cient 
evidence yet with regard to validation,38, 69 aromatherapy,70, 71 light therapy.72 Other 
psychosocial interventions, such as reminiscence,73 psychomotor therapy,38 caregiver 
training,74 cognitive stimulation therapy 74 are more effi cacious. Music therapy only 
seems to work during treatment sessions, but may have no longer-term effects.74, 75 
Snoezelen/ sensory stimulation, previously thought to have only short term effects,74 
has positive effects on apathetic and aggressive behaviour and depression,37 when 
integrated into 24-hour dementia care. 
Signifi cant other psychosocial factors in literature were the quality of staff-patient 
interaction,76, 77 policy with regard to managing diffi cult behaviours 78 or the use 
of physical restraints9 and concept of care (e.g. emotion-oriented care). Emotion-
oriented care is a multifaceted care approach of different psychosocial interventions 
(i.e. validation, reminiscence, sensory stimulation) which can be applied by the 
nursing staff in routine care. Yet, the evidence of the effects of integrated emotion 
oriented care on neuropsychiatric symptoms in institutionalized patients is limited; 
in a randomized controlled trial in nursing home patients with dementia, emotion 
oriented care had a small positive effect on anxious behaviour compared to usual care, 
but only in patients less in need of assistance/care, but not on physically of verbally 
aggressive behaviour. 79 In a randomized controlled trial in cognitively impaired 
patients residing in homes for the aged, emotion-oriented care only has an effect 
on anxious behaviour and physically non-aggressive behaviour at 6 months after 
randomisation, but not at 12 months. 80
The effect of psychosocial interventions may be more effective when individual 
psychosocial interventions are combined. A combination of didactic training and 
supervision, application of person centred care, positive care planning, awareness 
of environmental design issues, the use of behaviour therapy models, reminiscence 
techniques, was shown to be effi cacious; in a recent randomized controlled trial 
comparing this enhanced psychosocial care with regular care provided to nursing 
home patients with severe dementia, enhanced psychosocial care − however 
not effi cacious in reducing agitation levels and well-being − was able to reduce 
psychotropic drug use.81 A second study on the effect of a combination of enhanced 
education and activities, and implementing guidelines for drug use, showed signifi cant 
improvement in behaviour with a trend towards a reduction in neuroleptic use.82 
In conclusion, we advocate a restricted and careful use of psychotropic drugs, 
especially antipsychotics, since a tailored psychosocial intervention or a combination 
of psychosocial interventions should be the fi rst treatment option. 
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Implication for carers
The high prevalence rates of neuropsychiatric symptoms in general and agitation in 
particular (Chapter 2 and 4) is of major importance for accurate patient-oriented 
staff planning. This is not only true for aggressive and agitated behaviours, but also for 
apathy, a behaviour associated with deterioration of the disease resulting in patients 
being increasingly impaired in the basic activities of daily living and so resulting 
in high need of care.83 The numbers of patients showing apathy or resistance to 
(morning) care and of those with wandering in the afternoon should be important 
factors to be taken into consideration when determining the number of staff to be 
employed during the day. Recent work of Cohen-Mansfi eld confi rmed the steady 
increase of agitation throughout the day with a peak in the afternoon, due to fatigue 
of daytime nursing staff members and disruption during shift change.84 
In this respect, we argue not only for a more patient-oriented staff planning, that 
meets the care needs of the individual patient. More attention should also be paid 
to ‘care for the carers’. Perceived work-related stress and feeling of incompetence of 
nursing staff can be reduced by the introduction of patient oriented care.79 Anne-
Mei The, the writer of the book ‘Living and Dying with Dementia’,85 launched an 
initiative to focus on the carers/ nursing staff, as satisfi ed staff is more able to care for 
the patients. This program encompasses education, supervision, and coaching of staff, 
that should be integrated into the care process.86 This learning by practical experience 
or by other techniques such as role-playing or video-interaction techniques 
should provide tools for the nursing staff to deal adequately with patients with 
neuropsychiatric symptoms.
Implications for architects and nursing home 
management
The large variation of neuropsychiatric symptoms between SCUs in the WAALBED 
study highlights the importance of the nursing home environment. SCUs that had 
many staff members also had less patients with apathy. (Chapter 8) Staff in these SCUs 
may have had more opportunity to stimulate patients. This is in line with studies 
showing that patients with apathy benefi ted from getting attention from the activity 
therapist.36 The author of this study noted that ‘the mechanisms of action’ by which 
activity may diminish apathy are unknown. It may work by overcoming the inability 
of apathetic patients to motivate themselves by providing an external motivator and 
general social stimulation. Or, it may work by providing a context and structure for 
patients who cannot provide these for themselves’.36 
Other environmental correlates used in the WAALBED study did not explain the 
variation of neuropsychiatric symptoms between SCUs. The large variation of 
symptoms between SCUs may be explained by correlates that were not studied and 
there is a need for further study on this subject. 
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Signifi cant physical environmental correlates of neuropsychiatric symptoms stated in 
literature are: SCU environment quality in general,9, 87, 88 camoufl aged exit doors,89, 90 
tapelines on the fl oor 91, mirrors 92 in front of an exit door, enhanced visibility of the 
toilet (as a cue for residents to use it),93 personalized cues to enhance orientation to 
the bedroom,94 environmental enhances such as large pictorial murals,95 spatial density 
(more area per person) of a unit,96 the amount of privacy,90 gradation of space (i.e. 
the variety of spaces, such as quiet and stimulating rooms),90, 97 the presence of central 
open areas,98 the architectural design (shape) of the unit,99 the presence of outdoor 
spaces (gardens or patio’s), the presence of an ambient (residential) environment that 
residents can understand.90 (For relevant psychosocial aspects see: implications for 
physicians and psychologists.)
The absence of the association between neuropsychiatric symptoms and unit size 
in the WAALBED study does not mean that ‘small-scale housing’ is ineffective. For 
the concept of small-scale housing is not so much determined by unit size, but 
rather by organisational features such as the integration of staff and patients forming 
one household living in a archetype ‘house’ and the policy to provide long-term 
care for patients until the end of their lives.100 This concept is very similar to the 
ecologic model of care ‘that is responsive to the unique interplay of each person 
and the environment’ and that ‘encompasses a vision of long-term care that is more 
comfortable, more like home, and offers more choice, meaningful activity, and 
privacy than traditional settings’.101 A special care facility based on this model (small 
bungalows with 10 residents) showed to be effective in that residents with less decline 
in activities of daily living showed a more sustained interest in the environment and a 
less negative affect than cognitively-matched residents in traditional settings.101 In The 
Netherlands, a large multi-centred trial has currently been conducted on the effect 
of small scale housing on neuropsychiatric symptoms. The results of this study are 
expected to be published soon. 
Not all patients with dementia may benefi t from this special facility 101 and it is 
questionable whether these facilities can give life-long care for residents. In Sweden, 
for instance, the small-scale housing facilities are intermediate care facilities as a 
pre-phase for admission in a nursing home. Awaiting the results of further studies on 
small scale housing, we advocate that individual attempts to enhance the quality of 
the physical and social environment should be used within an integrated concept of 
special care such as patient/emotion oriented care or the ecological model of care, to 
maximize its effect on the presence of neuropsychiatric symptoms and quality of life.
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Implications for policy makers
The large variation of the SCU symptom prevalence independent of patient related 
factors (Chapter 8) suggests that other psychosocial and physical factors contribute to 
the frequency of neuropsychiatric symptoms, such as staff attitude and policy towards 
the use of pharmacological interventions, psychosocial interventions and the use of 
physical restraints. The proposed effect of SCU characteristics on neuropsychiatric 
symptoms might refl ect differences in quality of care. 
However, one should be cautious to use the level of neuropsychiatric symptoms as 
an indicator for the quality of nursing home care, since neuropsychiatric symptoms 
may not be the best indicator for quality of life. In cross-sectional studies both 
neuropsychiatric symptoms 102 and psychoactive drugs 60 were associated with 
low quality of life. Attempts to improve quality of life by enhancing psychosocial 
interventions were shown to reduce the amount of psychotropic drugs but did 
not change the prevalence of neuropsychiatric symptoms.81 It is possible that the 
frequency of psychotropic medication (especially antipsychotic drug) use within 
SCUs would be a better indicator for the quality of nursing home care. The 
antipsychotic drug use should be corrected for the amount of demented patients with 
high levels of symptoms (e.g. due to concomitant psychiatric diseases). The general use 
of such an indicator should not be advocated on a larger scale until further research 
defi nitely decides on the relationship between psychoactive drugs and quality of care.
Suggestions for future research
This thesis provides answers to the prevalence and predictors of neuropsychiatric 
symptoms and gives an overview of the current evidence of the usefulness of 
antipsychotic medication. However, the WAALBED study had a cross-sectional 
design, which only revealed ‘associations’ between correlates and neuropsychiatric 
symptoms. Longitudinal studies are better designed for collecting evidence for ‘causes’ 
of neuropsychiatric symptoms. Currently a longitudinal study in Dutch nursing 
home patients with dementia (WAALBED-2) is now being conducted to investigate 
whether changes in quality of life are caused by changes of neuropsychiatric 
symptoms or by changes in antipsychotic drugs use. 
Further studies on non-cognitive symptoms of dementia are necessary. Nursing home 
research should not focus on clusters of symptoms, such as agitation or psychosis, but 
on symptoms that are most distressful for carers, such as resistance to care or physical 
aggression or verbally disruptive behaviour. More sophisticated techniques, such as 
direct behavioural observation, video-taping care-giving activities or dementia care 
mapping should be used as appropriate assessment instruments, for they provide more 
specifi c information about the circumstances that initiate or exacerbate behaviour. 
Especially dementia care mapping is a valuable research tool that is more closely 
related to quality of life.8 
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More research is needed on the effect of psychosocial interventions and on care 
approaches to enhance quality of care or life in nursing home patients. Evidence on 
the effi cacy of psychosocial interventions is insuffi cient and quality of life is very 
rarely used as a primary or secondary outcome in intervention studies in patients with 
dementia.103 The insight in effective interventions on the physical and psychosocial 
environment provides valuable evidence for building the ‘ideal nursing home’ and for 
the combination of psychosocial interventions /care-strategies to be applied in daily 
practice. This insight is also helpful to develop guidelines on therapy for physicians, 
psychologists and nursing staff.104
General Conclusion
In this thesis on neuropsychiatric symptoms in Dutch nursing home patients with 
dementia prevalence rates are high and are infl uenced by disease related predictors 
and environmental factors. The fi ndings of the WAALBED study indicate a 
biopsychosocial origin of neuropsychiatric symptoms. This model provides a better 
understanding of the etiology and the treatment possibilities than a biological 
model. As biological (pharmacological) interventions have only modest effi cacy 
and considerable side effects, psychosocial interventions should be encouraged. We 
advocate a person-centred approach for the treatment of neuropsychiatric symptoms. 
This approach takes individual personality, coping strategies, history, dementia severity 
and co-morbidity into account when choosing the adequate therapeutic strategy. The 
person-centred approach provides a toolkit of interventions such as pharmacological 
interventions, validation, reminiscence, snoezelen, psychomotor therapy that can be 
tuned on the individual symptoms and needs of patients with dementia to reduce the 
burden of neuropsychiatric symptoms and increase the quality of life.
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Dementia is an incurable disease with substantial effects on cognition, activities of 
daily living and behaviour. Neuropsychiatric symptoms, often referred to as agitation/ 
aggression, psychosis, depression and apathy have major impact on both patient and 
caregiver, and are the main reasons for institutionalization. Also in nursing homes, 
patients with neuropsychiatric symptoms can be a serious burden on staff, leading to 
an increase of staff distress. The patients themselves are often subjected to high levels 
of physical restraints and to psychotropic medication which has considerable side-
effects. 
Earlier publications suggest that neuropsychiatric symptoms occur frequently and are 
related to dementia type and severity. There are also indications that neuropsychiatric 
symptoms are infl uenced by other factors associated with psychosocial interactions 
and the physical environment.  
In the last decade more research has been conducted with regard to community-
dwelling patients, but insuffi cient literature exists about nursing home patients. The 
typical environment of nursing homes with communal rooms in which patients 
–institutionalized because of their high levels of neuropsychiatric symptoms – spend 
their daytime provides an opportunity to study the value of the biopsychosocial 
model to explain the factors contributing to neuropsychiatric symptoms.
This thesis mainly describes the results of the Dutch WAAL BEhaviour in Dementia 
(WAALBED) study; a large study on neuropsychiatric symptoms in Dutch 
nursing home patients with dementia. In The Netherlands institutionalized care 
for people with dementia is provided in dementia Special Care Units (SCUs) by 
a multidisciplinary team of nurses, nursing home physicians, physical therapists, 
psychologists, activity therapists and other specialists, all of whom are employed by 
the nursing home. Such a team can also provide care for people with dementia in 
residential homes (outreaching nursing home care).  
The aim of the thesis is to gain further insight in (1) the prevalence of 
neuropsychiatric symptoms in nursing home patients with dementia and (2) patient 
predictors and environmental correlates of neuropsychiatric symptoms.
Chapter 2 gives an overview of current literature on the prevalence of 
neuropsychiatric symptoms in cognitively impaired nursing home patients. 
Neuropsychiatric symptoms are found in more than 80% of the cognitively impaired 
patients. Prevalence rates of specifi c symptoms range considerably, from 3% to 54% for 
delusions, 1% to 39% for hallucinations, 8% to 74% for depressed mood, 7% to 69% 
for anxiety, 17% to 84% for apathy, 48% to 82% for aggression or agitation, and 11% 
to 44% for physical aggression. The large variation in prevalence rates may be based 
on differences in patient populations, as well as on differences in assessment scales used 
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(with different ratings or symptom defi nitions). Neuropsychiatric symptoms seem 
to be predicted not only by dementia type or severity but also by the psychosocial 
environment, the amount of psychoactive medication and physical restraints used.
Chapter 3 is a systematic review of the effi cacy and adverse events of antipsychotic 
medication. Although antipsychotic medication is frequently prescribed to nursing 
home patients with dementia in The Netherlands (37% in the WAALBED study, 
see Chapter 4), limited evidence is available on the effi cacy of these drugs and 
there is a growing concern about the safety of these drugs, because of the alleged 
risk of stroke. In literature only 14 studies could be found describing the effi cacy 
of haloperidol, risperidone, olanzapine in more than one study (per drug) and 
quetiapine, tiapride, loxapine and perfenazine (in only one study per drug). It 
appears that the effi cacy of typical and atypical antipsychotics are comparable, and 
only low-dose risperidone seems to be associated with fewer (extrapyramidal) side 
effects. Risperidone and olanzapine were shown in two studies to be associated with 
a higher risk of cerebrovascular adverse events. The profi le of the adverse events of 
antipsychotic medication has been inadequately described in the published research 
and, consequently, the warnings for an increased mortality cannot be confi rmed. 
Chapter 4 describes the prevalence of neuropsychiatric symptoms in Dutch nursing 
home patients. Neuropsychiatric symptoms were measured with the Neuropsychiatric 
Inventory- Nursing Home version (NPI-NH) and the Cohen-Mansfi eld Agitation 
Inventory (CMAI). Overall, more than 80% of the nursing home patients of the 
WAALBED study suffered from at least one symptom. Delusions and hallucinations 
were present in 15% and 8% of the patients, respectively. Depressed mood and anxiety 
were present in 20% and 21% of the patients. Prevalence of aggressive/agitated 
behaviours were 31% for aggression/agitation, 20% for disinhibition, 34% for 
irritability and 29% for aberrant motor behaviour (measured with NPI-NH) and 
44% for general restlessness, 33% for cursing or verbal aggression, 13% for hitting 
(measured with the CMAI). Apathy was present in 34% of the patients. We conclude 
that prevalence rates are high, a fi nding which has practical consequences for staff 
planning.
Chapter 5 describes the factor structure of the NPI-NH. Factor analysis was used 
to examine behavioural dimensions underlying neuropsychiatric symptoms. We 
described the factor structure in the WAALBED population across dementia stages 
(as assessed with the Global Deterioration Scale) and in patients with or without 
psychoactive medication. In three stages of dementia severity a four or fi ve factor 
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solution was found, with factors referred to as agitation/aggression, depression, 
psychosis, psychomotor agitation and apathy. These symptom clusters were replicated 
in the group of drug-naïve patients, but only partially in the group of patients on 
psychoactive medication. The factor structure of the NPI-NH is consistent with the 
clinical taxonomy of symptoms, is relatively stable across dementia stages, and is only 
moderately infl uenced by psychoactive medication use. The clusters of symptoms 
were, however, too small to be used as subscales. The division of depression and apathy 
into separate behavioural dimensions – also in patients with severe dementia – may 
have important therapeutical consequences.
Chapter 6 describes the factor structure of the CMAI that was used to assess 
agitation or aggression in the WAALBED study population. A restricted 3-factor 
solution showed the factors associated with physically aggressive behaviour, physically 
non-aggressive behaviour and verbally agitated behaviour. The 3-factor solution is 
consistent with earlier fi ndings in community-dwelling and nursing home patients 
with various dementia severity. The symptom clusters originated from these 
behavioural dimensions were used as subscales in Chapter 7 and 8. In addition, 
an unrestricted factor solution revealed three additional behavioural dimensions: 
hiding/ hoarding, vocal agitation and a factor of miscellaneous items (i.e. repetitious 
mannerisms and spitting). These addition factors are too small to be used as a subscale, 
but these fi ndings may add to the taxonomy of agitation and aggression in dementia.
Chapter 7 describes the infl uence of gender and disease severity on neuropsychiatric 
symptoms in the sample of Dutch nursing home patients with dementia. Delusions, 
depression, physically non-aggressive behaviour, and verbally agitated behaviour 
were most common in moderately severe (GDS stage 5) and severe (GDS stage 6) 
cognitive deterioration with lower prevalences in very severe cognitive deterioration 
(GDS stage 7). Physically aggressive behaviour, apathy and anxiety showed highest 
prevalences in very severe cognitive deterioration (GDS stage 7). Physically aggressive 
behaviour and apathy were more prevalent in male patients, while depression and 
anxiety were more frequent in female patients with dementia. We conclude that both 
dementia severity and gender are important predictors of neuropsychiatric symptoms. 
Chapter 8 describes the infl uence of correlates associated with the physical and 
psychosocial environment on neuropsychiatric symptoms. The nursing home 
population resided in 56 dementia special care units. The infl uence of both patient-
related factors and SCU characteristics on symptom clusters of the CMAI and 
psychosis, depression/ anxiety, agitation and apathy was studied using multilevel 
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logistic regression analysis, a technique able to correct for the dependency of 
neuropsychiatric symptoms in patients in the same SCU. The results showed 
that there was a substantial variation of the level of  symptom prevalence among 
SCUs, accounting for 4-14% of the total variance of neuropsychiatric symptoms. 
Signifi cant patient related factors were dementia severity, gender, age, duration of 
institutionalization and psychoactive medication use, which accounted for another 
7-21% of the total variance. The range of SCU symptom prevalence was considerably 
large even after correction for signifi cant patient-related factors of each individual 
patient present in an SCU, highlighting the importance of nursing home environment 
contributing to neuropsychiatric symptoms. However, environmental correlates used 
in this study, i.e. the number of patients per unit or per living room, staff size/patient 
ratio, time spent by staff on care activities, presence of a walking circuit, had no 
signifi cant association with most of the neuropsychiatric symptoms. Only at SCUs of 
which the staff spent more time on care activities did the patients show lower levels 
of apathy. We feel that other factors associated with the physical and psychosocial 
environment, such as other architectural characteristics, staff-patient or patient-patient 
interactions, staff attitude towards (patients with) neuropsychiatric symptoms, policy 
on using physically restraints and psychoactive medication, may explain the large 
variation of SCU symptom levels in Dutch nursing homes.
Chapter 9 gives an overview of the research questions that had been addressed in 
this thesis, discusses the methodological limitations, the implications for researchers, 
physicians and psychologists, carers, architects and policy makers and provides some 
recommendations for further research. 
In conclusion, prevalence rates of neuropsychiatric symptoms in Dutch nursing 
home patients with dementia are high and are infl uenced by both disease related 
predictors and environmental factors. The fi ndings of the WAALBED study indicate  
a biopsychosocial origin of neuropsychiatric symptoms. This model provides a 
better understanding of the etiology and the treatment possibilities than a biological 
model. As biological (pharmacological) interventions have only modest effi cacy 
and considerable side effects, psychosocial interventions should be encouraged. We 
advocate a person-centred approach for the treatment of neuropsychiatric symptoms. 
This approach takes individual personality, coping strategies, history, dementia severity 
and co-morbidity into account when choosing the adequate therapeutic strategy. The 
person-centred approach provides a toolkit of interventions such as pharmacological 
interventions, validation, reminiscence, snoezelen, psychomotor therapy that can be 
tuned on the individual symptoms and needs of patients with dementia to reduce the 
burden of neuropsychiatric symptoms and increase the quality of life.
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Dementie is een ongeneeslijke aandoening met belangrijke effecten op cognitie, 
activiteiten van het dagelijks leven en gedrag. Neuropsychiatrische symptomen, 
vaak aangeduid als agitatie/agressie, psychose, depressie en apathie, hebben een grote  
invloed op patiënt en verzorger en zijn de belangrijkste reden voor opname in een 
instelling. Ook bij verpleeghuispatiënten vormen neuropsychiatrische symptomen  
een grote belasting voor het (verplegend) personeel, resulterend in een toename 
van werkbelasting en stress. Bij patiënten zelf worden voor neuropsychiatrische 
symptomen vrijheidsbeperkende maatregelen toegepast en psychofarmaca 
voorgeschreven met aanzienlijke bijwerkingen.
In eerdere literatuur wordt gesuggereerd dat neuropsychiatrische symptomen vaak 
voorkomen en gerelateerd zijn aan het type en de ernst van de dementie. Er zijn ook 
aanwijzingen dat neuropsychiatrische symptomen beïnvloed worden door andere 
factoren die te maken hebben met de psychosociale en fysieke leefomgeving.  
In het laatste decennium is er meer onderzoek gedaan bij thuiswonende 
dementiepatiënten, maar er is slechts weinig literatuur beschikbaar over patiënten 
in verpleeghuizen. Deze specifi eke omgeving van verpleeghuizen met huiskamers 
waarin patiënten met een hoge mate van neuropsychiatrische symptomen – deze zijn 
immers de reden van opname – hun dag doorbrengen, levert een geschikte setting 
om de waarde van het biopsychosociale model voor het verklaren van factoren die 
bijdragen neuropsychiatrische symptomen te bestuderen.
In dit proefschrift worden de resultaten beschreven van de Nederlandse 
‘WAAL BEhaviour in Dementia’ (WAALBED) studie, een grote studie over 
neuropsychiatrische symptomen bij Nederlandse verpleeghuispatiënten met 
dementie. Zorg voor mensen met dementie in Nederlandse verpleeghuizen wordt 
gegeven op psychogeriatrische (PG) afdelingen door een multidisciplinair team van 
verpleegkundigen, verzorgenden, verpleeghuisartsen, fysiotherapeuten, psychologen, 
activiteitenbegeleiders etc, die allen in dienst zijn van het verpleeghuis zelf. Een 
dergelijk team kan ook zorg voor mensen met dementie in verzorgingshuizen leveren 
(substitutie zorg).
Het doel van dit proefschrift is verder inzicht te krijgen in (1) de mate waarin 
neuropsychiatrische symptomen voorkomen bij Nederlandse verpleeghuispatiënten 
met dementia (prevalentie) en (2) de invloed van patiënt- en omgevingsfactoren op 
deze neuropsychiatrische symptomen.
Hoofdstuk 2 geeft een overzicht van de huidige literatuur over de prevalentie 
van neuropsychiatrische symptomen bij verpleeghuispatiënten met een cognitieve 
beperking. Neuropsychiatrische symptomen komen voor bij meer dan 80% van de 
patiënten met zo’n cognitieve beperking. Prevalenties van specifi eke symptomen 
lopen zeer uiteen, van 3% tot 54% voor wanen, van 1% tot 39% voor hallucinaties, 
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van 8% tot 74% voor depressieve stemming, van 7% tot 69% voor angst, van 17% tot 
84% voor apathie, van 48% tot 82% voor agressie of agitatie en van 11% tot 44% voor 
fysieke agressie. De grote spreiding in prevalenties kan mogelijk worden veroorzaakt 
door een verschil in patiënten populaties, maar ook door gebruik van verschillende 
meetinstrumenten (met verschillende scores en defi nities van symptomen). Neuro-
psychiatrische symptomen lijken niet alleen voorspeld te worden door het type of de 
ernst van de dementie maar ook door de psychosociale omgeving, de hoeveelheid 
psychofarmaca en de mate waarin vrijheidsbeperkende maatregelen worden toegepast.
Hoofdstuk 3 is een systematische review over de werkzaamheid en bijwerkingen 
van antipsychotica. Hoewel antipsychotica vaak worden voorgeschreven aan 
verpleeghuispatiënten met dementie in Nederland (37% in de WAALBED studie, zie 
hoofdstuk 4), is er slechts beperkte bewijskracht voor de werkzaamheid en bestaat 
er toenemende ongerustheid over de veiligheid van deze geneesmiddelen, vanwege 
een vermeend risico op beroerte. In de literatuur werden slechts 14 studies gevonden 
over de werkzaamheid van haloperidol, risperidon, olanzapine (in meer dan één 
onderzoek per geneesmiddel) en van quetiapine, tiapride, loxapine en perfenazine 
(in slechts één onderzoek per geneesmiddel). De werkzaamheid van typische en 
atypische antipsychotica is vergelijkbaar, en alleen risperidon in een lage dosering 
wordt geassocieerd met minder (extrapyramidale) bijwerkingen. Risperidon en 
olanzapine lieten in twee onderzoeken een verhoogde kans op beroerte zien. In het 
gepubliceerde onderzoek is het bijwerkingenprofi el van antipsychotica niet goed 
omschreven en de waarschuwingen voor een verhoogde sterfte kunnen op basis 
hiervan niet worden bevestigd.
Hoofdstuk 4 beschrijft de prevalentie van neuropsychiatrische symptomen bij 
Nederlandse verpleeghuispatiënten. Neuropsychiatrische symptomen werden 
gemeten met behulp van de Neuropsychiatrische Vragenlijst – Verpleeghuisversie 
(NPI-NH) en de Cohen Mansfi eld Agitatie Vragenlijst (CMAI). Meer dan 80% 
van alle verpleeghuispatiënten in de WAALBED studie hebben een of meerdere 
symptomen. Wanen en hallucinaties zijn aanwezig bij respectievelijk 15% en 8% van 
de patiënten. Depressieve stemming en angst waren aanwezig bij 20% en 21% van 
deze patiënten. De prevalentie van agressief/geagiteerd gedragingen was 31% voor 
agressie/agitatie, 20% voor ontremd gedrag, 34% voor prikkelbaar gedrag en 29% 
voor doelloos herhalend gedrag (gemeten met de NPI-NH) en 44% voor algemene 
rusteloosheid, 33% voor vloeken of verbale agressie, 13% voor slaan (gemeten met 
de CMAI). Apathie was aanwezig bij 34% van de patiënten. Wij concluderen dat 
prevalenties hoog zijn, hetgeen praktische consequenties heeft voor planning van zorg.
 
151
Neuropsychiatrische symptomen bij Nederlandse verpleeghuispatiënten met dementie
Hoofdstuk 5 beschrijft de factorstructuur van de NPI-NH. Factoranalyse werd 
gebruikt om gedragsdimensies die aan neuropsychiatrische symptomen ten grondslag 
liggen te onderzoeken. We beschreven de factorstructuur in de WAALBED 
populatie over de verschillende stadia van dementie (zoals gemeten met de Global 
Deterioration Scale) and bij patiënten met en zonder psychofarmaca. In drie 
stadia van de ernst van de dementie werd een 4 tot 5 factoren oplossing gevonden, 
met factoren die aangeduid werden met agitatie/agressie, depressie, psychose, 
psychomotore agitatie en apathie. Dezelfde clustering van symptomen werd gevonden 
bij patiënten die geen psychofarmaca gebruikten, maar slechts ten dele bij patiënten 
met psychofarmaca. De factorstructuur van de NPI-NH is consistent met de klinische 
indeling van symptomen, is relatief stabiel over de verschillende stadia van dementie, 
en wordt slechts in beperkte mate beïnvloed door het gebruik van psychofarmaca. De 
symptoomclusters zijn echter te klein om te kunnen worden gebruikt als subschalen. 
Het onderscheid tussen depressie en apathie in aparte gedragsdimensies – ook  
bij patiënten met ernstige dementie – heeft mogelijk belangrijke therapeutische 
consequenties. 
Hoofdstuk 6 beschrijft de factorstructuur van de CMAI, een meetinstrument dat 
werd gebruikt om agitatie en agressie in de WAALBED onderzoekspopulatie te 
meten. Er werd een beperkte 3-factoren oplossing gevonden, waarvan de symptomen 
bestonden uit fysiek agressief gedrag, fysiek niet agressief gedrag, en verbaal geagiteerd 
gedrag. Deze 3-factoren oplossing is consistent met eerder onderzoek bij zowel 
thuiswonende- als verpleeghuispatiënten met uiteenlopende stadia van dementie. 
De symptoomclusters die onderliggende gedragsdimensies vertegenwoordigen 
werden gebruikt als subschalen in hoofdstuk 7 en 8. Daarnaast werd een onbeperkte 
factor oplossing gevonden met drie extra gedragsdimensies: verstoppen/verzamelen, 
vocale agitatie en een factor met overige items (namelijk herhalende gedragingen 
en spugen). Deze extra factoren zijn te klein om te kunnen worden gebruikt als 
subschaal, maar deze bevinding voegt wel iets toe aan de bestaande kennis over de 
indeling van agitatie en agressie bij dementie. 
 
Hoofdstuk 7 beschrijft de invloed van geslacht en ernst van de ziekte op de 
neuropsychiatrische symptomen in de populatie van Nederlandse verpleeghuis-
patiënten met dementie. Wanen, depressie, fysiek niet-agressief gedrag en verbaal 
geagiteerd gedrag kwamen het meest voor in het stadium van matig-ernstige 
(GDS 5) en ernstige cognitieve achteruitgang (GDS 6) met lagere prevalenties in 
GDS 7. Fysiek agressief gedrag, apathie en angst lieten de hoogste prevalentie zien 
in het stadium van zeer ernstige cognitieve achteruitgang (GDS 7). Fysiek agressief 
gedrag en apathie kwam vaker voor bij mannen, terwijl depressie en angst vaker 
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voorkwamen bij vrouwen met dementie. Wij concluderen dat zowel het stadium 
van dementie als geslacht belangrijke predictoren zijn voor neuropsychiatrische 
symptomen.
Hoofdstuk 8 beschrijft de invloed van factoren geassocieerd met de 
fysieke en psychosociale omgeving op neuropsychiatrische symptomen. De 
verpleeghuispopulatie was verspreid over 56 PG afdelingen. De invloed van zowel 
patiëntfactoren als afdelingsgerelateerde factoren op de symptoomclusters van 
de CMAI en psychose, depressie/angst, agitatie en apathie werd onderzocht met 
behulp van multi-level logistische regressieanalyse, een techniek die het mogelijk 
maakt te corrigeren voor de statistische afhankelijkheid van neuropsychiatrische 
symptomen bij patiënten op eenzelfde PG afdeling.  De resultaten lieten zien 
dat er een substantiële spreiding bestaat in de prevalenties van symptomen tussen 
verschillende PG afdelingen. Deze spreiding verklaarde 4-14% van de totale variantie 
van neuropsychiatrische symptomen. Signifi cante patiënt factoren waren ernst 
van de dementie, geslacht, leeftijd, opname duur en psychofarmaca gebruik, die 
samen ook nog eens 7-21% van de totale variantie verklaarden. De spreiding in 
afdelingsprevalenties bleef aanzienlijk groot zelfs na correctie voor alle signifi cante 
patiëntfactoren van iedere individuele patiënt op een bepaalde PG afdeling. Dit 
resultaat onderstreept het belang van verpleeghuiskenmerken als bijdragen aan 
de mate van neuropsychiatrische symptomen. Echter, de afdelingskenmerken 
die gebruikt werden in dit onderzoek (het aantal patiënten per afdeling of per 
huiskamer, het aantal verzorgenden per bewoner, het aantal uren dat werd besteed 
aan directe patiëntenzorg en de aanwezigheid van een loopcircuit), hadden geen 
signifi cant verband met de meeste van de neuropsychiatrische symptomen. Alleen 
op PG afdelingen waarbij het verzorgend personeel meer tijd besteedde aan 
directe zorg waren patiënten minder apathisch. We denken dat andere factoren die 
geassocieerd worden met de fysieke en psychosociale omgeving, (zoals bouwkundige 
eigenschappen, interacties tussen verzorging en patiënt en tussen patiënten onderling, 
de attitude van de verzorging ten aanzien van patiënten met neuropsychiatrische 
symptomen, beleid ten aanzien van het gebruik van vrijheidsbeperkende maatregelen 
en psychofarmaca), de grote spreiding tussen afdelingsprevalenties in Nederlandse 
verpleeghuizen zouden kunnen verklaren.     
Hoofdstuk 9 geeft een overzicht van de onderzoeksvragen die werden beantwoord 
in dit proefschrift, bediscussieert de methodologische beperkingen, de implicaties voor 
onderzoekers, artsen en psychologen, verzorgenden, architecten en beleidsmakers en 
geeft aanbevelingen voor verder onderzoek.
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Concluderend kan gesteld worden dat de prevalenties van neuropsychiatrische 
symptomen bij Nederlandse verpleeghuispatiënten met dementia zeer hoog 
zijn en beïnvloed worden door ziekte-gerelateerde en omgevingsfactoren. De 
bevindingen van de WAALBED studie wijzen op de biopsychosociale grondslag van 
neuropsychiatrische symptomen.
Dit model levert een beter begrip van de therapeutische mogelijkheden dan 
het biologisch model. Omdat biologische (farmacologische) interventies slechts 
beperkt werkzaam zijn en belangrijke bijwerkingen hebben, moeten juist de 
psychosociale interventies worden gestimuleerd. We pleiten dan ook voor een patiënt-
georiënteerde/belevingsgerichte benadering ten aanzien van de behandeling van 
neuropsychiatrische symptomen. Deze benadering houdt rekening met de individuele 
persoonlijkheid, copingsstrategieën, voorgeschiedenis, ernst van de dementie en 
co-morbiditeit voor het kiezen van een adequate behandelstrategie. Deze patiënt-
georiënteerde/belevingsgerichte aanpak bestaat uit een scala aan interventies zoals 
farmacologische interventies, validatie, reminiscentie, snoezelen, psychomotore 
therapie die kan worden afgestemd op de individuele symptomen en behoeften van 
de patiënt met dementie om de belasting van neuropsychiatrische symptomen te 
verminderen en de kwaliteit van leven te verbeteren.  
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Een proefschrift wordt meestal achterstevoren gelezen, te beginnen bij het 
dankwoord, gevolgd door een samenvatting. Vaak worden daarna alleen nog de 
stellingen gelezen en blijft het daarbij. Toch hoop ik dat velen ook de rest van het 
proefschrift zullen lezen, omdat het onderwerp – neuropsychiatrische symptomen – 
zeer belangrijk is voor de zorg voor mensen met dementie. Ik hoop hiermee een 
bijdrage te hebben geleverd aan het dementie onderzoek. Dit onderzoek moet er 
uiteindelijk toe leiden dat de gevolgen van de ziekte beter hanteerbaar worden voor 
mensen met dementie, partners en verzorgenden. Verzorgenden hebben dagelijks te 
maken met neuropsychiatrische symptomen en zouden meer waardering moeten 
krijgen voor al de inspanningen die ze doen om het dagelijks leven van hun bewoners 
met dementie zo aangenaam mogelijk te maken.
 
Ik wil daarom eerst alle verzorgenden bedanken van de 59 psychogeriatrische 
afdelingen van verpleeghuizen en 13 ‘meerzorgafdelingen’ van verzorgingshuizen, 
van Venlo tot Emmen, van Bergen op Zoom tot Enschede, die tijd hebben 
gereserveerd om de meetinstrumenten in te vullen. Zonder jullie en de bijdrage 
van verpleeghuisartsen en psychologen van al deze instellingen was een dergelijk 
grootschalig onderzoek niet mogelijk geweest. 
Als tweede wil ik bedanken mijn promotor, Raymond Koopmans. Het was jouw idee 
om op de afdeling verpleeghuisgeneeskunde de ‘pas geboren’ onderzoekslijn over 
dementie te beginnen met dit onderzoek. In talloze besprekingen op je kamer op de 
afdeling, in de auto onderweg naar vergaderingen en in je omgebouwde garage annex 
studeerkamer, discussieerden we over de opzet en resultaten van het onderzoek en 
de vele conceptversies van artikelen. Je hebt me veel bijgebracht over het uitvoeren 
van wetenschappelijk onderzoek. Raymond, dank voor je vertrouwen dat ik ondanks 
mijn langdurige ziekte de promotie uiteindelijk wel zou afronden en dat je me in de 
gelegenheid stelt door te gaan als senior onderzoeker op de afdeling. 
Verder wil ik alle personen bedanken die direct of indirect een bijdrage hebben 
geleverd aan dit onderzoek:
Paul Froehling, in het begin was je even mijn beoogd promotor. Als toenmalig hoofd 
van de afdeling heb je me aangenomen; ik weet nog goed dat ik wetenschappelijk 
onderzoek wilde doen, maar je wilde dat ik dan ook ging promoveren. Het is er 
uiteindelijk, jaren na je emeritaat, toch van gekomen.
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Hetty Stieger, dankzij je bemiddeling als directeur van Kalorama is dit onderzoek 
gefi nancierd door Joannes de Deo en ben ik verhuisd van Enschede naar de regio 
Nijmegen om als verpleeghuisarts in Kalorama te komen werken. Je hebt voor mij de 
combinatie tussen wetenschappelijk onderzoek en patiëntenzorg mogelijk gemaakt. 
Frans Verhey, ik was onder de indruk van de MAASBED studie over 
neuropsychiatrische symptomen bij thuiswonende dementiepatiënten. Omdat ik blij 
was dat we delen van je onderzoeksprotocol mochten gebruiken, is de WAALBED 
studie naar de MAASBED studie vernoemd. Ik heb veel geleerd van je deskundige 
inbreng in de begeleidingscommissie, waarvoor je vaak de dienstverlening van de 
Nederlandse Spoorwegen trotseerde om naar Nijmegen te komen. Een keer ben je 
halverwege gewoon teruggekeerd omdat de trein zoveel vertraging had dat de te 
verwachte aankomsttijd viel na het eindtijd van de begeleidingscommissie. Ik herinner 
me ook de gezellige etentjes in Maastricht en op congressen in Stockholm en 
Istanbul, waar ik met veel plezier aan terugdenk. Frans, ik ben blij dat de opgebouwde 
samenwerking tussen Maastricht en Nijmegen ook tot uiting komt in je bijdrage aan 
andere onderzoeken op de afdeling verpleeghuisgeneeskunde.
Marjolein de Vugt en Pauline Aalten, dank voor jullie inzet in de vergaderingen van 
de  begeleidingscommissie in Maastricht. Ik heb het materiaal uit jullie proefschriften 
over het MAASBED onderzoek goed kunnen gebruiken.
Jos de Jonghe, de bijdrage van een psycholoog aan dit onderzoek op het grensvlak 
van de geneeskunde en de psychologie mocht natuurlijk niet ontbreken. Je had als 
psycholoog en als ‘schaaldier’ veel methodologische kennis over meetinstrumenten. Je 
gaf me de handreikingen om de statistische analyse zelf te doen. Dan hadden we vaak 
uitgebreide methodologische discussies waarbij Frans en Raymond ons maar lieten 
begaan. Hans Bor, je hebt daarom weinig hoeven doen, maar je was als statisticus wel 
een klankbord om te toetsen of ik wel de juiste analyse deed.
Marianne van Iersel, door je enthousiasme en niet afl atende inzet hebben we 
samen twee mooie artikelen gepubliceerd over het effect en bijwerkingen van 
antipsychotica bij dementie. Mijn proefschrift is hierdoor meer geworden dan alleen 
een beschrijving van het probleem en kon ik in de discussie sectie ook ingaan op de 
mogelijke ‘oplossingen’. 
Collegae op de afdeling verpleeghuisgeneeskunde en collegae verpleeghuisartsen van 
Kalorama, dank je wel voor jullie interesse en  steun in de afgelopen jaren. Roland 
Wetzels, ik heb in jou als promovendus van de WAALBED-2 beloopstudie een 
waardig opvolger.
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D A N K W O O R D
Ann Jenks, dorpsgenoot en vertaler, dank voor het nalopen van mijn Engelse 
teksten van de onderzoeksartikelen en Ingrid Kleine Koerkamp voor de uitstekende 
vormgeving van het proefschrift. 
Els Derksen en Margje Mahler, ik ben blij dat jullie mijn paranimfen willen zijn. 
Els, ik heb jou leren kennen als mijn onderzoeksassistent. Naast je eigen 
promotietraject wilde je ook wel als ex-verpleegkundige wat praktisch werk doen. 
Gewapend met beamer en laptop zijn we met z’n tweeën door half Nederland gereisd 
om alle 27 deelnemende verpleeghuizen te instrueren. Daarna heb je zeer nauwgezet 
alle gegevens ingevoerd in de database (met het laagste foutenpercentage ooit…?)  en 
de gegevens teruggekoppeld aan de deelnemende verpleeghuizen. Maar je was meer 
dan een onderzoeksassistent; door je uitgebreide kennis over dementie en jarenlange 
ervaring in de zorg hebben we veel kunnen discussiëren over het onderwerp en heb 
je ook meegeschreven aan het prevalentie artikel. 
Margje, als psycholoog in Kalorama heb je me het belang van de rol van de 
psycholoog in het omgaan met probleemgedrag bijgebracht en het leren kijken naar 
interacties tussen verzorgenden en bewoners. We hebben op ‘onze’ verpleegunit 
van zorgcentrum het Höfke, dwars door de gangbare gebruiken heen, samen de 
behandeling en begeleiding van cliënten met probleemgedrag op ons genomen. Ik 
ben blij dat ik je hierdoor beter heb leren kennen, niet alleen als collega, maar ook als 
vriendin en oppas voor Juan (en ik voor je zoon Thuur). 
Hielke de Boer, lieve schoonvader, je hebt niet alleen als oud-leraar Engels een 
bijdrage geleverd in het redigeren van een aantal hoofdstukken, maar je hebt ook als 
klusjesman ervoor gezorgd dat ons huis niet is vergaan in de tijd dat ik het te druk 
had met mijn promotie. 
Lieve mam, als huisarts heb je me het enthousiasme voor de geneeskunde bijgebracht 
en samen met pap het mogelijk gemaakt dat ik ging studeren.
Lieve Nienke, dank je wel dat je me al die jaren hebt bijgestaan en geduld met me 
hebt gehad als ik weer eens achter mijn computertje zat en je de zorg voor onze 
dochter Juan op je nam. Juan, ik hoop dat, als je later groot bent, je dit proefschrift 
eens zal doorbladeren.
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C U R R I C U L U M  V I TA E
Sytse Zuidema is op 6 oktober 1967 geboren in Sneek. In 1985 behaalde hij 
zijn VWO diploma aan het Christelijk Lyceum te Apeldoorn. Hij studeerde 
geneeskunde aan de Rijksuniversiteit Utrecht en verhuisde het laatste jaar van 
zijn studie naar Groningen voor het doen van wetenschappelijk onderzoek op 
het gebied van longziekten in het Academisch Ziekenhuis Groningen. Na zijn 
co-assistentschappen in het Medisch Spectrum Twente (MST) Enschede bleef hij 
ook na zijn artsexamen (1994) in dit ziekenhuis voor arts-assistentschappen 
longziekten voor zowel patiëntenzorg als wetenschappelijk onderzoek en was hij 
poortarts op de locatie van het MST in Oldenzaal. In de periode tussen 1998 en 
2000 deed hij de vervolgopleiding tot verpleeghuisarts aan het UMC St Radboud 
te Nijmegen en werkte hij tot 2003 bij Stichting Zorgpalet te Enschede. Vanaf 2001 
was hij tevens verpleeghuisarts-onderzoeker aan de afdeling Verpleeghuisgeneeskunde 
van het UMC St Radboud om de WAALBED studie naar probleemgedrag voor 
te bereiden. In 2003 verhuisde hij naar Nijmegen omdat Kalorama hem dankzij 
fi nanciering door Stichting Joannes de Deo in de gelegenheid stelde om op 
dit onderwerp te promoveren. Hij is sindsdien als verpleeghuisarts in Kalorama 
werkzaam. Momenteel is hij ook werkzaam op de afdeling Verpleeghuisgeneeskunde/
Vervolgopleiding tot Verpleeghuisarts als senioronderzoeker en coördinator Kennis 
en Wetenschap. Daarnaast heeft hij meegewerkt aan de richtlijn ‘gedragsproblemen 
bij dementie’ voor verpleegkundigen en verzorgenden en aan de herziene richtlijn 
‘probleemgedrag’ van de Nederlandse Vereniging van Verpleeghuisartsen (NVVA). 
Sytse is gehuwd met Nienke Zuidema-de Boer en ze hebben een dochter Juan.
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Neuropsychiatrische symptomen, ook wel probleemgedrag 
genoemd, komen veel voor bij mensen met dementie. Het 
omgaan met dit apathisch, angstig, achterdochtig, agressief 
of dwaalgedrag maakt het zorgen thuis voor de naaste van 
de persoon met dementie extra zwaar. Vaak is dit gedrag 
een reden voor opname in verpleeg- en verzorgingshuizen. 
Verzorgend en verplegend personeel van deze instellingen 
hebben ook dagelijks te maken met probleemgedrag bij 
bewoners met dementie. 
In dit proefschrift beschrijft Sytse Zuidema de resultaten van 
een grootschalig Nederlands onderzoek (WAALBED studie) 
in verpleeghuizen naar de aanwezigheid en oorzaken van 
probleemgedrag. Ook gaat hij in op de medicamenteuze 
behandelmogelijkheden en psychosociale interventies, om 
deze symptomen en de belasting die dit voor verzorgenden 
en verpleegkundigen met zich meebrengt te verminderen.
Dit proefschrift is een aanrader voor verpleeghuisartsen, 
sociaal geriaters, psychologen, psychiaters, klinisch geriaters 
en zorgmanagers, die regelmatig te maken hebben met 
mensen met dementie.
Sytse Zuidema (1967) is als verpleeghuisarts-onderzoeker 
werkzaam op de afdeling Verpleeghuisgeneeskunde van het 
UMC St Radboud te Nijmegen en bij Stichting Kalorama 
te Beek-Ubbergen.
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